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General remarks 
 
1. 1H NMR spectra were recorded on Bruker avance II 400 MHz NMR spectrometer using 
TMS as an internal reference. 
2. Mass spectra were recorded on GC-MS QP-2010 spectrometer. 
3. IR spectra were recorded on Schimadzu FT-IR-8400 spectrometer. 
4. Elemental analysis was carried out on Vario EL III Carlo Erba 1108. 
5. Thin layer chromatography was performed on Silica Gel (Merck 60 F254). 
6. The chemicals used for the synthesis of compounds were purchased from Spectrochem, 
Merck, Thomas-baker and SD fine chemical. 
7. Melting Points were taken in open capillary and are uncorrected. 
8. All the structures are drawn according to ACS Document 1996 style. 
 
 
 
 
 
 
 
 
 
 
 
Synopsis 
 
The work to be presented in thesis entitled “Studies on Some organic Compounds of 
Therapeutic Interest” is classified into following Chapters.  
 
Chapter 1 General Introduction  
Chapter 2 Biological and medicinal significance of Pyrimidines and related 
heterocycles 
Chapter 3 Synthesis and biological evaluation of 1,2,3,4 tetra hydro pyrimidines 
Chapter 4 Synthesis and biological evaluation of 1,2,4-triazolo[1,5-a]pyrimidines 
Chapter 5 Synthesis and biological evaluation of 1,4-dihydropyrimido[1,2-a] 
benzimidazole 
 
Chapter 1 General Introduction  
 
Nowadays, the entire pharmaceutical industry is faced with the challenge of 
increasing productivity and innovation. The major hurdles are the increasing costs of research 
and development and a simultaneous stagnating number of New chemical entities (NCEs). 
Chapter 1 gives a brief introduction for the pressing need of New chemical entity 
(NCE) for pharmaceutical industry. It also describes importance of bicyclic and tricyclic 
aromatic heterocycles in drug discovery. Concept of “privileged structures” is also explained 
in brief. Chapter 1 also describes aims and objective of the proposed research work. 
 
 
Chapter 2 Biological and medicinal significance of pyrimidines and related 
heterocycles 
 
Pyrimidines have a long and distinguished history extending from the days of their 
discovery as important constituents of nucleic acids to their current use in the chemotherapy 
of AIDS. 
Chapter 2 outlines the biological significance and medical significance of one of the 
most important heterocycles, the pyrimidine. An attempt has been made to cover most of the 
physiologically as well as medicinally important compounds containing pyrimidine and its 
derivatives. 
 
Chapter 3 Synthesis and biological evaluation of 1,2,3,4 tetra hydro pyrimidines 
 
The chemistry of pyrimidines and its derivatives has been studied for over a century 
due to their diverse biological activities against unrelated DNA and RNA viruses including 
antitubercular, antibacterial, immunodilator, antiallergic etc. The 1,2,3,4-tetrahydro 
pyrimidine ring system is of special biological interest because it has numerous 
pharmacological and medicinal applications. 
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Where R1= 4-OCH3, 4-Cl, 4-CH3 etc..
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RHK 131 to 160
Where R1= 4-OCH3, 4-Cl, 4-CH3 etc..
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Keeping in mind various biomedical applications and with a view to further assess the 
pharmacological profile of these class of compounds, six novel series of 1,2,3,4-tetrahydro 
pyrimidines (RHK- 101 to 160) are synthesized in chapter 3. The synthesis of 1,2,3,4-
tetrahydro pyrimidines (RHK- 101 to 160) was achieved by acid catalysed undergoing the 
Biginelli reaction of acetoacetamide, urea derivatives and the corresponding aldehydes. The 
products were characterized by FT-IR, mass spectra, 1H NMR and elemental analysis. The 
newly synthesized compounds are subjected to various biological activities viz., 
antimicrobial, antimycobacterial, anticancer and antiviral. 
  
Chapter 4 Synthesis and biological evaluation of 1,2,4-triazolo[1,5-a]pyrimidines 
 
The biological importance of 1,2,4-triazolo[1,5-a]pyrimidines is well documented. 
Over the years, various substituted derivatives of these heterocycles have shown utility 
against a range of biological targets. For example, they have demonstrated activity against 
malaria and bronchospasm and shown activity as coronary vasodilators, antihypertensive 
agents, leishmanicides, antibiotics, adenosine A2a antagonists, immunosuppressants, 
antitumor agents, fungicides, xanthine oxidase inhibitors, and phosphodiesterase inhibitors. 
 In chapter 4, synthesis of four new series of of 1,2,4-triazolo[1,5-a]pyrimidines 
(RHK- 161 to 190). The structures of all the newly synthesized compounds are elucidated by 
FT-IR, mass spectra, 1H NMR and elemental analysis. The newly synthesized compounds are 
subjected to various biological activities viz., antimicrobial, antimycobacterial, anticancer and 
antiviral. 
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Where R1= 4-OCH3, 4-Cl, 4-CH3 etc..
Where R2= 4-Cl,4-F,3-Cl 4-F.
RHK 161 to 190
 
Chapter 5  Synthesis and biological evaluation of 1,4-dihydropyrimido[1,2-a] 
benzimidazole                
 
Regioselectivity in the cyclizations of α-amino azoles with carbonyl 1,3-
biselectrophiles is the subject of a series of studies. However, work in this area has not lost 
current interest because of the many reagents used in similar reactions. Moreover, flat 
heterocyclic structures are fundamental moieties in anticancer compounds acting as DNA 
intercalating agents. In this context, 1,4-dihydropyrimido[1,2-a]benzimidazole have been 
little explored, and there are very few reports on the synthesis and chemical properties of 
these class of compounds. With the aim to extend the synthetic pathways to new planar 
heterocyclic ring systems we focused our studies on the 1,4-dihydropyrimido[1,2-
a]benzimidazole. 
Chapter 5 describes synthesis of 1,4-dihydropyrimido[1,2-a]benzimidazole (RHK- 
190 to 220), which was achieved by using a one-pot catalyst-free biginelli like condensation. 
All the newly synthesized characterized by FT-IR, mass spectra, 1H NMR and elemental 
analysis. The newly synthesized compounds are subjected to various biological activities viz., 
antimicrobial, antimycobacterial, anticancer and antiviral 
N
H
N
N
H
N
O
H3C
CH3
R1
R2
Where R1= 4-OCH3, 4-Cl, 4-CH3 etc..
When  R2= 4-Cl, 4-F, 3-Cl 4-F.
RHK = 191 to 120
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CHAPTER 1 
General Introduction 
 
 
1.1 Heterocycles in drug discovery 
 
Nowadays, the entire pharmaceutical industry is faced with the challenge of 
increasing productivity and innovation. The major hurdles are the increasing costs of 
research and development and a simultaneous stagnating number of new chemical 
entities (NCEs).  
The cause of this innovation deficit is definitively not the biology. Decoding of 
the human genome
a
 has led to a wealth of drug targets. With more than 20,000 human 
genes
b
, the assumption is that at least 1,000 are significantly involved in the 
emergence and course of disease. Furthermore, because each of these genes is linked 
to the function of between five and ten proteins, the conclusion is that there might be 
5,000-10,000 targets for new drugs [1]. Despite the successful introduction of protein 
therapeutics and the promise of gene therapy, major pharmaceutical companies are 
still focused on the discovery and development of low-molecular weight compounds. 
Hence, the challenge is to select the most drugable targets and to find the 
corresponding drug-like molecules, substances that not only interact with the target, 
but also have specific pharmacokinetic and toxicological properties, that allow them 
to be developed as a drug.  
 Medicinal chemistry as a scientific discipline has introduced several new 
techniques over the last few years in order to speed up the drug discovery process, 
such as combinatorial chemistry, microwave-assisted organic synthesis, and high-
throughput purification [2]. Despite this steady increase in R & D, the number of new 
chemical entities (NCEs) reaching the market has actually decreased dramatically. 
                                                           
a
  The complete genetic information (either DNA or, in some viruses, RNA) of an organism, typically    
expressed in number of basepairs. 
b
  According to the official Guidelines for Human Gene Nomenclature, a gene is defined as "a DNA 
segment that contributes to phenotype/function. In the absence of demonstrated function a gene may be 
characterized by sequence, transcription or homology." 
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 It seems clear that selecting the appropriate molecules to synthesize is one of 
the most troublesome questions. It has been estimated that the number of possible 
molecules with a molecular weight of less than 500 atomic mass unit (Da) is 10
200
, of 
which only 10
60
 may possess drug-like properties. The proportion of these drug-like 
molecules synthesized to date has been estimated as one part in 10
57
, or roughly the 
ratio of the mass of one proton to the mass of the sun! The issue is therefore the 
selection of new molecules from this vast universe that have the potential to be 
biologically active [3]. 
In order to start a new drug discovery project and to find biologically active 
compounds, different options are available. Hits can be obtained via a virtual 
screening approach or can be copied from scientific or patent literature. Very often, 
drug discovery projects start with a high-throughput screening campaign of 
commercially available compound libraries against the target of interest. It became 
clear in recent years that combinatorial libraries are not diverse enough. As the main 
interest of the Laboratory of Medicinal Chemistry lays in the synthesis and biological 
evaluation of bicyclic aromatic heterocycles, we performed an in-house survey of 
commercially available combinatorial libraries. This search revealed that the number 
of available bicyclic heterocycles is mainly limited to well-known nitrogen containing 
compounds, such as quinazolines (1), indoles (2) and benzimidazoles (3). 
 
N
N N
H
N
H
N
(1) Quinazoline (2) Indole (3) Benzimidazole
N
H
N
O
(4) 1,4-Benzodiazepine-2-one
O O
(5) Coumarine
N
N
(6) Quinoxaline
O
(7) Benzofuran
S
(8) Benzothiophene
Examples of privileged structures
 
  
These structural classes are considered to be privileged structures. The concept 
of “privileged structures” is first proposed by Evans B. E. et al. to describe select 
structural types that bind to multiple, unrelated classes of protein receptors and 
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enzymes as high affinity ligands [4]. These privileged structures are typically rigid, 
polycyclic heteroatomic systems capable of orienting the various substituents in a 
well-defined three-dimensional space. Well-known examples of privileged 
substructures include benzodiazepines (4), coumarins (5), quinoxalines (6), 
benzofurans (7) and benzothiophenes (8) [5]. In order to improve the hit rate in HTS 
campaigns, privileged structures provide an ideal source of lead compounds. A single 
library based upon privileged substructures can lead to active compounds in variety of 
biological assays. Several research groups have utilized these structures in such a 
manner. For example, Nicolau K. C. et al. constructed a library based on the 
benzopyran (9) privileged scaffold [6], whereas Schultz P. G. et al. made use of the 
purine (10) scaffold [7]. 
 
O
(9) Benzopyran
N
N N
H
N
(10) Purine
The benzopyran and purine privileged scaffold
 
 
1.2 Nomenclature of the fused ring system 
 As the following chapters deal with the synthesis of bicyclic fused ring 
systems, its nomenclature is herewith shortly reviewed. The nomenclature follows the 
following rules: 
 
(1) The individual components are named without any application of fused ring 
system. 
(2) The parent component is represented in the fusion name by citing it last in the 
name. The parent component is the one with highest priority according to the 
following criteria: 
(a) a heterocyclic component containing the heteroatom occurring earliest in 
the order: N, F, Cl, Br, I, O, S, Se, Te, P, As, Sb, Bi, Si, Ge, Sn, Pb, B, Hg. 
(b) a component containing the larger ring. 
(c) a component containing the greater number of heteroatoms. 
(d) a component containing the greater variety of heteroatoms. 
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(3) The attached component is then added as a prefix to the parent component. In 
the name of the prefix, the terminal 'e' is changed to 'o'.    
(4) The bonds of the parent component are indicated by a, b, c…starting with the 
bond normally occupying the 1,2 positions. The atoms of the attached 
component are numbered as usual, following the order of numbers in the 
original heterocycle. 
(5) The numbering of the final condensed heterocycle is carried out 
independently, starting at an atom adjacent to a bridged-head atom, whereby 
heteroatoms receive the smallest possible number. 
 
1.3 Objectives 
 
Our interest in the synthesis and biological evaluation of heterocyclic 
bi/tricycles and the fact that some of these compounds are not frequently used 1,2,3,4-
tetrahydropyrimidines (11), triazolo[1,5-a]pyrimidines (12) and pyrimido[1,2-
a]benzimidazoles (13) in commercial compound libraries, prompted us to elaborate 
this type of chemistry and to synthesize three different heterocyclic scaffolds. 
 
N
N N
N
(12) Triazolo[1,5-a]pyrimidine
N
N N
N
N
1,2,3,4-tetrahydropyrimidine(11)
(13) Pyrimido[1,2-a]benzimidazole
 
 
 Combinatorial and parallel chemistry
c
 are powerful tools for medicinal 
chemists in drug discovery programs. It has encouraged chemists to work out 
                                                           
c
  Parallel chemistry is used in medicinal chemistry to synthesis a number of analogues of compounds 
at the same time. This is typically done by performing the same type of reaction and applying the same 
reaction conditions to a number of reactors (flasks/vials/tubes etc.) but varying the substrates or 
reagents. 
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synthetic strategies and approaches that can be used for the construction of libraries. 
Combinatorial chemistry can be done on a solid support or in solution. Although 
solid-phase chemistry definitively has some advantages (mainly related to 
purification), we opted for the construction of libraries using the solution-phase 
approach. 
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CHAPTER 2 
Biological and medicinal significance of 
pyrimidines and related heterocycles 
 
 
2.1 Biological significance 
 
Pyrimidines have a long and distinguished history extending from the days of 
their discovery as important constituents of nucleic acids to their current use in the 
chemotherapy of Acquired Immunodeficiency Syndrome (AIDS). 
  Alloxan (1) is known for its diabetogenica action in a number of animals [1]. 
Uracil (2), thymine (3) and cytosine (4) are the three important constituents of nucleic 
acids. 
 
HN
H
NO O
O
O
HN
H
NO
O
HN
H
NO
O
N
N
H
CH3 O
NH2
(1) Alloxan (2) Uracil (3) Thymine (4) Cytosine
 
 
The pyrimidine ring is found in vitamins like thiamine (5), riboflavin (6) and 
folic acid (7) [2]. barbitone (8), the first barbiturate hypnotic, sedative and 
anticonvulsant is a pyrimidine derivative [1]. 
 
                                                 
a
 The substances or compounds which cause the disease diabetes are called diabetogenic and the 
mechanism action of such substances is called ‘diabetogenic action’.  
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H3C
H3C O
O
HHO
HHO
OHH
H2C
CH2OH(6) Riboflavin
 
 
O
OH
H
N
O
H
N
N
O
HN
H2N N N
OHO
(7) Folic acid
N
H
NH
O
O O
C2H5
C2H5
(8) Barbitone
 
 
2.2 Medicinal significance 
 
During the last two decades, several pyrimidine derivatives have been 
developed as chemotherapeutic agents and have found wide clinical applications. 
 
2.2.1 Antineoplastics
b
 and anticancer agents 
 
There are a large number of pyrimidine-based antimetabolites. They are 
usually structurally related to the endogenous
c
 substrates that they antagonize
d
. The 
structural modification may be on the pyrimidine ring or on the pendant sugar groups. 
One of the early metabolites prepared was 5-fluorouracil (9a) [3, 4] a pyrimidine 
derivative. 5- Thiouracil (9b) also exhibits some useful antineoplastic activities [5] the 
antineoplastic compounds [6] possessing the guanine nucleus (10) like azathioprine 
(11) [7], mercaptopurine (12) [8], thioguanine (13) [9], tegafur (14) [10], etc. were 
                                                 
b
Drugs that inhibit and combat the development of neoplasms (an abnormal mass of tissue due to the 
abnormal proliferation of cells). 
c
 Endogenous substrates are those that originate from within an organism, tissue, or cell.  
d
 To oppose or to compete the metabolites. 
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discovered after formulation of the antimetabolite theory by Woods and Fildes in 
1940. These drugs prevent the utilization of normal cellular metabolites [6].  
 
N
H
NH
O
X
R
R1
(9a) X = O, R = F, R1 = H, 5-fluorouracil
(9b) X = O, R = SH, R1 = H, 5-thiouracil
(9a, b)
HN
N N
N
S
R1
R
(10)
NH
N
O
O
O
F
(14) TegafurR R1
N
N
NO2
CH3
 Mercaptopurine
 Azathioprine
Thioguanine
–H,
–NH2,
–H,–H,
–H,
(11)
(12)
(13)
 
 
There are many more in recent times, like mopidamol (15) [11], nimustine (16) 
[12], raltitrexed (17) [13], uramustine (18) [14] and trimetrixate (19) [15]. 1-β-D-
Arabinosylcytosine
 
(Ara-C, 20) [16] is also an example of a pyrimidine antimetabolite 
in which the sugar is arabinose having a beta configuration. It is mainly used as an 
anticancer agent and also exhibits significant therapeutic effects in patients with 
herpes virus infections and herpes encephalitis. 
 Gemcitabine (21), a pyrimidine antimetabolite, shows excellent antitumour 
activity against murine solid tumours [17].  
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N
H
N
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O
N
H
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HOOC
CH3
O
CH3
(17) Raltitrexed
NH
H
N
N
Cl
Cl
O
O
N
N
N NH2
CH3
H
NO
O
H3C
H3C
O
H3C
(18) Uramustine (19) Trimetrexate glucuronate
N
NH2
ON
O
OH
HO
HO
(20) Ara-C
 
 
1.2.2 Drugs for hyperthyroidism
e
 
 
2-Thiouracil (9c) and its alkyl analogue, thiobarbital (9e) are effective drugs 
against hyperthyroidism. Propylthiouracil (9d) is used as a drug for hyperthyroidism 
with minimum side effects [18]. 
 
N
H
NH
O
R
R2 X
R1
(9c) R = R1 = R2 = H, X = S; 2-thiouracil 
(9d) R = R1 = H, R2 = C3H7, X = S; Propylthiouracil 
(9e) R = R1  = C2H5, R2 = O, X = S; Thiobarbital
(9c–e)
 
                                                 
e
 The term used for overactive tissue within the thyroid gland causing an overproduction of thyroid 
hormones 
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2.2.3 Antifolates
f
, antibacterials
g
 and antiprotozoals
h
 
 
In 1948, Hitchings made an important observation that a large number of 2,4-
diaminopyrimidines and some 2-amino-4-hydroxypyrimidines are antagonists of folic 
acid [19]. Since then, a large number of 2,4-diaminopyrimidines have been 
synthesized as antifolates. It was eventually proved that these pyrimidines are 
inhibitors of the enzyme Dihydrofolate reductase (DHFR) [20, 21]. Notable amongst 
the 2,4-diaminopyrimidine drugs are pyrimethamine (22), a selective inhibitor of the 
Dihydrofolate reductase (DHFR) of malarial plasmodia; trimethoprim (23), an 
antibacterial drug which selectively inhibits bacterial Dihydrofolate reductase (DHFR) 
and most importantly, the very potent but non selective Dihydrofolate reductase 
(DHFR) inhibitors, methotrexate (24a) and aminopterin (24b), both used in cancer 
chemotherapy [22]. 3’,5’-Dichloromethotrexate (24c), which is less toxic and more 
readily metabolized than methotrexate, has recently been introduced for anticancer 
therapy [23]. Brodimoprim (25) is also found to be an effective antibacterial 
compound [24]. 
 
N
N
NH2
NH2
C2H5
Cl
N
N NH2H2NH3CO
OCH3
H3CO
N
N N
N
NH2
H2N
CH2N
R
X
X
CONH CH
COOH
(CH2)2
COOH
(24a) R = CH3, X = H; Methotrexate
(24b) R = X = H; Aminopterin
(24c) R = CH3, X = Cl; 3',5'-dichloromethotrexate
(22) Pyrimethamine (23) Trimethoprim
(24)
N
N NH2H2NBr
OCH3
H3CO
(25) Brodimoprim
 
 
 
 
                                                 
f
 Antifolates are drugs which impair the function of folic acids. 
g
 The drugs having the capability of either to kill or to stop the growth of bacteria.   
h
 An antiprotozoal agent is a class of pharmaceuticals used in treatment of protozoan infection. 
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2.2.4 Sulfa drugs
i
 
 
Pyrimidine derivatives of sulfa drugs, Viz; sulfadiazine, sulfamerazine and 
sulfadimidine are superior to many other sulfonamides and are used in some acute 
Urinary Tract Infection (UTIs
j
) infections, cerebrospinal meningitis and for patients 
allergic to pencillins [25]. Sulfonamide-trimethoprim combinations are used 
extensively for opportunistic infections in patients with acquired immunodeficiency 
syndrome (AIDS) [26]. Sulfadoxine (26a) [27], a short and intermediate acting 
sulfonamide with a half-life of 7-9 days is used for malarial prophylaxis. 
Sulfisomidine (26b) with a half-life of 7 h is used as a combination sulfa therapy in 
veterinary medicine [28]. Sulfadiazine (27a), sulfamerzine (27b) and sulfadimidine 
(27c) possess good water solubility and therefore carry minimum risk of kidney 
damage, which makes them safe even for patients with impaired renal functions. 
 
NH2S
O
O
HNR
(26)
R
Sulfadoxine (26a)
N
N
CH3
H3C
N
N
OCH3
H3CO
H3C
Sulfisomidine (26b)
CH3
N
N
R1
R
R2
NH S
O
O
NH2
(27)
 R         R1       R2
 H,        H,         H,
 H,        CH3,     H,
 H,        CH3,    CH3,
 OCH3,  H,         H,
 CH3,     H,         H,
N
N
OCH3
H3CO
NH S
O
O
NH2
(27d) Sulfadimethoxine
N
N
H3CO
S
H
N NH2
OCH3
O
O
(28) Sulfamethoxine
Sulfadiazine
Sulfamerazin
Sulfadimidine
Sulfametoxydiazine
Methyldiazine
(27a)
(27b)
(27c)
(27f)
(27e)
 
 In 1959, sulfadimethoxine (27d) [29] was introduced with a half-life of 
approximately 40 h. The related 4-sulfonamidopyrimidine, sulfamethoxine (28) [29] 
having two methoxy groups in 5 and 6 positions, has by far the longest half-life of 
about 150 h. Methyldiazine (27e) has a half-life of 65 h. Also, sulfamethoxydiazine 
(27f) [29] possesses good half-life. A new broad-spectrum sulfonamide, 
                                                 
i
 The synthetic antimicrobial agents that contain the sulfonamide group are called sulpha drugs. 
j
 A Urinary Tract Infection (UTI) is a bacterial infection that affects any part of the urinary tract. 
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sulfamethomidine (29) [29] is relatively nontoxic and patients do not need extra fluid 
intake or alkalization. Sulfacytine (30) [29] has been reported to be 3–10 times more 
potent than sulfaisoxazole and sulfisodimidine [29]. 
 
N
N
OCH3
CH3HN
O2S
NH2
N
H
N
OHN
O2S
NH2
C2H5
(29) Sulfamethomidine (30) Sulfacytine
 
 
2.2.5 Antivirals
k
 and anti-AIDS
l
 
 
Recently, pyrimidine derivatives have generated widespread interest due to 
their antiviral properties. 5-Iododeoxyuridine(IDU) (31) [30] is an antiviral agent of 
high selectivity. 
 
NH
O
ON
O
HOH
HH
HH
HO
I
NH
O
ON
O
OH
HO
X
(31) 5-Iododeoxyuridine (32)
N
NN
N
NH2
O
OH
HO
HO
(33) Ara-A
NH
O
ON
O
N3
HO
H3C
(34) Retrovir
(32a)X = I, 5-iodo-2'-deoxyuridine
(32b) X = CF3, 5-trifluromethyl-2'-deoxyuridine
 
 
5-iodo-2’-deoxyuridine (IDU) (32a) has been extensively utilized for viral 
infections. 5-Trifluromethyl-2’-deoxyuridine (F3 TDR, 32b) has been found useful 
against infections resistant to 5-iodo-2’-deoxyuridine (IDU) therapy [30]. Ara-A 9-β-
D-arabinofuranosyl adenine (33), a relatively new antiviral drug, is effective against 
                                                 
k
 Antiviral drugs are a class of medication used specifically for treating viral infections. 
l
 The drugs which are used to treat the disease AIDS (acquired immunodeficiency syndrome). 
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herpes infections of eye, brain and skin. It is especially effective against 5-iodo-2’-
deoxyuridine (IDU)-resistant herpes virus [30]. 
Some purine nucleosides are equally noteworthy. Retrovir, Azidothymidine 
(AZT-16, 34) is a potent inhibitor of the in vivo replication and cytopathnic effects of 
Human immunodeficiency virus (HIV) and has been recently approved for use against 
Acquired immunodeficiency syndrome (AIDS) and severe AIDS related complex 
(ARC) [31]. At present Acyclovir (35a) is the only remedy for genital herpes. The 
oral formulation of Acyclovir is effective against both first and second-degree 
recurrence-genital herpes with minimal side effects [32]. Ganciclovir
 
(35b) [33] has 
shown good in vivo activity against Hepatitis C virus (HCV1&2). 
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O
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O
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O
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HO
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(37) Zidovudine
N
NH2
ON
O
HO
H3C
(38) Zalcitabine
NH
NN
N
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O
HO
(39) Didanosine
NH
O
ON
O
HO
H3C
(40) Stavudine
N
NN
N
NH
O
HO
NH2
(41) Abacavir
 
 
Several members of a series of acyclic nucleosides, which contain a fused 
pyrimidine ring (mainly purine), are found to be effective antivirals. Famiciclovir 
(35c) and valacyclovir (35d) are drugs used for several deoxyribonucleic acid (DNA) 
viruses, including Varicella-zoster virus and Epstein-Barr virus [34]. Penciclovir (35e) 
[35] is useful for topical treatment of recurrent herpes, Libialis. Cidofovir (36b) [35], 
an antimetabolite for deoxycytosine triphosphate is used for treatment of 
Cytomegalovirus (CMV) in AIDS patients. Lamivudine (36a) [35] is an effective anti-
AIDS drug when used in combination with zidovudine (37) [35]. Zidovudine [36] is 
an analogue of thymidine in which the azido group is substituted at the 3-position of 
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the dideoxyribose moiety. It is active against Ribonucleic acid (RNA) tumour viruses 
(retroviruses) that are the causative agents of Acquired immunodeficiency syndrome 
(AIDS) and T-cell leukaemia. It is used in Acquired immunodeficiency syndrome 
(AIDS) and Acquired immunodeficiency syndrome (AIDS)-related complex (ARC) to 
control opportunistic infections by raising absolute CD4
+
 lymphocyte counts. Also, 
zalcitabine (38) [36] is another useful alternative drug to zidovudine. It is given in 
combination with zidovudine, when [cluster of differentiation 4 (CD4
+
 T helper cells) 
CD4
+
 cell] counts fall below 300 cells/mm
3
. Didanosine (39) [37] is a purine 
dideoxynucleoside, which is an analogue of inosine. Didanosine inhibits HIV Drug 
Resistance Database (HIV RT) and exerts a virustatic effect on the retroviruses. 
Combined with zidovudine, antiretroviral activity of didanosine is increased. 
Stavudine (40) [37] is a pyrimidine nucleoside analogue that has significant activity 
against major type of HIV (HIV-1) after intracellular conversion of the drug to a 
Stavudine (D4T-triphosphate). It is more effective than zidovudin or didenosine for 
treatment in patients for delaying the progression of Human immunodeficiency virus 
(HIV) infection. It is recommended for patients with advanced HIV infection. 
Abacavir sulfate (41) [37] was approved in 1998 as a Nucleoside Reverse 
Transcriptase Inhibitor (NRTIs) to be used in combination with other drugs for the 
treatment of Human immunodeficiency virus (HIV) and Acquired immunodeficiency 
syndrome (AIDS). The major use of abacavir appears to be in combination with other 
Nucleoside reverse transcriptase inhibitor (NRTIs). 
 
2.2.6 Antibiotics
m
 
 
There are few examples of pyrimidine antibiotics. The simplest of all is 
bacimethrin (5-hydroxymethyl-2-methoxypyrimidin-4-amine) (42), which is active 
against several staphylococcal infections [38]. Gourgetin (43), a cytosine derivative is 
active against mycobacteria as well as several Gram-positive and Gram-negative 
bacteria [39]. There are more derivatives of cytosine, namely amicetin (44) and 
plicacetin (45), which exhibit activity against acid fast and Gram-positive bacteria as 
well as some other organisms [38]. Puromycin (46) has a wide spectrum of 
antitrypanosomal activity. Aminoglycoside antibiotics phleomycin (47a), bleomycin 
                                                 
m
 An antibiotic is a substance or compound  that kills bacteria or inhibits their growth. 
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(47b) and related families are wide-spectrum antibiotics containing the pyrimidine 
ring. Another antibiotic tubercidine (48) is reported to exhibit antitumour properties 
[39]. In addition, they have antineoplastic activity. Bleomycin is already in clinical 
use against certain tumours like Hodgkin’s lymphoma and disseminated testicular  
cancer [40]. 
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2.2.7 Antifungals
n
 
 
Pyrimidines also exhibit antifungal properties. Flucytosine (49) [41] is a 
fluorinated pyrimidine used as nucleosidal antifungal agent for the treatment of 
serious systemic infections caused by susceptible strains of candida and Cryptococcus 
[42]. Hexitidine [43] (50) is mainly used for the treatment of aphthous ulceration. 
 
N
H
N
F
O
NH2
(49) Flucytosine
N
N
H2N
CH3
CH3
CH3
CH3
CH3
(50) Hexitidine
 
 
2.2.8 Anthelmentics
o
 
 
These drugs have the ability of ridding the body of parasitic worms. Pyrantel 
pamoate (51) is a depolarizing neuromuscular blocking agent that causes spastic 
paralysis in helminthes and is employed in the treatment of infestations caused by 
pinworms and roundworms [44]. 
 
N
N
SCH3
(51) Pyrantel pamoate
 
 
 
 
 
                                                 
n
 An antifungal drug is a medication used to treat fungal infections such as athlete's foot, ringworm, ca-
didiasis (thrush), serious systemic infections such as cryptococcal meningitis and others. 
o
 Anthelmintics or antihelminthics are drugs that expel parasitic worms (helminths) from the body, by 
either stunning or killing them. They may also be called vermifuges (stunning) or vermicides (killing). 
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2.2.9 Antitubercular drugs
p
 
 
N
H
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O
H
N
NH
O
H2N
O
N
H
CH2RH
N
O NH2
NH2
O
O
H
N
CH3
O
(52) Capreomycin
 
 
Capreomycin (52) produced by Streptomyces capreolus is a second-line 
bacteriostatic antituberculin drug containing pyrimidine [45, 46].  
 
HN
N
H
OHHN
NH
O
HN
CHNHCONH2
O
CH2OH
HN
O
NH
H2NOC
O
N
H
ONH2
H2N NH
O
(53) Viomycin
 
 
Viomycin (53) is more tuberculostatic than p-aminosalicyclic acid. It is 
effective in the treatment of experimental tuberculosis. 
 
 
 
 
 
 
                                                 
p
 Antitubercular drugs are the antibiotics used in prevention and treatment of tuberculosis caused by the 
bacteria mycobacterium tuberculosis. 
 
Chapter: - 2                                                                                                      Significance of pyrimidine 
Studies on Some Organic Compounds of Therapeutic Interest 
21 
2.2.10 CNS active agents 
 
2.2.10.1 Sedative
q
/Hypnotic/Antiepileptic agents 
 
N
N
O
R1
O
R
O
R2
(54)
R2R R1
Allobarbital-H -H
-H -H
-H -CH3
-H -H
Pentobarbital-H -H
R R1
-H -H
-H -H
-H -CH3
-H -H
Br
R2
Aprobarbital
Hexobarbital
, ,
, ,
, ,
Cyclobarbital, ,
, ,
 Propallylonal
Phenobarbital
 Secbutabarbital
, ,
, ,
, ,
 Secobarbital, ,
(54a)
(54b)
(54c)
(54d)
(54e)
(54f)
(54g)
(54h)
(54i)
 
Agents of the anxiolytic, sedative and hypnotic group include a wide variety 
of barbiturates (54a–i) used as sedative and hypnotics and are classified as drugs 
having short, intermediate and long duration of action [47, 48]. Allobarbital (54a), 
aprobarbital (54b), pentobarbital (54e), phenobarbital (54g) and secobarbital (54i) are 
frequently used clinically as hypnotic barbiturates [49]. Hexobarbital (54c), 
cyclobarbital (54d) and propallylonal (54f) are some of the current drugs in the 
market used as sedative, hypnotics [50]. Barbiturates as sedative hypnotics have a 
long and fascinating history. In fact Eli Lilly [51] patented secbutabarbital (54h) in 
1932, while barbitone (8), the first of the barbiturates [1] was introduced in 1903. 
 
 
 
 
 
                                                 
q
 A sedative is a substance that induces sedation by reducing irritability or excitement. 
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2.2.10.2 Anxiolytic
r
 agents 
 
Few of the pyrimidine derivatives are also used as anxiolytics. Most important 
of these is buspirone (55), indicated in the management of anxiety disorders 
accompanied with or without depression. It lacks sedative, anticonvulsant and muscle-
relaxant effects and most importantly abuse potential [52]. Buspirone lacks affinity to 
benzodiazepine receptors, but binds avidly to one subclass of serotonin receptors, the 
5-HT1A subtype [53, 54]. Ritanserin (56), a 5HT2 antagonist with anxiolytic activity is 
a pyrimidine derivative [55]. A simple pyrimidine derivative, mezilamine (57) is 
classified as an antipsychotic agent [56]. Risoperidone (58) is an antipsychotic drug, 
which is a structural hybrid of butyrophenone and can be used as anxiolytic, 
antidepressant and antiparkinsonian drug [57]. 
 
N
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N N (CH2)5 N
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2.2.10.3 Pyrimidine anaesthetics
s
 
 
Thimylal (59) is a short acting general anaesthetic drug, which is also a 
pyrimidine analogue [58,59]. 
                                                 
r
 An anxiolytic (also antipanic or antianxiety agent) is a drug used for the treatment of symptoms of 
anxiety. 
s
 An anesthetic (or anaesthetic) is a drug that causes anesthesia—reversible loss of sensation. 
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(59) Thimylal (60) Saxitoxin
 
 
Saxitoxin (60) [58] is a naturally occurring pyrimidine containing anaesthetic 
agent, but is too toxic to be of clinical use. Saxitoxin is isolated from some marine 
dinoflagellates. 
 
2.2.10.4 Diuretics
t
 and uricosurics
u
 
 
Several xanthine derivatives (61) containing fused pyrimidine ring systems 
like caffeine (61a) [60], etamiphylline
 
(61b) [61], lomiphylline (61c) [62], etophylline 
[63] (61d), theophylline (56e) [60] and theodrendaline (61f) [64] are known to 
promote a weak diuresis by stimulation of cardiac function and by a direct action on 
the nephron, acting as adenosine receptor antagonists [60]. 
 
N
N N
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O
H3C
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R
CH3
(61b) Etamiphylline N
O
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t
 A diuretic is any drug that elevates the rate of urination and thus provides a means of forced diuresis. 
u
 Uricosuric medications (drugs) are substances that increase the excretion of uric acid in the urine, thus 
reducing the concentration of uric acid in blood plasma. 
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There are a few examples of diuretics which contain a pyrimidine ring. 
Noteworthy are quinethazine (62a), metolazone (62b) [65] and triamterene (63) [66]. 
 
N
N
N
N
N
NCl
H2NO2S
H
H
R
C6H5
H2N NH2
NH2O
R1
 (63) Triamterene(62)
(62a) R = C2H5, R1 = H; Quinethazine
(62b) R = CH3, R1 = 2-CH3C6H4; Metolazone
 
 
2.2.11 Cardiac agents 
 
2.2.11.1 Antihypertensives
v
 
 
Several pyrimidine ring-containing drugs have exhibited antihypertensive 
activity. Prazosin (64a), a quinozoline derivative, is a selective α1-adrenergic 
antagonist [67, 68]. Its related analogues bunazosin (64b) [69], terazosin (64c) [70] 
and trimazosin (64d) [71] are potent antihypertensive agents. Another quinazoline 
derivative, ketanserin (65) [72] having a similar effect is an antagonist of both a1-
adrenergic and serotonin-S2 receptors. Its mechanism of action however is still 
controversial. A triaminopyrimidine derivative, minoxidil (66), whose mechanism of 
action and therapeutic action are similar to Prazosin, has been introduced in therapy 
for its side effects, in the treatment of alopecia, male baldness [73]. Besides these, 
some more pyrimidine derivatives given below were found to be antihypertensives 
[74, 75]. 
                                                 
v
 The antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure). 
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Alfuzocin (67) [74], a prazocin analogue and an α1-adrenergic receptor 
antagonist as well as urapidil (68) [75] are used especially in urinary obstruction 
caused by benign prostate hyperplasia. 
 
2.2.11.2 Vasodilators
w
 
 
A series of xanthine derivatives are used as peripheral and cerebral 
vasodilators. Especially, pentifylline (69a) and pentoxyphilline (69b) are used in 
cardiovascular disorders [76]. Other derivatives like xantinol nicotinate [77] (70b), a 
vasodilator with general properties like nicotinic acid used in cerebral and peripheral 
vascular disorders and pimephylline (70a) and pyridophylline [78] (70c) are 
noteworthy. A new dopamine receptor stimulant, pirebidil (71) [79] is reported to 
                                                 
w
 The term vasodilation refers to the widening of blood vessels, resulting from relaxation of smooth 
muscle cells within the vessel walls, and the drugs to which are used in phenomena are called 
vasodilators. 
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have produced significant improvement in ADL (Activity of Daily Living) in patients 
suffering from Parkinson’s syndrome. 
 
N
N N
N
O
O
R2
R3
H3C
R1
(69)
 Pentifylline
 Pentoxifylline
 Propentophylline
R1 R2 R3
-H,
-H,
O,
CH3, CH3,
CH3, CH3,
CH3,C5H12,
N
N N
N
O
O
R
CH3
H3C
(70)
 Pimefylline
 Xantinol nicotinate
 Pyridofylline
R
N
N
H
OH
N
CH3
OH
N
COOH
O
SO3H
N
N
N N O
O
(71) Piribedil
(69a)
(69b)
(69c)
(70a)
(70b)
(70c)
 
2.2.11.3 Cardiotonics
x
/Bronchodialators 
 
Several xanthine derivatives theophylline (61e), aminophylline (72a) [80] and 
proxyphylline (72b) [80] exhibit good bronchodilator activity. 
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x
 Agents that have a strengthening effect on the heart or that can increase cardiac output. 
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2.2.12 Antihistaminic
y
pyrimidines 
 
Taziphylline (73) is ten times more potent than either astemizole or 
terfenadine in its affinity for H1-histaminebinding site and appears to be devoid of 
Central nervous system (CNS) activity [81]. Another pyrimidine containing 
antihistaminic drug, temelastine (73a) is comparable to mepyramine [82]. 
Radiolabelled studies have indicated that it does not penetrate the Central nervous 
system (CNS) appreciably. Icotidine (73b), a structural analogue of temelastine lacks 
Central nervous system (CNS) activity and is a dual antagonist of both H1 and H2 
receptors [83]. 
 
N
NN
N
O
CH3
CH3
O
(72a) Aminophylline
(73a) R1 = Br, R2 = CH3, Temelastine
(73b) R1 = H, R2 = OCH3, Icotidine
N
N
S
N
N N CH3
O
HNN
R2R1
N
N
CH3
O N N
N
H
N
(74) Pemirolast
N
O
CH3
.
HN
N
H
N
H
N
O
O
Cl
(75) Piprinhydrinate
 
 
Pemirolast (74) [84], a new oral nonbronchodilator antihistaminic agent is also 
a pyrimidine derivative. It has demonstrated sufficient antihistaminic activity to 
warrant its use in severe asthma. Another compound, piprinhydrinate (75) [85] is also 
a pyrimidine derivative. 
 
                                                 
y
 A histamine antagonist is an agent that inhibits action of histamine or the drug which is used to treat 
the allergy is called antihistaminic agent. 
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2.2.13 Analgesics
z
 and NSAID drugs
aa
 
 
Acetiamine
 
(76a) [86], bentiamine (76b) [86] and fursultiamine (76c) [87] are 
new lipid-soluble forms of thiamine (vitamin B1) having therapeutic use in beriberi, 
polyneuritis, encephalopathy, pain, malnutrition and alcoholism and especially in the 
treatment of long-standing insulin-dependent diabetes mellitus. Fursultamine has been 
reported to inhibit the arachadonic acid cascade-line activation and reverse the 
increase in Coronary Blood Flow (CBF). 
 
CH3
NH2
N
O
O
R
CHO
CH3
R1
(76)
(76a) Acetiamine
(76b) Bentiamine
R R1
CH3,
C6H5,
S
O
O S
N
N CH3
NH2
N
CHO
CH3
HO
S
S
O
(76c) Fursultiamine
 
 
Afloqualone (77) [88] has been evaluated as a successful anti-inflammatory 
agent with lower back pain patients. Epirazole (78) [89], another Nonsteroidal anti-
inflammatory drugs (NSAID), is suggested to be a COX-2 inhibitor. Ademetionine 
(79) [90] is primarily used in conjunction to glucosamine and chondroitin therapy. 
Octotiamine (80) [91], a vitamin B1 derivative also exhibits anti-inflammatory 
activity. Proquazone (81) [92], a condensed pyrimidin-2-one derivative has been 
reported to exhibit good Nonsteroidal anti-inflammatory drugs (NSAID) potential. 
                                                 
z
 An analgesic (also known as a painkiller) is any member of the group of drugs used to relieve pain. 
aa
 Nonsteroidal anti-inflammatory drugs, usually abbreviated to NSAIDs or NAIDs, are drugs with ana- 
lgesic and antipyretic effects and which have, in higher doses, anti-inflammatory effects (reducing 
inflammation). 
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2.2.14 Metabolic electrolytes 
 
Orotic acid (82) [93], a simple pyrimidine derivative and its mineral forms are 
used in metabolic therapy, especially for cardiovascular patients to prevent heart 
failure in cardiomyopathy. Oroate is needed as a key intermediate in biosynthesis of 
pyrimidine nucleotides, which are building blocks for deoxyribonucleic acid (DNA) 
and ribonucleic acid (RNA) required for the final protein synthesis. 
 
NH
ON
H
O
O OH
(82) Orotic acid
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2.3 Conclusion 
 
Pyrimidines occupy a distinct and unique place in our life. This heterocyclic 
moiety has great biological and medicinal significance. A large array of pyrimidine 
drugs possesses a variety of medicinal properties. These properties include anticancer, 
antibacterial, antiprotozoal, antimicrobial, antiviral, antihypertensive, antihistaminic, 
anti-inflammatory, analgesic, and Central nervous system (CNS)-active to metabolic 
adjuvant. 
Keeping in mind various biomedical applications and with a view to further 
assess the pharmacological profile of bi/tricyclic aromatic heterocycles related to 
pyrimidines, three different heterocyclic scaffolds related to pyrimidines (1,2,3,4-
tetrahydropyrimidines, 1,2,4-triazolo[1,5-a]pyrimidines and pyrimido[1,2-a]benzi-
midazole) have been synthesized in the work of this doctoral thesis. 
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CHAPTER 3 
Synthesis and biological evaluation of 
1,2,3,4-tetrahydro pyrimidines 
 
 
3.1 Introduction 
 
In 1893, Italian chemist Biginelli reported on the acid-catalyzed 
cyclocondensation reaction of ethyl acetoacetate, benzaldehydes and urea [1]. The 
reaction was carried out simply by heating a mixture of the three components 
dissolved in ethanol with a catalytic amount of hydrochloric acid (HCl) at reflux 
temperature. The product of this novel one-pot, three-component synthesis that 
precipitated on cooling of the reaction mixture was identified correctly by Biginelli as 
3,4-dihydro pyrimidin-2(1H)-one. 
 
OH
EtO2C
CH3O
H2N NH2
O
EtOH
H+
NH
N
H
H3C
EtO2C
O
+
Scheme 3.1
(1)
 
The Biginelli dihydropyrimidine synthesis. 
 
A part from a series of publications by the late Folkers K. et al. [2] in the mid 
1930s, the “Biginelli reaction” or “Biginelli condensation” as it was henceforth called 
was largely ignored in the early part of the 20th century. The synthetic potential of 
this new heterocycle synthesis therefore remained unexplored for quite some time. In 
the 1970s and 1980s, interest slowly increased, and the scope of the original 
cyclocondensation reaction shown in (Scheme 3.1) was gradually extended by 
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variation of all three building blocks, allowing access to a large number of 
multifunctionalized dihydropyrimidines (1) [3]. 
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Building blocks in Beginelli MCRs.
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3.2 Biological importance 
 
The tremendously growing number of publications and patents on the 
dihydropyrimidine is mainly due to the fact that the multifunctionalized 
dihydropyrimidine scaffold (DHPMs, “Biginelli compounds”) represents a heterocylic 
system of remarkable pharmacological efficiency. In the past decades, a broad range 
of biological effects, including antiviral, antitumor, antibacterial, and 
antiinflammatory activities, has been ascribed to these partly reduced pyrimidine 
derivatives. More recently, appropriately functionalized DHPMs have emerged as, 
e.g., orally active antihypertensive agents (2) [4-6] or adrenoceptor-selective 
antagonists (3) [7,8]. A very recent highlight in this context has been the identification 
of the structurally rather simple dihydropyrimidine (DHPM) monastrol  as a novel 
cell-permeable molecule that blocks normal bipolar spindle assembly in mammalian 
cells and therefore causes cell cycle arrest (4) [9]. Monastrol specifically inhibits the 
mitotic kinesin motor protein and can be considered as a new lead for the 
development of anticancer drugs (5) [10].  Furthermore, apart from synthetic DHPM 
derivatives, several marine natural products with interesting biological activities 
containing the dihydropyrimidine-5-carboxylate have recently been isolated [11]. 
Most notable among these are the batzelladine alkaloids A and B, which inhibit the 
binding of Human immunodeficiency virus (HIV) envelope glycoprotein (protein gp-
120) to human cluster of differentiation 4 (CD
4
) cells and, therefore, are potential new 
leads for Acquired immunodeficiency syndrome (AIDS) therapy (6) [12]. 
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3.3 Mechanism of Biginelli reaction 
 
The first mechanistic studies of the Biginelli reaction were conducted by 
Folkers and Johnson forty years after Biginelli’s initial report [13]. A second 
mechanistic proposal was suggested by Sweet F. et al. forty years after Folkers K.  et 
al. [14]. Kappe C. O. et al. further explored the mechanism of the Biginelli reaction 
using Nuclear magnetic resonance (NMR) spectroscopy and trapping experiments 
[15]. Kappe C. O.  et al. proposal is currently the accepted mechanism for the 
Biginelli reaction.  
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3.4 Reaction advancements 
 
 
3.4.1 Improved Reaction Conditions 
 
A number of improved variants in traditional Biginelli reaction employing 
new reagents, catalyst, methodologies and technique have emerged. Numerous 
synthetic method for the preparation of these compounds have been reported using 
indium(III) chloride (InCl3) [16], lanthanide triflate [17], diethoxytrifluoroborane 
(BF3•OEt2) [18], polyphosphate ester (PPE) [19], KSF clay [20], lanthanum(III) 
chloride (LaCl3) [21], sulphuric acid (H2SO4) [22], ceric ammonium nitrate(CeNO2) 
[23], manganese(III)acetate (Mn(OAc3) [24], ion-exchange resin [25], 
indium(III)bromide (InBr3) [26], ferric chloride (FeCl3) [27], cadmium(II)chloride 
(CdCl2) [28], 1-n-butyl-3- methyl imidazoliumtetrafluoroborate [29], ytterbium 
triflates [30], silicond ioxide (SiO2)/sodium bisulphate (NaHSO4) [31], bismuth 
chloride (BiCl3) [32], Lithium per chlorate (LiClO4) [33], zirconium chloride (ZrCl4) 
[34], copper bistrifluoromethane-sulfonicacid (Cu(OTf)2) [35], bismuththri-
strifluoromethane-sulfonicacid (Bi(OTf)3) [36], lithum bromide (LiBr) [37], 
ammonium chloride (NH4Cl) [38], stenus chloride (SnCl2.2H2O) [39], aluminium 
chloride (AlCl3)/potassium iodide (KI) [40], cobalt chloride (CoCl2)/manganese 
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chloride (MnCl2) [41], aluminium chloride AlCl3/ aluminium bromide AlBr3 [42], 
Phosphorus pentoxide (P2O5) [43], BiO ClO4.H2O [44], calcium chloride (CaCl2) 
[45], 1,3-Dibromo-5,4-dimethylhydantoin [46], zinc tetrafluoro borate [47].  
 
3.5 Alternative synthetic strategies 
 
One noticeable alternate is the so-called “Atwal modification” of the Biginelli 
reaction. [48-50]. Here, an enone of type  is first condensed with a suitable protected 
urea or thiourea derivative  under almost neutral conditions. Deprotection of the 
resulting 1,4-dihydropyrimidine with hydrochloric acid (HCl) or trifluoroacetic acid 
(TFA) leads to the desired DHPMs.  
Although this method requires prior synthesis of enones, its reliability and 
broad applicability make it an attractive alternative to the traditional one step Biginelli 
condensation. 
 
OR1
O
OR2
Ar-
H
HN
NH2
X
R
NaHCO3
DMF
NH2
R2
OR1
Ar-
O
NH
N
H
R2
OR1
-Ar
X
Odeprotecationa: x=O, R = Me
b: x=O, R = 4-methoxybenzyl
+
Scheme 3.5 (8)
 
 
One other novel approach to DHPMs has been described by Shutalev A. D. et 
al. [51]. This synthesis is based on the condensation of readily available R-tosyl-
substituted thioureas with the (in situ prepared) enolates of acetoacetates or 1,3-
dicarbonyl compounds. The resulting hexahydropyrimidines need not to be isolated 
and can be converted directly into DHPMs.  
This method works particularly well for aliphatic aldehydes and thioureas and 
produces high overall yields of the desired target compounds. 
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The interesting and diverse biological activity of dihydropyrimidines has been 
explored through the generation of libraries of compounds via microwave, solid-
phase, and fluorous-phase technologies. Significant rate and yield enhancements were 
also reported for Biginelli reactions carried out under microwave irradiation [52-54]. 
Kappe C. O. et al. have recently demonstrated that, by using neat polyphosphate ester 
(PPE) as reaction mediator coupled with microwave irradiation, excellent yields of 
variously substituted DHPMs can be obtained.  
The first actual solid-phase modification of the Biginelli condensation was 
reported by Wipf P. et al. in 1995 [55]. In this sequence, amino butyric acid-derived 
urea was attached to wang resin (the wang resin is the most commonly used resin for 
peptides with C-terminal carboxylic acids if a C-terminal amide is desired, the rink) 
using standard procedures. The resulting polymer-bound urea was condensed with 
excess ketoesters and aromatic aldehydes in tetra hydro furan (THF) at 55°C in the 
presence of a catalytic amount of hydrochloric acid (HCl) to afford the corresponding 
immobilized DHPMs. Subsequent cleavage of product from the resin by 50% 
trifluoroacetic acid (TFA) provided DHPMs in high yields and excellent purity.   
 
 Chapter- 3                                                                                                  1,2,3,4-tetrahydro pyrimidines 
 
Studies on Some Organic Compounds of Therapeutic Interest 
43 
H
O
Ar-
HN
NH2
O
O
Si(Rfh)3
O
NH
N
Ar-
OR1
R2
O
CH2
O
1.HCl,THF/BTF,
2.exatracation with FC-72
3.TBAF,THF/BTF
R1O
O O
R2 (10)
Scheme 3.7
Asymmetric Biginelli Reaction
 
 
Several methods have been developed for the asymmetric synthesis of 
enantioenriched dihydropyrimidines. The first of these methods to give synthetically 
useful enantiomeric ratios was reported by Zhu C. et al. in 2005, over one-hundred 
years after discovery of the Biginelli reaction [56]. Zhu C. et al. found that the use of 
chiral ytterbium catalyst allowed for dihydropyrimidines to be synthesized in high 
yield and enantioselectivity. The ytterbium catalyst is recoverable and can be recycled 
several times without diminishing the product. A second protocol for the synthesis of 
enantioenriched dihydropyrimidines was introduced by Gong L. et al. [57]. 
The frontier of the Biginelli reaction will continue to be developed as new 
methods are reported and as the biological importance of this class of compounds is 
explored in greater detail. 
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3.6 Current Work 
 
The chemistry of pyrimidines and its derivatives has been studied for over a 
century due to their diverse biological activities. The 1,2,3,4-tetrahydropyrimidines 
ring system is of special biological interest because it has numerous pharmacological 
and medicinal applications viz:antimicrobial, immunodilator, tuberculosis, antiallergic 
and radioprotective.  
In section-I keeping in mind various biomedical applications and with a view 
to further assess the pharmacological profile of these class of compounds, three novel 
series of 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(substituted phenyl)-1,2,3,4-tetrahydro-
6-methyl-2-oxopyrimidine-5-carboxamide (RHK- 101 to 130) are synthesized. The 
synthesis of (RHK- 101 to 130) was achieved by acid catalysed cyclocondensation of 
N-(substituted)-3-oxobutanamide, substituted urea and 4-(2,4-dinitrophenoxy)- 
benzaldehydes. The products were characterized by FT-IR, mass spectra, 
1
H NMR 
and elemental analyses. The newly synthesized compounds were subjected to various 
biological activities viz., antimicrobial. 
 
In section-II keeping in mind various biomedical applications and with a view 
to further assess the pharmacological profile of these class of compounds, three novel 
series of 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-substitutedphenyl)-1,2,3,4-tetrahydro 
-6-isopropyl-2-oxopyrimidine-5-carboxamide (RHK- 131 to 160) are synthesized. 
The synthesis of (RHK- 131 to 160) was achieved by acid catalysed 
cyclocondensation of N-(substituted phenyl)-4-methyl-3-oxopentanamide, substituted 
urea and 4-(2,4-dinitrophenoxy)benzaldehydes. The products were characterized by 
FT-IR, mass spectra, 
1
H NMR and elemental analyses. The newly synthesized 
compounds were subjected to various biological activities viz., antimicrobial. 
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3.7 Section: - I 
 
3.7.1 Reaction scheme 
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TLC Solvent system Rf1:- Hexane : Ethyl acetate – 6:4, 
                             Rf2:- Chloroform : methanol – 9:1. 
 
 
 
 
 
 
 
 
 
 
 
 
Code R1 M.F. M.W. M.P.
0
C Yield 
% 
Rf1 Rf2 
RHK-101 2-OCH3 C25H21N5O8 519 207           68                        0.48                     0.65                     
RHK-102 3-Cl C24H18ClN5O7 523 217 63 0.53 0.61 
RHK-103 2-F C24H18FN5O7 507 202 59 0.49 0.58 
RHK-104 3-Cl 4-F C24H17ClFN5O7 541 212 70 0.50 0.66 
RHK-105 4-OCH3 C25H21N5O8 519 205 75 0.55 0.70 
RHK-106 4-Cl C24H18ClN5O7 523 224 71 0.41 0.68 
RHK-107 4-CH3 C25H21N5O7 503 201 69 0.59 0.68 
RHK-108 4-F C24H18FN5O7 507 195 55 0.55 0.71 
RHK-109 2-Cl C24H18ClN5O7 523 185 70 0.40 0.75 
RHK-110 H C24H19N5O7 489 235 75 0.55 0.70 
RHK-111 2-OCH3 C25H21N5O7S 535 245 61 0.41 0.69 
RHK-112 3-Cl C24H18ClN5O6S 539 233 58 0.58 0.68 
RHK-113 2-F C24H18FN5O6S 523 211 68 0.58 0.65 
RHK-114 3-Cl 4-F C24H17ClFN5O6S 557 200 79 0.49 0.72 
RHK-115 4-OCH3 C25H21N5O7S 535 213 67 0.57 0.63 
RHK-116 4-Cl C24H18ClN5O6S 539 218 73 0.44 0.64 
RHK-119 2-Cl C24H18ClN5O6S 539 202 80 0.43 0.63 
RHK-120 H C24H19N5O6S 505 255 73 0.50 0.70 
RHK-121 2-OCH3 C26H23N5O8 533 233 80 0.42 0.62 
RHK-122 3-Cl C25H20ClN5O7 537 229 72 0.56 0.66 
RHK-123 2-F C25H20FN5O7 521 224 76 0.48 0.58 
RHK-124 3-Cl 4-F C25H19ClFN5O7 555 219 68 0.52 0.72 
RHK-125 4-OCH3 C26H23N5O8 533 227 82 0.59 0.69 
RHK-126 4-Cl C25H20ClN5O7 537 222 59 0.54 0.64 
RHK-127 4-CH3 C26H23N5O7 517 226 64 0.52 0.72 
RHK-128 4-F C25H20FN5O7 521 197 62 0.44 0.64 
RHK-129 2-Cl C25H20ClN5O7 537 243 74 0.40 0.70 
RHK-130 H C25H21N5O7 503 250 60 0.48 0.68 
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3.7.2 Plausible Reaction Mechanism  
 
The reaction mechanism of pyrimidine formation can be depicted as under: 
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3.7.3 Experimental 
 
3.7.3.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. IR spectra were recorded 
shimadzu FT-IR-8400 instrument using potassium bromide (KBr) pellet method. 
Mass spectra were recorded on shimadzu GC-MS-QP-2010 model using Direct 
Injection Probe technique. 
1
H NMR was determined in DMSO-d6 solution on a bruker 
Ac 400 MHz spectrometer. Elemental analysis of the all the synthesized compounds 
was carried out on elemental vario EL III Carlo erba 1108 model and the results are in 
agreements with the structures assigned. 
 
3.7.3.2 Synthesis of N-(substituted phenyl)-3-oxobutanamides 
 
Syntheses of N-(substituted phenyl)-3-oxobutanamides were achieved using 
previously published methods [58].  
 
3.7.3.3 General procedure for the synthesis of 4-(4-(2,4-dinitrophenoxy)phenyl)-N-
(substituted phenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxopyrimidine-5-carboxamide 
(RHK-101 to110) 
 
A mixture of N-(substituted phenyl)-3-oxobutanamides (0.01 M), 4-(2,4-
dinitrophenoxy)benzaldehydes (0.01 M), urea (0.015 M) and catalytic amount of 
conc. hydrochloric acid (HCl) in ethanol (30 ml) was heated under reflux condition 
for 8 to 10 hrs. The reaction mixture was kept at room temperature for 24 hrs. The 
crystalline product obtained and recrystallized from ethanol. 
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3.7.3.3.1 4-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,4-tetrahydro-N-(2-methoxyphenyl)- 
6-methyl-2-oxopyrimidine-5-carboxamide (RHK-101) 
Yield: 68%; mp 207ºC; Anal. Calcd. for C25H21N5O8: C, 
57.80; H, 4.07; N, 13.48; O, 24.64 Found: C, 57.65; H, 
4.00; N, 13.21; O, 24.29%; IR (cm
-1
): 3410 (N-H 
stretching of amide), 3070 (C-H stretching of aromatic 
ring), 2935 (C-H asymmetrical stretching of CH3 group), 
2900 (C-H symmetrical stretching of CH3 group), 1693 
(C=O stretching of amide), 1693 (C=O stretching of 
cyclic) 1600 (N-H deformation of pyrimidine ring), 1525 (C=C stretching of aromatic 
ring), 1525 (C-NO2 asymmetrical deformation of NO2 group), 1469 (C-H 
asymmetrical deformation of CH3 group), 1344 (C-H symmetrical deformation of 
CH3 group), 1344 (C-N-C stretching vibration of pyrimidine ring), 1344 (C-NO2 
symmetrical deformation of NO2 group), 1278 (C-N stretching), 1247 (C-O-C 
asymmetrical stretching OCH3), 1074 (C-H in plane deformation of aromatic ring), 
1030 (C-O-C symmetrical stretching OCH3) 824 (para-substituted); MS: m/z 519; 
1
H 
NMR (DMSO-d6) δ ppm: 2.19 (s, 3H, Ha), 3.72 (s, 3H, Hb), 5.35 (s, 1H, Hc), 6.84-
6.86 (d, 1H, Hd, J = 7.60 Hz), 6.87-7.14 (m, 3H, He-g), 7.29-7.31 (d, 2H, Hhh’, J = 8.40 
Hz), 7.44 (d, 2H, Hii’), 7.68 (s, 1H, Hj), 7.75-7.78 (d, 1H, Hk, J = 12.00), 8.37 (s, 1H, 
Hl). 
 
3.7.3.3.2 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(3-chlorophenyl)-1,2,3,4-tetrahydro-6- 
methyl-2-oxopyrimidine-5-carboxamide (RHK-102) 
Yield: 63%; mp 217ºC; Anal. Calcd. for C24H18ClN5O7: 
C, 55.02; H, 3.46; Cl, 6.77; N, 13.37; O, 21.38; Found: 
C, 54.96; H, 3.25; Cl, 6.63; N, 13.13; O, 21.22%; MS: 
m/z 523. 
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3.7.3.3.3 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(2-fluorophenyl)-1,2,3,4-tetrahydro-6- 
methyl-2-oxopyrimidine-5-carboxamide (RHK-103) 
Yield: 59%; mp 202ºC; Anal. Calcd. for C24H18FN5O7: 
C, 56.81; H, 3.58; F, 3.74; N, 13.80; O, 22.07; Found: C, 
56.74; H, 3.45; F, 3.67; N, 13.72; O, 22.00%; MS: m/z 
507. 
 
 
 
 
3.7.3.3.4 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(3-chloro-4-fluorophenyl)-1,2,3,4-tetr 
-ahydro-6-methyl-2-oxopyrimidine-5-carboxamide 
(RHK-104) 
Yield: 70%; mp 212ºC; Anal. Calcd. for C24H17ClFN5O7: 
C, 53.20; H, 3.16; Cl, 6.54; F, 3.51; N, 12.92; O, 20.67; 
Found: C, 53.11; H, 3.08; Cl, 6.42; F, 3.43; N, 12.78; O, 
20.56%; MS: m/z 441. 
 
 
 
3.7.3.3.5 4-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,4-tetrahydro-N-(4-methoxyphenyl)- 
6-methyl-2-oxopyrimidine-5-carboxamide (RHK-105) 
Yield: 75%; mp 205ºC; Anal. Calcd. for C25H21N5O8: C, 
57.80; H, 4.07; N, 13.48; O, 24.64; Found: C, 57.71; H, 
4.01; N, 13.32; O, 24.52%; MS: m/z 519. 
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3.7.3.3.6 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-chlorophenyl)-1,2,3,4-tetrahydro-6- 
methyl-2-oxopyrimidine-5-carboxamide (RHK-106) 
Yield: 71%; mp 224ºC; Anal. Calcd. for C24H18ClN5O7: 
C, 55.02; H, 3.46; Cl, 6.77; N, 13.37; O, 21.38; Found: 
C, 55.00; H, 3.35; Cl, 6.61; N, 13.23; O, 21.22%; IR (cm
-
1
): 3311 (N-H stretching of amide), 3101 (C-H stretching 
of aromatic ring), 2945 (C-H asymmetrical stretching of 
CH3 group), 2945 (C-H symmetrical stretching of CH3 
group), 1703 (C=O stretching of amide), 1681 (C=O 
stretching of cyclic) 1589 (N-H deformation of pyrimidine ring), 1531 (C=C 
stretching of aromatic ring), 1531 (C-NO2 asymmetrical deformation of NO2 group), 
1438 (C-H asymmetrical deformation of CH3 group), 1398 (C-H symmetrical 
deformation of CH3 group), 1342 (C-NO2 symmetrical deformation of NO2 group), 
1342 (C-N-C stretching vibration of pyrimidine ring), 1240 (C-N stretching), 1089 
(C-H in plane deformation of aromatic ring), 824 (para-substituted), 761 (C-H in out 
plane deformation of aromatic ring), 709 (C-Cl stretching) ; MS: m/z 523; 
1
H NMR 
(DMSO-d6) δ ppm: 2.02 (s, 3H, Ha), 5.43 (s, 1H, Hb), 6.96-6.99 (d, 1H, Hc, J = 
9.20Hz),  7.10  (s, 1H, Hd), 7.14-7.17 (m, 1H, He), 7.26-7.28 (d, 3H, Hfh J = 8.80Hz), 
7.51-7.54 (m, 3H, Hi-k, J = 12.40Hz), 7.67 (s, 1H, Hl), 8.20-8.23 (m, 1H, Hm, J = 
12.00Hz), 8.82 (s, 1H, Hn), 8.86 (s, 1H,  Ho), 9.70 (s, 1H, Hp). 
 
3.7.3.3.7 4-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-p- 
tolylpyrimidine-5-carboxamide (RHK-107) 
Yield: 69%; mp 201ºC; Anal. Calcd. for C25H21N5O7: C, 
59.64; H, 4.20; N, 13.91; O, 22.25; Found: C, 59.54; H, 
4.11; N, 13.75; O, 22.14%; MS: m/z 503. 
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3.7.3.3.8 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-fluorophenyl)-1,2,3,4-tetrahydro-6- 
methyl-2-oxopyrimidine-5-carboxamide (RHK-108) 
Yield: 55%; mp 195ºC; Anal. Calcd. for C24H18FN5O7: 
C, 56.81; H, 3.58; F, 3.74; N, 13.80; O, 22.07; Found: C, 
56.77; H, 3.44; F, 3.65; N, 13.71; O, 22.00%; IR (cm
-1
): 
3410 (N-H stretching of amide), 3070 (C-H stretching of 
aromatic ring), 2935 (C-H asymmetrical stretching of 
CH3 group), 2830 (C-H symmetrical stretching of CH3 
group), 1710 (C=O stretching of amide), 1670 (C=O 
stretching of cyclic) 1608 (N-H deformation of pyrimidine ring), 1521 (C=C 
stretching of aromatic ring), 1521 (C-NO2 asymmetrical deformation of NO2 group), 
1456 (C-H asymmetrical deformation of CH3 group), 1344 (C-H symmetrical 
deformation of CH3 group), 1313 (C-NO2 symmetrical deformation of NO2 group), 
1313 (C-N-C stretching vibration of pyrimidine ring), 1244 (C-N stretching), 1089 
(C-H in plane deformation of aromatic ring), 1012 (C-F stretching), 810 (para-
substituted), 744 (C-H in out plane deformation of aromatic ring); MS: m/z 503; 
1
H 
NMR (DMSO-d6) δ ppm: 2.06 (s, 3H, Ha), 5.42-5.43 (s, 1H, Hb), 7.07-7.11 (m, 3H, 
Hc-e), 7.24-7.26 (d, 2H, Hff’, J = 8.80Hz), 7.40-7.42 (d, 2H, Hgg’ J = 8.40Hz), 7.54-
7.57 (m, 3H, Hhh’), 7.68 (s, 1H, Hi), 8.43-8.46 (m, 1H, Hj, J = 12.00Hz), 8.81 (m, 1H, 
Hk), 8.88-8.89 (d, 1H, Hl, J = 2.80Hz), 9.65 (s, 1H, Hm). 
 
3.7.3.3.9 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(2-chlorophenyl)-1,2,3,4-tetrahydro-6- 
methyl-2-oxopyrimidine-5-carboxamide (RHK-109) 
Yield: 70%; mp 185ºC; Anal. Calcd. for C24H18ClN5O7 
C, 55.02; H, 3.46; Cl, 6.77; N, 13.37; O, 21.38; Found: 
C, 54.89; H, 3.35; Cl, 6.54; N, 13.26; O, 21.22%; MS:  
m/z 523. 
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3.7.3.3.10 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(3-chlorophenyl)-1,2,3,4-tetrahydro- 
6-methyl-2-oxopyrimidine-5-carboxamide (RHK-110) 
Yield: 75%; mp 235ºC; Anal. Calcd. for C24H19N5O7: C, 
58.90; H, 3.91; N, 14.31; O, 22.88; Found: C, 58.79; H, 
3.81; N, 14.21; O, 22.74%; MS: m/z 489. 
 
 
 
 
  
3.7.3.4 General procedure for the synthesis of 4-(4-(2,4-dinitrophenoxy)phenyl)-N-
(substituted phenyl)-1,2,3,4-tetrahydro-6-methyl-2-thioxopyrimidine-5-carboxamide 
(RHK-111 to120) 
 
A mixture of N-(substituted phenyl)-3-oxobutanamides (0.01 M), 4-(2,4-
dinitrophenoxy)benzaldehydes (0.01 M), thiourea (0.015 M) and catalytic amount of 
conc. acid in ethanol (30 ml) was heated under reflux condition for 11 to 12 hrs. The 
reaction mixture was kept at room temperature for 24 hrs. The crystalline product 
obtained and recrystallized from ethanol. 
 
3.7.3.4.1 4-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,4-tetrahydro-N-(2-methoxyphenyl)- 
6-methyl-2-thioxopyrimidine-5-carboxamide       
 (RHK-111) 
Yield: 61%; mp 245ºC; Anal. Calcd. for C25H21N5O8: C, 
56.07; H, 3.95; N, 13.08; O, 20.91; S, 5.99; Found: C, 
56.00; H, 3.85; N, 13.01; O, 20.81; S, 5.86%; MS: m/z 
535. 
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3.7.3.4.2 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(3-chlorophenyl)-1,2,3,4-tetrahydro-6- 
methyl-2-thioxopyrimidine-5-carboxamide (RHK-112) 
Yield: 58%; mp 233ºC; Anal. Calcd. for C24H18ClN5O6S: 
C, 53.28; H, 3.26; Cl, 6.46; N, 12.88; O, 17.71; S, 5.82; 
Found: C, 54.96; H, 3.25; Cl, 6.63; N, 13.13; O, 21.22%; 
IR (cm
-1
): 3363 (N-H stretching of amide), 3109 (C-H 
stretching of aromatic ring), 2955 (C-H asymmetrical 
stretching of CH3 group), 2871 (C-H symmetrical 
stretching of CH3 group), 1703 (C=O stretching of 
amide), 1662 (N-H deformation of pyrimidine ring), 1597 (C=C stretching of 
aromatic ring), 1523 (C-NO2 asymmetrical deformation of NO2 group), 1423 (C-H 
asymmetrical deformation of CH3 group), 1342 (C-H symmetrical deformation of 
CH3 group), 1342 (C-N-C stretching vibration of pyrimidine ring), 1269  (C-NO2 
symmetrical deformation of NO2 group), 1246 (C-N stretching), 1163 (C=S stretching 
of cyclic), 1070 (C-H in plane deformation of aromatic ring), 833 (para-substituted), 
777 (C-H in out plane deformation of aromatic ring), 677 (C-Cl stretching) ; MS: m/z 
523; 
1
H NMR (DMSO-d6) δ ppm: 2.10 (s, 3H, Ha), 5.43-5.44 (s, 1H, Hb), 7.07-7.10 
(m, 1H, Hc, J = 9.20Hz), 7.12-7.14 (d, 1H, Hd), 7.27-7.32 (m, 3H, He-g), 7.38-7.40 (d, 
2H, Hhh’ J = 8.40Hz), 7.45-7.47 (d, 1H, Hi, J = 9.20Hz), 7.75-7.76 (s, 1H, Hj), 8.43-
8.46 (m, 1H, Hk, J = 12.00Hz), 8.88-8.89 (s, 1H, Hl), 9.57 (s, 1H, Hm) 9.93 (s, 1H, 
Hn), 10.13 (s,1H,Ho).  
 
3.7.3.4.3 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(2-fluorophenyl)-1,2,3,4-tetrahydro-6- 
methyl-2-thioxopyrimidine-5-carboxamide (RHK-113) 
Yield: 68%; mp 211ºC; Anal. Calcd. for C24H18FN5O6S : 
C, 55.00; H, 3.34; F, 3.55; N, 13.25; O, 18.23; S, 6.04; 
Found: C, 56.74; H, 3.45; F, 3.67; N, 13.72; O, 22.00%; 
MS: m/z 507. 
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3.7.3.4.4 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(3-chloro-4-fluorophenyl)-1,2,3,4-tetr- 
ahydro-6-methyl-2-thioxopyrimidine-5-carboxamide 
(RHK-114) 
Yield: 79%; mp 200ºC; Anal. Calcd. for 
C24H17ClFN5O6S: C, 51.66; H, 3.07; Cl, 6.35; F, 3.41; N, 
12.55; O, 17.21; S, 5.75; Found: C, 51.56; H, 3.00; Cl, 
6.24; F, 3.32; N, 12.42; O, 17.11; S, 5.66%; MS: m/z 
557. 
 
 
3.7.3.4.5 4-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,4-tetrahydro-N-(4-methoxyphenyl)- 
6-methyl-2-thioxopyrimidine-5-carboxamide             
(RHK-115) 
Yield: 67%; mp 213ºC; Anal. Calcd. for C25H21N5O7S: 
C, 56.07; H, 3.95; N, 13.08; O, 20.91; S, 5.99; Found: C, 
56.00; H, 3.84; N, 13.01; O, 20.82; S, 5.87 %; MS: m/z 
535. 
 
 
 
3.7.3.4.6 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-chlorophenyl)-1,2,3,4-tetrahydro-6- 
methyl-2-thioxopyrimidine-5-carboxamide (RHK-116) 
Yield: 74%; mp 218ºC; Anal. Calcd. for C24H18ClN5O6S: 
C, 53.39; H, 3.36; Cl, 6.57; N, 12.97; O, 17.78; S, 5.94; 
Found: C, 53.27; H, 3.28; Cl, 6.49; N, 12.88; O, 17.65; 
S, 5.86%; MS: m/z 539. 
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3.7.3.4.7 4-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,4-tetrahydro-6-methyl-2-thioxo-N- 
p-tolylpyrimidine-5-carboxamide (RHK-117) 
Yield: 71%; mp 203ºC; Anal. Calcd. for C25H21N5O6S: 
C, 57.80; H, 4.07; N, 13.48; O, 18.48; S, 6.17; Found: C, 
57.71; H, 4.00; N, 13.33; O, 18.34; S, 6.11%; IR (cm
-1
): 
3377 (N-H stretching of amide), 3109 (C-H stretching of 
aromatic ring), 2949 (C-H asymmetrical stretching of 
CH3 group), 2844 (C-H symmetrical stretching of CH3 
group), 1680 (C=O stretching of amide), 1600 (N-H 
deformation of pyrimidine ring), 1589 and 1521 (C=C stretching of aromatic ring), 
1521 (C-NO2 asymmetrical deformation of NO2 group), 1467 (C-H asymmetrical 
deformation of CH3 group), 1344 (C-H symmetrical deformation of CH3 group), 1344 
(C-N-C stretching vibration of pyrimidine ring), 1344 (C-NO2 symmetrical 
deformation of NO2 group), 1267 (C-N stretching), 1192 (C=S stretching of cyclic), 
1111 (C-H in plane deformation of aromatic ring), 817 (para-substituted), 740 (C-H in 
out plane deformation of aromatic ring); MS: m/z 519; 
1
H NMR (DMSO-d6) δ ppm: 
2.08 (s, 3H, Ha), 2.22 (s, 3H, Hb), 5.42 (s, 1H, Hc,), 7.05-7.08 (d, 2H, Hdd’, J = 
8.40Hz), 7.10-7.13 (d, 1H, He, J = 9.2Hz), 7.26-7.29 (d, 2H, Hff’ J = 8.80Hz), 7.39-
7.44 (m, 4H, Hg-g’,h-h’), 8.41-8.45 (m, 1H, Hi), 8.88-8.89 (s, 1H, Hj), 9.49 (s, 1H, Hk), 
9.68 (s, 1H,  Hl), 10.05 (s, 1H, Hm). 
 
3.7.3.4.8 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-fluorophenyl)-1,2,3,4-tetrahydro-6- 
methyl-2-thioxopyrimidine-5-carboxamide (RHK-118) 
Yield: 65%; mp 213ºC; Anal. Calcd. for C24H18FN5O7: 
C, 56.81; H, 3.58; F, 3.74; N, 13.80; O, 22.07; Found: C, 
56.77; H, 3.44; F, 3.65; N, 13.71; O, 22.00%; IR (cm
-1
): 
3246 (N-H stretching of amide), 3115 (C-H stretching of 
aromatic ring), 2902 (C-H asymmetrical stretching of 
CH3 group), 2842 (C-H symmetrical stretching of CH3 
group), 1676 (C=O stretching of amide), 1606 (N-H 
deformation of pyrimidine ring), 1562 (C=C stretching of aromatic ring), 1512 (C-H 
asymmetrical deformation of CH3 group), 1512 (C-NO2 asymmetrical deformation of 
NO2 group), 1469 (C-H symmetrical deformation of CH3 group), 1342 (C-N-C 
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stretching vibration of pyrimidine ring), 1342  (C-NO2 symmetrical deformation of 
NO2 group), 1269 (C-N stretching), 1201 (C=S stretching of cyclic), 1064 (C-H in 
plane deformation of aromatic ring), 1016 (C-F stretching),  827 (para-substituted), 
777 (C-H in out plane deformation of aromatic ring); MS: m/z 523; 
1
H NMR (DMSO-
d6) δ ppm: 2.09 (s, 3H, Ha), 5.42-5.43 (s, 1H, Hb), 7.12-7.14 (m, 3H, Hc-e, J = 9.2), 
7.27-7.29 (d, 2H, Hff’, J = 8.40Hz), 7.39-7.41 (d, 2H, Hgg’, J = 8.4Hz), 7.54-7.58 (m, 
2H, Hhi, J = 14.00Hz), 8.44-8.47 (m, 4H, Hg-g’,h-h’), 8.41-8.45 (d, 1H, Hj), 8.88-8.89 (s, 
1H, Hk), 9.53 (s, 1H, Hl), 9.82 (s, 1H,  Hm), 10.08 (s, 1H, Hn). 
 
3.7.3.4.9 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(2-chlorophenyl)-1,2,3,4-tetrahydro-6- 
methyl-2-thioxopyrimidine-5-carboxamide (RHK-119) 
Yield: 73%; mp 202ºC; Anal. Calcd. for 
C24H18ClN5O6S: C, 53.39; H, 3.36; Cl, 6.57; N, 12.97; 
O, 17.78; S, 5.94; Found: C, 53.28; H, 3.29; Cl, 6.46; N, 
12.84; O, 17.70; S, 5.88%; MS:  m/z 539. 
 
 
 
 
3.7.3.4.10 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(3-chlorophenyl)-1,2,3,4-tetrahydro- 
6-methyl-2-thioxopyrimidine-5-carboxamide  
(RHK-120) 
Yield: 80%; mp 255 ºC; Anal. Calcd. for C24H19N5O6S: 
C, 57.02; H, 3.79; N, 13.85; O, 18.99; S, 6.34; Found: C, 
56.86; H, 3.67; N, 13.75; O, 18.88; S, 6.22%; MS: m/z 
505. 
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3.7.3.5 General procedure for the synthesis of 6-(4-(2,4-dinitrophenoxy)phenyl)-N-  
(substituted  phenyl)-1,2,3,6-tetrahydro-1,4-dimethyl-2-oxopyrimidine-5-carbox- 
amide (RHK-121 to130) 
 
A mixture of N-(substituted phenyl)-3-oxobutanamides (0.01 M), 4-(2,4-
dinitrophenoxy)benzaldehydes (0.01 M), N-methyl urea (0.015 M) and catalytic 
amount of conc. acid in ethanol (30 ml) was heated under reflux condition for 12 to 
13 hrs. The reaction mixture was kept at room temperature for 24 hrs. The crystalline 
product obtained and recrystallized from ethanol. 
 
3.7.3.5.1 6-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,6-tetrahydro-N-(2-methoxyphenyl)  
-1,4-dimethyl-2-oxopyrimidine-5-carboxamide     
(RHK-121) 
Yield: 72%; mp 233ºC; Anal. Calcd. for C26H23ClN5O8: 
C, 58.54; H, 4.35; N, 13.13; O, 23.99; Found: C, 58.46; 
H, 4.26; N, 13.06; O, 23.92%; MS: m/z 533. 
 
 
 
 
3.7.3.5.2 6-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,6-tetrahydro-N-(3-chlorophenyl)- 
1,4-dimethyl-2-oxopyrimidine-5-carboxamide 
 (RHK-122) 
Yield: 76%; mp 229ºC; Anal. Calcd. for C25H20ClN5O7: 
C, 55.82; H, 3.75; Cl, 6.59; N, 13.02; O, 20.82; Found: , 
55.76; H, 3.68; Cl, 6.50; N, 13.00; O, 20.68%; MS: m/z 
537. 
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3.7.3.5.3 6-(4-(2,4-dinitrophenoxy)phenyl)-N-(2-flurophenyl)-1,2,3,6-tetrahydro- 
1,4-dimethyl-2-oxopyrimidine-5-carboxamide       
(RHK-123) 
Yield: 59%; mp 202ºC; Anal. Calcd. for C24H18FN5O7: 
C, 56.81; H, 3.58; F, 3.74; N, 13.80; O, 22.07; Found: C, 
56.74; H, 3.45; F, 3.67; N, 13.72; O, 22.00%; MS: m/z 
507. 
 
 
 
3.7.3.5.4 6-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-chloro-3-fluorophenyl)-1,2,3,6-tetr- 
ahydro-1,4-dimethyl-2-oxopyrimidine-5-carboxamide  
(RHK-124) 
Yield: 68%; mp 224ºC;
 
Anal. Calcd. for C25H19ClFN5O7: 
C, 54.01; H, 3.45; Cl, 6.38; F, 3.42; N, 12.60; O, 20.15; 
Found: C, 54.00; H, 3.33; Cl, 6.27; F, 3.35; N, 12.51; O, 
20.02%; IR (cm
-1
): 3315 (N-H stretching of amide), 3070 
(C-H stretching of aromatic ring), 2923 (C-H 
asymmetrical stretching of CH3 group), 2868 (C-H 
symmetrical stretching of CH3 group), 1660 (C=O stretching of amide), 1600 (C=O 
stretching of cyclic) 1600 (N-H deformation of pyrimidine ring), 1529 (C=C 
stretching of aromatic ring), 1529 (C-NO2 asymmetrical deformation of NO2 group), 
1491 (C-H asymmetrical deformation of CH3 group), 1406 (C-H symmetrical 
deformation of CH3 group), 1344 (C-N-C stretching vibration of pyrimidine ring), 
1344 (C-NO2 symmetrical deformation of NO2 group), 1267 (C-N stretching), 1163 
(C-F stretching), 1062 (C-H in plane deformation of aromatic ring), 835 (para-
substituted), 736 (C-H in out plane deformation of aromatic ring), 653 and 526 (C-Cl 
stretching); MS: m/z 555;
 1
H NMR (DMSO-d6) δ ppm: 2.19 (s, 3H, Ha), 3.09 (s, 3H, 
Hb), 5.31-5.32 (s, 1H, Hc), 7.08-7.10  (d, 1H, Hd, J = 9.20Hz), 7.23-7.32 (d, 2H, He-e’, 
J = 8.80Hz), 7.34-7.36 (d, 1H, Hf,J = 9.20Hz), 7.37-7.39 (m, 1H, Hg-g’, J = 8.80Hz), 
7.47-7.51(m, 1H, Hh), 7.88-7.90 (m, 2H, Hij, J = 9.20Hz), 8.43-8.46 (m, 1H, Hk), 
8.88-8.89 (d, 1H,  Hl, J = 2.80Hz), 10.07 (s, 1H, Hm). 
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3.7.3.5.5 6-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,6-tetrahydro-N-(4-methoxyphenyl)- 
1,4-dimethyl-2-oxopyrimidine-5-carboxamide       
(RHK-125) 
Yield: 59%; mp 227ºC; Anal. Calcd. for C26H23N5O8: C, 
58.54; H, 4.35; N, 13.13; O, 23.99; Found: C, 58.42; H, 
4.24; N, 13.00; O, 23.87%; MS: m/z 533. 
 
 
 
 
3.7.3.5.6 6-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,6-tetrahydro-N-(4-chlorophenyl)- 
1,4-dimethyl-2-oxopyrimidine-5-carboxamide       
(RHK-126) 
Yield: 64%; mp 222ºC; Anal. Calcd. for C25H20ClN5O7: 
C, 55.82; H, 3.75; Cl, 6.59; N, 13.02; O, 20.82; Found: 
C, 55.78; H, 3.66; Cl, 6.46; N, 13.00; O, 20.68%; MS: 
m/z 537. 
 
 
 
3.7.3.5.7 6-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,6-tetrahydro-1,4-dimethyl-2-oxo-N- 
p-tolylpyrimidine-5-carboxamide (RHK-127) 
Yield: 62%; mp 226 ºC; Anal. Calcd. for C26H23N5O7: C, 
60.34; H, 4.48; N, 13.53; O, 21.64; Found: C, 60.28; H, 
4.44; N, 13.43; O, 21.60%; IR (cm
-1
): 3425 (N-H 
stretching of amide), 3097 (C-H stretching of aromatic 
ring), 2947 (C-H asymmetrical stretching of CH3 group), 
2892 (C-H symmetrical stretching of CH3 group), 1695 
(C=O stretching of amide), 1635 (C=O stretching of 
cyclic) 1597 (N-H deformation of pyrimidine ring), 1529 
(C=C stretching of aromatic ring), 1529 (C-NO2 asymmetrical deformation of NO2 
group), 1489 (C-H asymmetrical deformation of CH3 group), 1409 (C-H symmetrical 
deformation of CH3 group), 1346 (C-N-C stretching vibration of pyrimidine ring), 
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1346 (C-NO2 symmetrical deformation of NO2 group), 1273 (C-N stretching), 1072 
(C-H in plane deformation of aromatic ring), 827 (para-substituted), 748 (C-H in out 
plane deformation of aromatic ring); MS: m/z 517;
 1
H NMR (DMSO-d6) δ ppm: 2.08 
(s, 3H, Ha), 2.22 (s, 3H, Hb), 3.45 (s, 3H, Hc), 5.42-5.43  (s, 1H, Hd), 7.07-7.11 (m, 
2H, Hef), 7.24-7.26 (d, 2H, Hg-g’, J = 8.80Hz), 7.40-7.42 (d, 2H, Hh-h’, J = 8.40Hz), 
7.54-7.57 (d, 2H, Hi-i’, J = 14.00), 7.68 (s, 1H, Hj) 8.43-8.46 (m, 1H, Hk, J = 12.00), 
8.81 (s, 1H, Hm), 8.88-8.89 (d, 1H, Hl, J = 2.80Hz), 10.07 (s, 1H, Hm). 
 
3.7.3.5.8 6-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-fluorophenyl)-1,2,3,6-tetrahydro- 
1,4-dimethyl-2-oxopyrimidine-5-carboxamide       
(RHK-128) 
Yield: 74%; mp 197ºC; Anal. Calcd. for C25H20FN5O7: 
C, 57.58; H, 3.87; F, 3.64; N, 13.43; O, 21.48; Found: C, 
57.46; H, 3.75; F, 3.55; N, 13.35; O, 21.32%; IR (cm
-1
): 
3284 (N-H stretching of amide), 3053 (C-H stretching of 
aromatic ring), 2952 (C-H asymmetrical stretching of 
CH3 group), 2844 (C-H symmetrical stretching of CH3 
group), 1676 (C=O stretching of amide), 1693 (C=O stretching of cyclic) 1599 (N-H 
deformation of pyrimidine ring), 1539 (C=C stretching of aromatic ring), 1539 (C-
NO2 asymmetrical deformation of NO2 group), 1411 (C-H asymmetrical deformation 
of CH3 group), 1346 (C-H symmetrical deformation of CH3 group), 1346 (C-N-C 
stretching vibration of pyrimidine ring), 1265 (C-NO2 symmetrical deformation of 
NO2 group), 1265 (C-N stretching), 1161 (C-F stretching), 1068 (C-H in plane 
deformation of aromatic ring), 829 (para-substituted), 663 (C-F stretching); MS: m/z 
521; 
1
H NMR (DMSO-d6) δ ppm: 2.19 (s, 3H, Ha), 3.09 (s, 3H, Hb), 5.40 (m, 1H, Hc), 
7.08-7.14 (m, 3H, Hd-f), 7.27-7.30 (d, 2H, Hgg’ J = 11.20Hz), 7.39-7.41 (d, 2H, Hhh’ J 
= 8.00Hz), 7.54-7.58 (m, 1H, Hi J = 4.80Hz), 8.44-8.47 (m, 1H, Hj, J = 12.00Hz), 
8.88-8.89 (d, 1H, Hk, J = 2.80Hz), 9.53 (s, 1H, Hl,), 9.82 (s, 1H, Hm), 10.07 (s, 1H, 
Hn). 
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3.7.3.5.9 6-(4-(2,4-dinitrophenoxy)phenyl)-N-(2-chlorophenyl)-1,2,3,6-tetrahydro- 
1,4-dimethyl-2-oxopyrimidine-5-carboxamide       
(RHK-129) 
Yield: 60%; mp 243ºC; Anal. Calcd. for C25H20ClN5O7: 
C, 55.82; H, 3.75; Cl, 6.59; N, 13.02; O, 20.82; Found: 
C, 55.75; H, 3.67; Cl, 6.46; N, 13.00; O, 20.75%; MS:  
m/z 537. 
 
 
 
3.7.3.5.10 6-(4-(2,4-dinitrophenoxy)phenyl)-N-(phenyl)-1,2,3,6-tetrahydro-1,4-di- 
methyl-2-oxopyrimidine-5-carboxamide  (RHK-130) 
Yield: 68%; mp 250ºC; Anal. Calcd. for C25H21N5O7: C, 
58.90; H, 3.91; N, 14.31; O, 22.88; Found: C, 58.79; H, 
3.81; N, 14.21; O, 22.74%; MS: m/z 503. 
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3.8 Section: - II 
 
3.8.1 Reaction scheme 
R
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Code R1 M.F. M.W. M.P.
0
C Yield 
% 
Rf1 Rf2 
RHK-131 2-OCH3 C27H25N5O8 547 223           69                        0.47                     0.66                     
RHK-132 3-Cl C26H22ClN5O7 551 219 65 0.52 0.62 
RHK-133 2-F C26H22FN5O7 535 210 70 0.48 0.54 
RHK-134 3-Cl 4-F C26H21ClFN5O7 569 201 75 0.49 0.65 
RHK-135 4-OCH3 C27H25N5O8 543 198 71 0.54 0.71 
RHK-136 4-Cl C26H22ClN5O7 551 220 72 0.43 0.65 
RHK-137 4-CH3 C27H25N5O7 531 200 69 0.55 0.63 
RHK-138 4-F C26H22FN5O7 535 199 59 0.54 0.76 
RHK-139 2-Cl C26H22ClN5O7 551 195 72 0.44 0.73 
RHK-140 H C26H23N5O7 517 232 74 0.52 0.72 
RHK-141 2-OCH3 C27H25N5O7S 563 241 66 0.43 0.69 
RHK-142 3-Cl C26H22ClN5O6S 567 232 59 0.57 0.67 
RHK-143 2-F C26H22FN5O6S 551 201 63 0.56 0.63 
RHK-144 3-Cl 4-F C26H21ClFN5O6S 585 222 75 0.47 0.71 
RHK-145 4-OCH3 C27H25N5O7S 563 212 64 0.58 0.60 
RHK-146 4-Cl C26H22ClN5O6S 567 219 74 0.43 0.62 
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TLC Solvent system Rf1:- Hexane : Ethyl acetate – 6:4, 
                             Rf2:- Chloroform : methanol – 9:1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RHK-147 4-CH3 C27H25N5O6S 547 206 71 0.52 0.75 
RHK-148 4-F C26H22FN5O6S 551 223 60 0.44 0.65 
RHK-149 2-Cl C26H22ClN5O6S 567 241 70 0.43 0.63 
RHK-150 H C26H23N5O6S 533 250 81 0.50 0.70 
RHK-151 2-OCH3 C28H27N5O8 561 230 77 0.46 0.63 
RHK-152 3-Cl C27H24ClN5O7 565 218 76 0.53 0.65 
RHK-153 2-F C27H24FN5O7 549 216 68 0.47 0.55 
RHK-154 3-Cl 4-F C27H23ClFN5O7 583 227 59 0.53 0.70 
RHK-155 4-OCH3 C28H27N5O8 561 229 64 0.58 0.65 
RHK-156 4-Cl C27H24ClN5O7 565 218 61 0.52 0.62 
RHK-157 4-CH3 C28H27N5O7 545 220 62 0.53 0.70 
RHK-158 4-F C27H24FN5O7 549 200 74 0.44 0.62 
RHK-159 2-Cl C27H24ClN5O7 565 241 60 0.49 0.71 
RHK-160 H C27H25N5O7 531 249 70 0.42 0.63 
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3.8.2 Plausible Reaction Mechanism  
 
The reaction mechanism of pyrimidine formation can be depicted as under: 
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+
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3.8.3 Experimental 
 
3.8.3.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. IR spectra were recorded 
shimadzu FT-IR-8400 instrument using potassium bromide (KBr) pellet method. 
Mass spectra were recorded on shimadzu GC-MS-QP-2010 model using direct 
injection probe technique. 
1
H NMR was determined in DMSO-d6 solution on a bruker 
Ac 400 MHz spectrometer. Elemental analyses of the all the synthesized compounds 
were carried out on elemental vario EL III carlo erba 1108 model and the results are 
in agreements with the structures assigned. 
 
3.8.3.2 Synthesis of N-(substituted phenyl)-4-methyl-3-oxopentanamide  
 
Synthesis of N-(substituted phenyl)-4-methyl-3-oxopentanamide were 
achieved using previously published methods [60].  
 
3.8.3.3 General procedure for the synthesis of 4-(4-(2,4-dinitrophenoxy)phenyl)-N-
(4-substitutedphenyl)-1,2,3,4-tetrahydro-6-isopropyl-2-oxopyrimidine-5-carbox- 
amide  (RHK-131 to140) 
 
A mixture of N-(substituted phenyl)-4-methyl-3-oxopentanamide (0.01 M), 4-
(2,4-dinitrophenoxy)benzaldehydes (0.01 M), urea (0.015 M) and catalytic amount of 
conc. hydrochloric  acid in ethanol (30 ml) was heated under reflux condition for 8 to 
10 hrs. The reaction mixture was kept at room temperature for 24 hrs. The crystalline 
product obtained and recrystallized from ethanol. 
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3.8.3.3.1 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(2-methoxyphenyl)-1,2,3,4-tetrahydro- 
6-isopropyl-2-oxopyrimidine-5-carboxamide       
(RHK-131) 
Yield: 69%; mp 223ºC; MS: m/z 547; Anal. Calcd. for 
C27H25N5O8: C, 59.23; H, 4.60; N, 12.79; O, 23.38; 
Found: C, 59.11; H, 4.51; N, 12.70; O, 23.31%; MS: m/z 
547. 
 
 
 
3.8.3.3.2 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(3-chlorophenyl)-1,2,3,4-tetrahydro-6- 
isopropyl-2-oxopyrimidine-5-carboxamide (RHK-132) 
Yield: 65%; mp 219ºC; Anal. Calcd. for C26H22ClN5O7: 
C, 56.58; H, 4.02; Cl, 6.42; N, 12.69; O, 20.29; Found: 
C, 56.45; H, 4.00; Cl, 6.36; N, 12.55; O, 20.12%; IR (cm
-
1
): 3425 (N-H stretching of amide), 3107 (C-H stretching 
of aromatic ring), 2951 (C-H asymmetrical stretching of 
CH3 group), 2887 (C-H symmetrical stretching of CH3 
group), 1653 (C=O stretching of amide), 1589 (C=O 
stretching of cyclic) 1589 (N-H deformation of 
pyrimidine ring), 1529 (C=C stretching of aromatic ring), 1529 (C-NO2 asymmetrical 
deformation of NO2 group), 1479 (C-H asymmetrical deformation of CH3 group), 
1417 (C-H symmetrical deformation of CH3 group), 1346 (C-N-C stretching vibration 
of pyrimidine ring), 1305  (C-NO2 symmetrical deformation of NO2 group), 1287 (C-
O-C stretching), 1278 (C-N stretching), 1068 (C-H in plane deformation of aromatic 
ring), 837 (para-substituted), 786 (C-H in out plane deformation of aromatic ring), 
671 (C-Cl stretching); MS: m/z 551; 
1
H NMR (DMSO-d6) δ ppm: 1.48 (s, 3H, Ha), 
1.58 (s, 1H, Hb), 3.87 (s, 1H, Hc),  4.82-4.83  (s, 1H, Hd), 7.13-7.15 (d, 1H, He, J = 
6.80Hz), 7.15 (d, 1H, Hf), 7.21-7.22 (d, 2H, Hg, J = 4.80Hz), 7.27-7.30 (d, 2H, Hhh’, J 
= 8.80Hz), 7.35-7.39 (m, 1H, Hi), 7.44-7.47 (d, 2H, Hjj’, J = 8.80Hz), 7.48-7.51 (d, 
1H, Hk, J = 9.20Hz), 7.83-7.84 (d, 1H,  Hl, J = 4.00Hz), 7.91 (s, 1H, Hm), 8.47-8.50 
(m, 1H, Hn, J = 12.00), 8.90 (d, 1H, Ho), 10.08 (s, 1H, Hp).  
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 3.8.3.3.3 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(2-flurophenyl)-1,2,3,4-tetrahydro-6- 
isopropyl-2-oxopyrimidine-5-carboxamide (RHK-133) 
Yield: 70%; mp 210ºC; Anal. Calcd. for C26H22FN5O7: 
C, 58.32; H, 4.14; F, 3.55; N, 13.08; O, 20.92; Found: C, 
58.16; H, 4.09; F, 3.35; N, 13.00; O, 20.85%; MS: m/z 
535. 
 
 
 
 
3.8.3.3.4 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(3-chloro 4-flurophenyl)-1,2,3,4-tetra  
-hydro-6-isopropyl-2-oxopyrimidine-5-carboxamide 
(RHK-134) 
Yield: 75%; mp 207ºC; Anal. Calcd. For 
C26H21ClFN5O7: C, 54.79; H, 3.71; Cl, 6.22; F, 3.33; N, 
12.29; O, 19.65; Found: C, 54.64; H, 3.62; Cl, 6.14; F, 
3.24; N, 12.22; O, 19.51% IR (cm
-1
): 3439(N-H 
stretching of amide), 3013 (C-H stretching of aromatic 
ring), 2985 (C-H asymmetrical stretching of CH3 group), 
2855 (C-H symmetrical stretching of CH3 group), 1651 
(C=O stretching of amide), 1597 (C=O stretching of cyclic) 1597 (N-H deformation 
of pyrimidine ring), 1529 (C=C stretching of aromatic ring), 1529 (C-NO2 
asymmetrical deformation of NO2 group), 1475 (C-H asymmetrical deformation of 
CH3 group), 1406 (C-H symmetrical deformation of CH3 group), 1346 (C-N-C 
stretching vibration of pyrimidine ring), 1274 (C-NO2 symmetrical deformation of 
NO2 group), 1274 (C-N stretching), 1134 (C-F stretching), 1064 (C-H in plane 
deformation of aromatic ring), 835 (para-substituted), 777 (C-H in out plane 
deformation of aromatic ring), 682 and 592 (C-Cl stretching); MS: m/z 569;  
1
H NMR 
(DMSO-d6) δ ppm: 1.47 (s, 3H, Ha), 1.58 (s, 1H, Hb), 3.85 (s, 1H, Hc),  4.83-4.84  (s, 
1H, Hd), 7.09-7.11 (d, 1H, He, J = 9.60Hz), 7.20-7.21 (d, 1H, Hf J = 4.80Hz), 7.27-
7.29 (d, 2H, Hg-g’, J = 8.80Hz), 7.38-7.40 (d, 1H, Hh, J = 9.20Hz), 7.43-7.44 (d, 2H, 
Hii’, J = 3.60Hz), 7.50-7.54 (m, 1H, Hj), 7.90 (s, 1H,  Hk), 7.93-7.95 (m, 1H, Hl J = 
9.60Hz), 8.47-8.50 (m, 1H, Hm, J = 12.40), 8.90 (d, 1H, Hn), 10.09 (s, 1H, Ho). 
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3.8.3.3.5 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-methoxyphenyl)-1,2,3,4-tetrahydro- 
6-isopropyl-2-oxopyrimidine-5-carboxamide         
(RHK-135) 
Yield: 71%; mp 198ºC; Anal. Calcd. for C27H25N5O8: C, 
59.23; H, 4.60; N, 12.79; O, 23.38; Found: C, 59.13; H, 
4.55; N, 12.69; O, 23.28%; MS: m/z 543. 
 
 
 
 
3.8.3.3.6 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-chlorophenyl)-1,2,3,4-tetrahydro-6- 
isopropyl-2-oxopyrimidine-5-carboxamide (RHK-136) 
Yield: 72%; mp 220ºC; Anal. Calcd. for C26H22ClN5O7: 
C, 56.58; H, 4.02; Cl, 6.42; N, 12.69; O, 20.29; Found: 
C, 56.50; H, 4.00; Cl, 6.34; N, 12.60; O, 20.20% MS: 
m/z 551. 
 
 
 
 
3.8.3.3.7 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-methylphenyl)-1,2,3,4-tetrahydro- 
6-isopropyl-2-oxopyrimidine-5-carboxamide        
(RHK-137) 
Yield: 69%; mp 200ºC; Anal. Calcd. for C27H25N5O7: C, 
61.01; H, 4.74; N, 13.18; O, 21.07; Found: C, 59.31; H, 
4.61; N, 13.08; O, 21.00%; MS: m/z 531. 
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3.8.3.3.8 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-flurophenyl)-1,2,3,4-tetrahydro-6- 
isopropyl-2-oxopyrimidine-5-carboxamide (RHK-138) 
Yield: 59%; mp 199ºC; Anal. Calcd. for C26H22FN5O7: 
C, 58.32; H, 4.14; F, 3.55; N, 13.08; O, 20.92; Found: C, 
58.24; H, 4.08; F, 3.45; N, 13.01; O, 20.85%; IR (cm
-1
): 
3313 (N-H stretching of amide), 3101 (C-H stretching of 
aromatic ring), 2944 (C-H asymmetrical stretching of 
CH3 group), 2841 (C-H symmetrical stretching of CH3 
group), 1658 (C=O stretching of amide), 1602 (C=O 
stretching of cyclic) 1602 (N-H deformation of 
pyrimidine ring), 1535 (C=C stretching of aromatic ring), 1535 (C-NO2 asymmetrical 
deformation of NO2 group), 1471 (C-H asymmetrical deformation of CH3 group), 
1404 (C-H symmetrical deformation of CH3 group), 1346 (C-N-C stretching vibration 
of pyrimidine ring), 1346 (C-NO2 symmetrical deformation of NO2 group), 1269 (C-
N stretching), 1205 (C-O-C stretching), 1151 (C-F stretching), 1051 (C-H in plane 
deformation of aromatic ring), 835 (para-substituted), 772 (C-H in out plane 
deformation of aromatic ring); MS: m/z 535; 
1
H NMR (DMSO-d6) δ ppm: 1.48 (s, 
3H, Ha), 1.58 (s, 1H, Hb), 3.86 (s, 1H, Hc),  4.82-4.86  (s, 1H, Hd), 7.09-7.11 (d, 1H, 
He, J = 9.20Hz), 7.15-7.21 (m, 3H, Hfgh), 7.27-7.29 (d, 2H, Hi-i’, J = 8.40Hz), 7.43-
7.44 (d, 2H, Hjj’, J = 8.80Hz), 7.61-7.65 (m, 2H, Hkl J = 14.00Hz), 7.88 (s, 1H,  Hm), 
8.47-8.50 (d, 1H, Hn, J = 12.00), 8.90 (d, 1H, Ho J = 2.8Hz), 9.93 (s, 1H, Hp). 
 
3.8.3.3.9 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(2-chlorophenyl)-1,2,3,4-tetrahydro-6- 
isopropyl-2-oxopyrimidine-5-carboxamide (RHK-139) 
Yield: 72%; mp 195ºC; Anal. Calcd. for C26H22ClN5O7: 
C, 56.58; H, 4.02; Cl, 6.42; N, 12.69; O, 20.29; Found: 
C, 56.46; H, 4.00; Cl, 6. 35; N, 12.56; O, 20.13%; MS:  
m/z 551. 
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3.8.3.3.10 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(phenyl)-1,2,3,4-tetrahydro-6-iso-pro  
-pyl-2-oxopyrimidine-5-carboxamide (RHK-140) 
Yield: 74%; mp 232ºC; Anal. Calcd. for C26H23N5O7: C, 
60.34; H, 4.48; N, 13.53; O, 21.64; Found: C, 60.24; H, 
4.33; N, 13.42; O, 21.51%; MS: m/z 517. 
 
 
 
 
 
3.8.3.4  General procedure for the synthesis of 4-(4-(2,4-dinitrophenoxy)phenyl)-N-
(4-substitutedphenyl)-1,2,3,4-tetrahydro-6-isopropyl-2-thioxopyrimidine-5-carbox- 
amide (RHK-141 to150) 
 
A mixture of  N-(substituted phenyl)-4-methyl-3-oxopentanamide  (0.01 M), 
4-(2,4-dinitrophenoxy)benzaldehydes (0.01 M), thiourea (0.015 M) and catalytic 
amount of conc. acid in ethanol (30 ml) was heated under reflux condition for 11 to 
12 hrs. The reaction mixture was kept at room temperature for 24 hrs. The crystalline 
product obtained and recrystallized from ethanol.                                                                                            
 
 
3.8.3.4.1 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(2-methoxyphenyl)-1,2,3,4 tetrahydro- 
6-isopropyl-2-oxopyrimidine-5-carboxamide        
(RHK-141) 
Yield: 66%; mp 241ºC; Anal. Calcd. for C27H25N5O7S: 
C, 57.54; H, 4.47; N, 12.43; O, 19.87; S, 5.69; Found: C, 
57.44; H, 4.37; N, 12.33; O, 19.77; S, 5.57%; MS: m/z 
563. 
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3.8.3.4.2 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(3-chlorophenyl)-1,2,3,4-tetrahydro-6-
isopropyl-2-oxopyrimidine-5-carboxamide (RHK-142) 
Yield: 59%; mp 232ºC; Anal. Calcd. for 
C26H22ClN5O6S: C, 54.98; H, 3.90; Cl, 6.24;N, 12.33; 
O, 16.90; S, 5.65; Found: C, 54.87; H, 3.82; Cl, 6.12; N, 
12.24; O, 16.81; S, 5.60%; IR (cm
-1
): 3404 (N-H 
stretching of amide), 3095 (C-H stretching of aromatic 
ring), 2956 (C-H asymmetrical stretching of CH3 
group), 2958(C-H symmetrical stretching of CH3 
group), 1676 (C=O stretching of amide), 1597 (N-H 
deformation of pyrimidine ring), 1518 (C=C stretching of aromatic ring), 1518 (C-
NO2 asymmetrical deformation of NO2 group), 1410 (C-H asymmetrical deformation 
of CH3 group), 1344 (C-H symmetrical deformation of CH3 group), 1344 (C-N-C 
stretching vibration of pyrimidine ring), 1344 (C-NO2 symmetrical deformation of 
NO2 group), 1269 (C-N stretching), 1165 (C=S stretching of cyclic), 1064 (C-H in 
plane deformation of aromatic ring), 823 (para-substituted), 723 (C-H in out plane 
deformation of aromatic ring), 545 (C-Cl stretching); MS: m/z 567; 
1
H NMR (DMSO-
d6) δ ppm: 1.49 (s, 3H, Ha), 1.67 (s, 1H, Hb), 3.92 (s, 1H, Hc),  4.92-4.93  (s, 1H, Hd), 
7.16 (d, 2H, Hee’), 7.29-7.31 (d, 2H, Hff’, J = 8.00Hz), 7.35-7.39 (m, 3H, Hghi), 7.48-
7.50 (m, 1H, Hj, J = 8.40Hz), 7.81-7.82 (s, 1H, Hk), 8.43-8.50 (m, 1H,  Hl, J = 
12.00Hz), 8.90 (d, 1H, Hm, J = 2.90), 8.94-8.95 (m, 1H, Hn, J = 5.60Hz), 9.15 (s, 1H, 
Ho), 10.06 (s, 1H, Hp).  
 
3.8.3.4.3 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(2-fluorophenyl)-1,2,3,4-tetrahydro-6-
isopropyl-2-oxopyrimidine-5-carboxamide   (RHK-143) 
Yield: 63%; mp 201ºC; Anal. Calcd. for C26H22FN5O6S: 
C, 56.62; H, 4.02; F, 3.44; N, 12.70; O, 17.40; S, 5.81; 
Found: C, 56.54; H, 4.00; F, 3.34; N, 12.64; O, 17.34; S, 
5.72%; MS: m/z 551. 
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3.8.3.4.4 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(3-chloro 4-flurophenyl)-1,2,3,4-tetra- 
hydro-6-isopropyl-2-oxopyrimidine-5-carboxamide 
(RHK-144) 
Yield: 75%; mp 222ºC; Anal. Calcd. for 
C26H21ClFN5O6S: C, 53.29; H, 3.61; Cl, 6.05; F, 3.24; 
N, 11.95; O, 16.38; S, 5.47; Found: C, 53.16; H, 3.49; 
Cl, 6.00; F, 3.12; N, 11.82; O, 16.24; S, 5.33%; MS: m/z 
585. 
 
 
3.8.3.4.5 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-methoxyphenyl)-1,2,3,4-tetrahydro-
6-isopropyl-2-oxopyrimidine-5-carboxamide        
(RHK-145) 
Yield: 64%; mp 212 ºC; Anal. Calcd. for  
C27H25N5O7S: C, 57.54; H, 4.47; N, 12.43; O, 19.87; S, 
5.69; Found: C, 57.45; H, 4.38; N, 12.33; O, 19.75; S, 
5.54 %; MS: m/z 563. 
 
 
 
3.8.3.4.6 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-chlorophenyl)-1,2,3,4-tetrahydro-6-
isopropyl-2-oxopyrimidine-5-carboxamide (RHK-146) 
Yield: 74%; mp 219ºC; Anal. Calcd. for 
C26H22ClN5O6S: C, 54.98; H, 3.90; Cl, 6.24; N, 12.33; 
O, 16.90; S, 5.65; Found: C, 54.84; H, 3.80; Cl, 6.11; N, 
12.21; O, 16.81; S, 5.57%; IR (cm
-1
): 3412 (N-H 
stretching of amide), 3051 (C-H stretching of aromatic 
ring), 2951 (C-H asymmetrical stretching of CH3 
group), 2855 (C-H symmetrical stretching of CH3 
group), 1658 (C=O stretching of amide), 1597 (N-H 
deformation of pyrimidine ring), 1527 (C=C stretching of aromatic ring), 1527 (C-
NO2 asymmetrical deformation of NO2 group), 1483 (C-H asymmetrical deformation 
of CH3 group), 1346 (C-H symmetrical deformation of CH3 group), 1346 (C-N-C 
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stretching vibration of pyrimidine ring), 1346  (C-NO2 symmetrical deformation of 
NO2 group), 1273 (C-N stretching), 1165 (C=S stretching of cyclic), 1060 (C-H in 
plane deformation of aromatic ring), 827 (para-substituted), 740 (C-H in out plane 
deformation of aromatic ring), 671 (C-Cl stretching); MS: m/z 567; 
1
H NMR (DMSO-
d6) δ ppm: 1.49 (s, 3H, Ha), 1.66 (s, 3H, Hb) 3.91 (s, 1H, Hc),  4.92-4.93  (s, 1H, Hd), 
7.08-7.11 (d, 1H, He, J = 9.20Hz), 7.28-7.30 (d, 2H, Hff’, J = 8.80Hz), 7.36-7.41 (m, 
3H, Hg-i’), 7.47-7.50 (d, 2H, Hjj’, J = 8.80Hz), 8.63-8.65 (d, 1H, Hk, J = 8.80Hz), 8.28-
8.33 (m, 1H,  Hl), 8.47-8.50 (m, 1H, Hm, J = 12.40Hz), 8.93-8.94 (m, 1H, Hn), 9.13 (s, 
1H, Ho), 10.01 (s, 1H, Hp). 
 
3.8.3.4.7 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-methylphenyl)-1,2,3,4-tetrahydro-
6-isopropyl-2-oxopyrimidine-5-carboxamid (RHK-147) 
Yield: 71%; mp 206ºC; Anal. Calcd. For C27H25N5O6S: 
C, 59.22; H, 4.60; N, 12.79; O, 17.53; S, 5.86; Found: 
C, 59.11; H, 4.54; N, 12.67; O, 17.45; S, 5.77%; IR (cm
-
1
): 3421 (N-H stretching of amide), 3099 (C-H 
stretching of aromatic ring), 2949 (C-H asymmetrical 
stretching of CH3 group), 2839 (C-H symmetrical 
stretching of CH3 group), 1681 (C=O stretching of 
amide), 1597 (N-H deformation of pyrimidine ring), 
1521 (C=C stretching of aromatic ring), 1521 (C-NO2 asymmetrical deformation of 
NO2 group), 1464 (C-H asymmetrical deformation of CH3 group), 1344 (C-H 
symmetrical deformation of CH3 group), 1344 (C-N-C stretching vibration of 
pyrimidine ring), 1344 (C-NO2 asymmetrical deformation of NO2 group), 1269 (C-N 
stretching), 1063 (C-H in plane deformation of aromatic ring), 835 (para-substituted), 
740 (C-H in out plane deformation of aromatic ring); MS: m/z 547; 
1
H NMR (DMSO-
d6) δ ppm: 1.07 (s, 3H, Ha), 1.50 (s, 3H, Hb), 2.26 (s, 3H, Hc), 3.90 (s, 1H, Hd),  4.90-
4.91  (s, 1H, He), 7.08-7.10 (d, 1H, Hf, J = 9.20Hz), 7.12-7.15 (d, 2H, Hgg’, J = 
8.40Hz), 7.28-7.30 (d, 2H, Hhh’, J = 8.80Hz), 7.47-7.49 (d, 2H, Hjj’, J = 8.40Hz), 8.47-
8.50 (d, 1H, Hk, J = 12.00Hz), 8.90 (d, 1H,  Hl, J = 3.20Hz), 8.93-8.94 (d, 1H, Hm, J = 
5.20Hz), 9.10 (s, 1H, Hn), 9.75 (s, 1H, Ho). 
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3.8.3.4.8 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-flurophenyl)-1,2,3,4-tetrahydro-6-
isopropyl-2-oxopyrimidine-5-carboxamide (RHK-148) 
Yield: 60%; mp 223ºC; Anal. Calcd. for C26H22FN5O6S: 
C, 56.62; H, 4.02; F, 3.44; N, 12.70; O, 17.40; S, 5.81; 
Found: C, 56.46; H, 3.89; F, 3.31; N, 12.64; O, 17.34; S, 
5.74%; MS: m/z 551. 
 
 
 
 
 
3.8.3.4.9 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(2-chlorophenyl)-1,2,3,4-tetrahydro-6-
isopropyl-2-oxopyrimidine-5-carboxamide (RHK-149) 
Yield: 76%; mp 241ºC; Anal. Calcd. for 
C26H22ClN5O6S: C, 54.98; H, 3.90; Cl, 6.24; N, 12.33; 
O, 16.90; S, 5.65; Found: C, 54.84; H, 3.82; Cl, 6.12; N, 
12.21; O, 16.81; S, 5.55%; MS:  m/z 567. 
 
 
 
 
 
3.8.3.4.10 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(phenyl)-1,2,3,4-tetrahydro-6-iso- 
pro -pyl-2-oxopyrimidine-5-carboxamide (RHK-150) 
Yield: 81%; mp 250ºC; Anal. Calcd. for C26H23N5O6S: 
C, 58.53; H, 4.34; N, 13.13; O, 17.99; S, 6.01; Found: C, 
58.46; H, 4.12; N, 13.00; O, 17.85; S, 5.89%; MS: m/z 
533. 
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3.8.3.5 General procedure for the synthesis of 6-(4-(2,4-dinitrophenoxy)phenyl)-N-
(substitutedphenyl)-1,2,3,6-tetrahydro-4-isopropyl-1-methyl-2-oxopyrimidine-5-
carboxamide (RHK-151 to160) 
 
A mixture of  N-(substitutedphenyl)-4-methyl-3-oxopentanamide  (0.01 M), 4-
(2,4-dinitrophenoxy)benzaldehydes (0.01 M), N-methyl urea (0.015 M) and catalytic 
amount of conc. acid in ethanol (30 ml) was heated under reflux condition for 12 to 
13 hrs. The reaction mixture was kept at room temperature for 24 hrs. The crystalline 
product obtained and recrystallized from ethanol. 
 
3.8.3.5.1 6-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,6-tetrahydro-N-(2-methoxyphenyl)- 
1,4-dimethyl-2-oxopyrimidine-5-carboxamide      
(RHK-151) 
Yield: 77%; mp 230ºC; Anal. Calcd. For C28H27ClN5O8: 
C, 59.89; H, 4.85; N, 12.47; O, 22.79; Found: C, 59.78; 
H, 4.74; N, 12.35; O, 22.64 %; MS: m/z 561. 
 
 
 
 
 
3.8.3.5.2 6-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,6-tetrahydro-N-(3-chlorophenyl)- 
1,4-dimethyl-2-oxopyrimidine-5-carboxamide 
(RHK-152) 
Yield: 76%; mp 218ºC; Anal. Calcd. for C27H24ClN5O7: 
C, 57.30; H, 4.27; Cl, 6.26; N, 12.37; O, 19.79; Found: , 
C, 57.21; H, 4.19; Cl, 6. 13; N, 12.28; O, 19.67 %; MS: 
m/z 565.  
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3.8.3.5.3 6-(4-(2,4-dinitrophenoxy)phenyl)-N-(2-flurophenyl)-1,2,3,6-tetrahydro-1,4  
-dimethyl-2-oxopyrimidine-5-carboxamide 
(RHK-153) 
Yield: 68%; mp 216ºC; Anal. Calcd. for C26H24FN5O7: 
C, 59.01; H, 4.40; F, 3.46; N, 12.74; O, 20.38; Found: C, 
59.00; H, 4.31; F, 3.35; N, 12.67; O, 20.23 %; MS: m/z 
549. 
 
 
 
 
3.8.3.5.4 6-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-chloro-3-fluorophenyl)-1,2,3,6-tetr- 
ahydro1,4-dimethyl-2-oxopyrimidine-5-carboxamide 
(RHK-154) 
Yield: 59%; mp 227ºC; Anal. Calcd. for  
C27H23ClFN5O7: C, 55.53; H, 3.97; Cl, 6.07;F, 3.25; N, 
11.99; O, 19.18; Found: C, 55.46; H, 3.88; Cl, 6.00;F, 
3.13; N, 1186; O, 19.03 %; IR (cm
-1
): 3475 (N-H 
stretching of amide), 3070 (C-H stretching of aromatic 
ring), 2959 (C-H asymmetrical stretching of CH3 
group), 2874 (C-H symmetrical stretching of CH3 
group), 1653 (C=O stretching of amide), 1600 (C=O stretching of cyclic) 1541 (N-H 
deformation of pyrimidine ring), 1541 (C=C stretching of aromatic ring), 1491 (C-H 
asymmetrical deformation of CH3 group), 1491 (C-NO2 asymmetrical deformation of 
NO2 group), 1396 (C-H symmetrical deformation of CH3 group), 1346 (C-N-C 
stretching vibration of pyrimidine ring), 1346 (C-NO2 symmetrical deformation of 
NO2 group), 1276 (C-N stretching), 1087 (C-F stretching), 1087 (C-H in plane 
deformation of aromatic ring), 825 (para-substituted), 746 (C-H in out plane 
deformation of aromatic ring), 692 and 532 (C-Cl stretching); MS: m/z 583;
 1
H NMR 
(DMSO-d6) δ ppm: 1.26 (s, 3H, Ha), 1.61 (s, 3H, Hb), 2.95-2.96 (s, 3H, Hc), 3.75 (s, 
1H, Hd),  4.97  (s, 1H, He), 7.03-7.05 (d, 2H, Hff’, J = 9.20Hz), 7.23-7.25 (d, 2H, Hgg’, 
J = 8.80Hz), 7.38-7.42 (m, 3H, Hh-j), 7.52-7.53 (m, 1H, Hk, J = 6.40Hz), 8.91-8.92 (m, 
NH
O N
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1H, Hl, J = 6.80Hz), 8.50-8.53 (d, 1H,  Hm, J = 11.60Hz), 8.90 (s, 1H, Hn), 10.00 (s, 
1H, Ho). 
 
3.8.3.5.5 6-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,6-tetrahydro-N-(4-methoxyphenyl)-
1,4-dimethyl-2-oxopyrimidine-5-carboxamide       
(RHK-155) 
Yield: 64%; mp 229ºC; Anal. Calcd. for C28H27N5O8: C, 
59.89; H, 4.85; N, 12.47; O, 22.79; Found: C, 59.79; H, 
4.75; N, 12.34; O, 22.64 %; MS: m/z 561; MS: m/z 561 
 
 
 
 
 
3.8.3.5.6 6-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,6-tetrahydro-N-(4-chlorophenyl)-
1,4-dimethyl-2-oxopyrimidine-5-carboxamide      
(RHK-156) 
Yield: 61%; mp 218ºC; Anal. Calcd. for C27H24ClN5O7: 
C, 57.30; H, 4.27; Cl, 6.26; N, 12.37; O, 19.79; Found: 
C, 57.24; H, 4.15; Cl, 6.13; N, 12.23; O, 19.68 %; MS: 
m/z 565. 
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3.8.3.5.7 6-(4-(2,4-dinitrophenoxy)phenyl)-1,2,3,6-tetrahydro-1,4-dimethyl-2-oxo-N-
p-tolylpyrimidine-5-carboxamide (RHK-157) 
Yield: 62%; mp 220ºC; Anal. Calcd. for C28H27N5O7: C, 
61.64; H, 4.99; N, 12.84; O, 20.53; Found: C, 61.52s; H, 
4.87; N, 12.74; O, 20.44 %;
 
IR (cm
-1
): 3471 (N-H 
stretching of amide), 3057 (C-H stretching of aromatic 
ring), 2980 (C-H asymmetrical stretching of CH3 
group), 2852 (C-H symmetrical stretching of CH3 
group), 1716 (C=O stretching of amide), 1654 (C=O 
stretching of cyclic) 1600 (N-H deformation of 
pyrimidine ring), 1537 (C=C stretching of aromatic ring), 1537 (C-NO2 asymmetrical 
deformation of NO2 group), 1496 (C-H asymmetrical deformation of CH3 group), 
1396 (C-H symmetrical deformation of CH3 group), 1346 (C-N-C stretching vibration 
of pyrimidine ring), 1346  (C-NO2 symmetrical deformation of NO2 group), 1274 (C-
N stretching), 1066 (C-H in plane deformation of aromatic ring), 829 (para-
substituted), 742 (C-H in out plane deformation of aromatic ring); MS: m/z 545; 
 1
H 
NMR (DMSO-d6) δ ppm: 1.48 (s, 3H, Ha), 1.58 (s, 3H, Hb), 2.72 (s, 3H, Hc) 3.09 (s, 
1H, Hd),  3.73  (s, 1H, He), 5.27-5.28 (s, 1H, Hf), 6.86-6.89 (m, 1H, Hg), 6.99-7.01 (d, 
1H, Hh, J = 8.00Hz), 7.06-7.08 (d, 1H, Hi, J = 7.20Hz), 7.10-7.14 (m, 1H, Hj, J = 
14.80Hz), 7.27-7.29 (d, 2H, Hkk’, J = 8.40Hz), 7.46-7.48 (d, 2H, Hll’, J = 8.80Hz), 
7.67-7.69 (d, 1H,  Hm, J = 7.60Hz), 7.82-7.83 (d, 1H, Hn, J = 3.20Hz), 8.44-8.47 (m, 
1H, Ho, J = 12.00Hz), 8.71 (s, 1H, Hp), 8.89-8.90 (s, 1H, Hq). 
 
3.8.3.5.8 6-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-fluorophenyl)-1,2,3,6-tetrahydro-1 
,4-dimethyl-2-oxopyrimidine-5-carboxamide        
(RHK-158) 
Yield: 74%; mp 200ºC; Anal. Calcd. for C27H24FN5O7: 
C, 59.01; H, 4.40; F, 3.46; N, 12.74; O, 20.38; Found: C, 
58.79; H, 4.34; F, 3.33; N, 12.63; O, 20.24 %; IR (cm
-1
): 
3362 (N-H stretching of amide), 3103 (C-H stretching of 
aromatic ring), 2933  (C-H asymmetrical stretching of 
CH3 group), 2838 (C-H symmetrical stretching of CH3 
group), 1705 (C=O stretching of amide), 1662 (C=O 
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stretching of cyclic) 1593 (N-H deformation of pyrimidine ring), 1527 (C=C 
stretching of aromatic ring), 1527 (C-NO2 asymmetrical deformation of NO2 group), 
1477 (C-H asymmetrical deformation of CH3 group), 1429 (C-H symmetrical 
deformation of CH3 group), 1342 (C-N-C stretching vibration of pyrimidine ring), 
1342 (C-NO2 symmetrical deformation of NO2 group), 1244 (C-N stretching), 1099 
(C-F stretching), 1070 (C-H in plane deformation of aromatic ring), 839 (para-
substituted), 786 (C-H in out plane deformation of aromatic ring); MS: m/z 549; 
1
H 
NMR (DMSO-d6) δ ppm: 1.21 (s, 3H, Ha), 1.55 (s, 3H, Hb), 3.06 (s, 3H, Hc), 5.31-
5.32 (s, 1H, Hd),  7.08-7.01 (d, 1H, He), 7.23-7.25 (d, 2H, Hff’, J = 8.40Hz), 7.34-7.36 
(d, 2H, Hgg’, J = 9.60Hz), 7.37-7.39 (d, 2H, Hhh’, J = 9.20Hz), 7.47-7.51 (m, 1H, Hi, J 
= 16.00Hz), 7.88-7.94 (m, 2H, Hjk), 8.43-8.46 (m, 1H, Hl, J = 12.80Hz), 8.89-8.90 (d, 
1H, Hm, J = 2.40Hz), 10.06 (s, 1H, Hn). 
 
3.8.3.5.9 6-(4-(2,4-dinitrophenoxy)phenyl)-N-(2-chlorophenyl)-1,2,3,6-tetrahydro-
1,4-dimethyl-2-oxopyrimidine-5-carboxamide      
(RHK-159) 
Yield: 60%; mp 241ºC; Anal. Calcd. for C27H24ClN5O7: 
C, 57.30; H, 4.27; Cl, 6.26; N, 12.37; O, 19.70; Found: 
C, 57.20; H, 4.15; Cl, 6.13; N, 12.23; O, 19.64 %; MS:  
m/z 565 
 
 
 
3.8.3.5.10 6-(4-(2,4-dinitrophenoxy)phenyl)-N-(phenyl)-1,2,3,6-tetrahydro-1,4-di- 
methyl-2-oxopyrimidine-5-carboxamide  (RHK-160) 
Yield: 70%; mp 249ºC; Anal. Calcd. for C27H25N5O7: C, 
61.01; H, 4.74; N, 13.18; O, 21.07; Found: C, 59.89; H, 
4.65; N, 13.02; O, 21.00 %; MS: m/z 531. 
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3.9 Spectral discussion 
 
3.9.1 Mass spectral study 
 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using 
Direct Injection Probe technique. Systematic fragmentation pattern was observed in 
mass spectral analysis. Molecular ion peak was observed in agreement with molecular 
weight of respective compound. Mass fragmentation pattern for a representative 
compound of each series is depicted below. 
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3.9.1.1 Mass fragmentation pattern for RHK-101 
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3.9.1.2 Mass fragmentation pattern for RHK-112 
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3.9.1.3 Mass fragmentation pattern for RHK-127 
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3.9.1.4 Mass fragmentation pattern for RHK-138 
NH
O
NH
N
H
O
O
O2N NO2
NH2
O
NH
N
H
O
O
O2N NO2
NH
N
H
O
NH
O
NH
N
H
O
O
H3C
O2N NO2
OH
NH
N
H
O
NH
N
H
O
O
O
O2N NO2
NHH3C
H2N O
NH
N
N
H
O
O
m/z =535
m/z =202
m/z =489
m/z =275m/z =218
m/z =126
m/z =164
H3C
CH3
H3C
H3C
CH3
H3C
O
NH
N
H
O
O
H3C
O2N
N
H
N
O
O2N
N
H
N
H3C
H3C
O
O2N
CH3
m/z =398
m/z =327
m/z =368
m/z =382
H3C
CH3
F
F O
N
H
N
m/z =292
H3C
m/z =427
NH
O
NH
N
H
O
O
O2N NO2
m/z =535
CH3
H3C
F
CH3
NO2
+ + +
+
+
+
+
+
+
+
+
+
NO2
NO2
+
 
 
 
 
 
 
 Chapter- 3                                                                                                  1,2,3,4-tetrahydro pyrimidines 
 
Studies on Some Organic Compounds of Therapeutic Interest 
86 
3.9.1.5 Mass fragmentation pattern for RHK-147 
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3.9.1.6 Mass fragmentation pattern for RHK-154 
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3.9.2 IR spectral study 
 
IR spectra were recorded on Shimadzu FT-IR-8400 model using potassium 
bromide (KBr) pellet method. Various functional groups present in molecule were 
identified by characteristic frequency obtained for them. For tetrahydropyrimidines 
RHK-101 to 160, confirmatory bands for secondary amine and amidic carbonyl 
groups were observed at 3450-3200 cm
-1 
and 1715-1600 cm
-1 
respectively. Another 
characteristic C-N-C (stretching vibration of pyrimidine ring) was observed at 1360-
1300 cm
-1
, which suggested formation of desired products RHK- 101 to 160.
 
  
 
3.9.3 
1
H NMR spectral study 
 
1
H NMR spectra were recorded in DMSO-d6 solution on a bruker Ac 400 
MHz spectrometer using TMS as an internal standard. Number of protons and their 
chemical shifts were found to support the structure of the synthesized compounds.
1
H 
NMR spectra confirmed the structures of tetrahydropyrimidines RHK- 101 to 160 on 
the basis of following signals: a singlet for the methane proton of pyrimidine ring at 
5.90-4.30 δ ppm, and singlets for N-H of primidine at 7.80-9.60 δ ppm and amide 
group protons at 9.10-10.32 δ ppm, respectively. The aromatic ring protons and J 
value were found to be in accordance with substitution pattern on phenyl ring. 
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IR spectrum of RHK - 101 
 
Mass spectrum of RHK - 101 
 
 
 Chapter- 3                                                                                                  1,2,3,4-tetrahydro pyrimidines 
 
Studies on Some Organic Compounds of Therapeutic Interest 
90 
1
H NMR spectrum of RHK - 101 
 
Expanded 
1
H NMR spectrum of RHK - 101 
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IR spectrum of RHK - 106 
 
Mass spectrum of RHK - 106 
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1
H NMR spectrum of RHK - 106 
 
Expanded 
1
H NMR spectrum of RHK - 106 
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IR spectrum of RHK - 108 
 
Mass spectrum of RHK - 108 
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1
H NMR spectrum of RHK - 108 
 
Expanded 
1
H NMR spectrum of RHK - 108 
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IR spectrum of RHK - 112 
 
Mass spectrum of RHK - 112 
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1
H NMR spectrum of RHK - 112 
 
Expanded 
1
H NMR spectrum of RHK - 112 
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IR spectrum of RHK - 117 
Mass spectrum of RHK - 117 
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1
H NMR spectrum of RHK - 117 
 
Expanded 
1
H NMR spectrum of RHK - 117 
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IR spectrum of RHK - 118 
 
Mass spectrum of RHK - 118 
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1
H NMR spectrum of RHK - 118 
 
Expanded 
1
H NMR spectrum of RHK - 118 
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IR spectrum of RHK - 124 
 
Mass spectrum of RHK - 124 
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1
H NMR spectrum of RHK - 124 
 
Expanded 
1
H NMR spectrum of RHK - 124 
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IR spectrum of RHK - 127 
 
Mass spectrum of RHK - 127 
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1
H NMR spectrum of RHK - 127 
 
IR spectrum of RHK - 128 
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Mass spectrum of RHK - 128 
 
1
H NMR spectrum of RHK - 128 
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IR spectrum of RHK - 132 
 
Mass spectrum of RHK - 132 
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1
H NMR spectrum of RHK - 132 
 
Expanded 
1
H NMR spectrum of RHK - 132 
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IR spectrum of RHK - 134 
 
Mass spectrum of RHK - 134 
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1
H NMR spectrum of RHK - 134 
 
Expanded 
1
H NMR spectrum of RHK - 134 
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IR spectrum of RHK - 138 
 
Mass spectrum of RHK - 138 
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1
H NMR spectrum of RHK - 138 
 
Expanded 
1
H NMR spectrum of RHK - 138 
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IR spectrum of RHK - 142 
 
Mass spectrum of RHK - 142 
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1
H NMR spectrum of RHK - 142 
 
Expanded 
1
H NMR spectrum of RHK - 142 
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IR spectrum of RHK - 146 
 
Mass spectrum of RHK - 146 
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1
H NMR spectrum of RHK - 146 
 
Expanded 
1
H NMR spectrum of RHK - 146 
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IR spectrum of RHK - 147 
 
Mass spectrum of RHK - 147 
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1
H NMR spectrum of RHK - 147 
 
Expanded 
1
H NMR spectrum of RHK - 147 
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IR spectrum of RHK - 154 
 
Mass spectrum of RHK - 154 
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1
H NMR spectrum of RHK - 154 
 
Expanded 
1
H NMR spectrum of RHK - 154 
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IR spectrum of RHK - 157 
 
Mass spectrum of RHK - 157 
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1
H NMR spectrum of RHK - 157 
 
Expanded 
1
H NMR spectrum of RHK - 157 
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IR spectrum of RHK - 158 
 
Mass spectrum of RHK - 158 
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1
H NMR spectrum of RHK - 158 
 
 
3.10 Biological evaluation 
 
3.10.1 Antimicrobial evaluation 
 
All of the synthesized compounds (RHK- 101 to 160) were tested for their 
antibacterial and antifungal activity (MIC) in vitro by broth dilution method [98-100] 
with two Gram-positive bacteria Staphylococcus aureus MTCC-96, Streptococcus 
pyogenes MTCC 443, two Gram-negative bacteria Escherichia coli MTCC 442, 
Pseudomonas aeruginosa MTCC 441 and three fungal strains Candida albicans 
MTCC 227, Aspergillus Niger MTCC 282, Aspergillus clavatus MTCC 1323 taking 
gentamycin, ampicillin, chloramphenicol, ciprofloxacin, norfloxacin, nystatin and 
greseofulvin as standard drugs. The standard strains were procured from the Microbial 
Type Culture Collection (MTCC), Institute of Microbial Technology, Chandigarh, 
India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the compound 
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preventing the visible growth, were determined by using micro dilution broth method 
according to NCCLS standards [98].  
 
Minimal Inhibition Concentration [MIC]:- 
 
The main advantage of the ‘Broth Dilution Method’ for MIC determination 
lies in the fact that it can readily be converted to determine the MIC as well. 
 
1. Serial dilutions were prepared in primary and secondary screening. 
2. The control tube containing no antibiotic is immediately subcultured (before 
inoculation) by spreading a loopful evenly over a quarter of plate of medium 
suitable for the growth of the test organism and put for incubation at 37
 0
C 
overnight.  
3. The MIC of the control organism is read to check the accuracy of the drug 
concentrations.  
4. The lowest concentration inhibiting growth of the organism is recorded as the 
MIC.  
5. The amount of growth from the control tube before incubation (which 
represents the original inoculums) is compared.  
 
Methods used for primary and secondary screening: - 
 
Each synthesized drug was diluted obtaining 2000 µg mL
-1 
concentration, as a 
stock solution. Inoculum size for test strain was adjusted to 10
8
 cfu (colony forming 
unit) per milliliter by comparing the turbidity. 
Primary screen: - In primary screening 1000 µg mL
-1
, 500 µg mL
-1 
and 250 µg mL
-1 
concentrations of the synthesized drugs were taken. The active synthesized drugs 
found in this primary screening were further tested in a second set of dilution against 
all microorganisms.  
Secondary screen: - The drugs found active in primary screening were similarly 
diluted to obtain 200 µg mL
-1
, 100 µg mL
-1
, 50 µg mL
-1
, 25 µg mL
-1
, 12.5 µg mL
-1
, 
and 6.250 µg mL
-1
 concentrations.  
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Reading Result: - The highest dilution showing at least 99 % inhibition zone is taken 
as MIC. The result of this is much affected by the size of the inoculums. The test 
mixture should contain 10
8 
organism/mL.           
                 
The results obtained from antimicrobial susceptibility testing are depicted in Table 1. 
 
Table-1:-   in vitro Antimicrobial Screening Results for RHK-101 to 160 
 
Code Minimal inhibition concentration (µg mL
-1 
) 
Gram-positive Gram-negative Fungal species 
S.a. S. p. E.c. P.a. C. a. A. n. A.c. 
RHK-101 
RHK-102 
500 
500 
500 
1000 
500 
1000 
500 
1000 
250 
>1000 
1000 
>1000 
500 
>1000 
RHK-103 100 100 250 200 1000 500 500 
RHK-104 1000 500 1000 1000 1000 500 1000 
RHK-105 200 100 100 200 250 1000 1000 
RHK-106 1000 1000 500 500 250 1000 1000 
RHK-107 500 500 250 250 250 1000 1000 
RHK-108 100 100 200 250 1000 500 1000 
RHK-109 62.5 1000 200 1000 500 >1000 1000 
RHK-110 150 250 100 150 500 500 1000 
RHK-111 1000 500 62.5 62.5 >1000 >1000 >1000 
RHK-112 200 200 100 100 >1000 1000 500 
RHK-113 500 1000 500 500 500 >1000 >1000 
RHK-114 150 250 100 150 500 500 500 
RHK-115 100 62.5 200 250 500 500 500 
RHK-116 200 200 200 250 500 500 500 
RHK-117 200 200 100 200 250 500 500 
RHK-118 100 100 250 500 500 250 250 
RHK-119 1000 500 1000 500 500 500 500 
RHK-120 1000 1000 1000 500 1000 1000 1000 
RHK-121 250 500 500 250 500 500 500 
RHK-122 250 500 200 250 250 200 200 
RHK-123 100 62.5 500 250 100 250 250 
RHK-124 250 250 500 500 200 >1000 >1000 
RHK-125 62.5 500 200 1000 500 500 500 
RHK-126 250 500 250 250 250 >1000 >1000 
RHK-127 200 200 100 100 250 >1000 >1000 
RHK-128 150 200 250 150 1000 500 500 
RHK-129 62.5 500 500 1000 1000 500 1000 
RHK-130 250 500 1000 1000 250 1000 1000 
RHK-131 1000 250 62.5 62.5 250 1000 1000 
RHK-132 200 200 62.5 100 500 >1000 >1000 
RHK-133 500 500 250 500 1000 500 500 
RHK-134 200 200 100 200 >1000 >1000 >1000 
RHK-135 250 250 100 250 250 >1000 >1000 
RHK-136 62.5 100 1000 250 250 >1000 >1000 
RHK-137 250 250 500 500 500 500 >1000 
RHK-138 100 62.5 250 250 100 250 250 
RHK-139 250 500 500 1000 >1000 250 250 
RHK-140 200 500 62.5 62.5 >1000 1000 1000 
RHK-141 150 500 100 1000 500 500 500 
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RHK-142 62.5 100 200 250 500 500 500 
RHK-143 500 100 250 250 250 1000 500 
RHK-144 250 500 250 1000 >1000 >1000 >1000 
RHK-145 62.5 250 200 100 1000 500 500 
RHK-146 250 500 250 500 1000 1000 1000 
RHK-147 250 250 100 100 500 500 500 
RHK-148 200 250 62.5 100 500 500 500 
RHK-149 1000 500 500 1000 250 1000 1000 
RHK-150 250 500 100 100 500 250 250 
RHK-151 62.5 200 200 62.5 500 200 200 
RHK-152 100 1000 200 250 >1000 500 250 
RHK-153 100 500 1000 1000 500 500 500 
RHK-154 150 200 100 150 250 250 250 
RHK-155 250 250 100 250 500 500 500 
RHK-156 500 500 250 250 500 500 500 
RHK-157 200 200 62.5 250 500 250 250 
RHK-158 1000 500 500 250 500 200 200 
RHK-159 62.5 200 250 1000 >1000 500 250 
RHK-160 250 250 500 200 500 500 500 
Gentamycin 0.25 0.5 0.05 1 - - - 
Ampicillin 250 100 100 100 - - - 
Chloramphenicol 50 50 50 50 - - - 
Iprofloxacin 50 50 25 25 - - - 
Norfloxacin 10 10 10 10 - - - 
Nystatin - - - - 100 100 100 
Greseofulvin - - - - 500 100 100 
 
3.10.2 Antimycobacterial, anticancer and antiviral evaluation 
 
Antimycobacterial, anticancer and antiviral screening of all the newly 
synthesized compounds RHK-101 to 160 is currently under investigation and results 
are awaited.  
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CHAPTER 4 
Synthesis and biological evaluation of 
1,2,4-triazolo[1,5-a]pyrimidines 
 
 
4.1 Introduction 
 
The condensation of a ring of 1,2,4-triazole and another one of pyrimidine 
gives rise to the formation of bicyclic heterocycles known as 1,2,4-
triazolopyrimidines. Four different possibilities exist for the relative orientation of 
both rings, so four different isomeric families of compounds are defined: 1,2,4-
triazolo[1,5-a]pyrimidine (1), 1,2,4-triazolo[1,5-c]pyrimidine (2), 1,2,4-triazolo[4,3-
a]pyrimidine (3) and 1,2,4-triazolo[4,3-c]pyrimidine (4). 
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N
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(1) 1,2,4-triazolo[1,5-a]pyrimidine (2) 1,2,4-triazolo[1,5-c]pyrimidine
(3) 1,2,4-triazolo[4,3-a]pyrimidine (4) 1,2,4-triazolo[4,3-c]pyrimidine
 
 
Among these isomeric families of compounds, 1,2,4-triazolo[1,5-a]pyrimidine 
derivatives are  thermodynamically more stable and, thus, the most studied ones [1], a 
few of them being commercially available. Revisions surveying the synthesis, 
reactivity, spectroscopic characterization and crystallographic studies of 1,2,4-
triazolo[1,5-c]pyrimidines [2], 1,2,4-triazolo[4,3-a]pyrimidines [3] and 1,2,4-triazolo 
[4,3-c]pyrimidines [4] have also been published. 
 
Chapter 4                                                                                                 1,2,4-triazolo[1,5-a]pyrimidines 
     
Studies on Some Organic Compounds of Therapeutic Interest 
   131
 From the standpoint of biological activity, fused heteroaromatic systems are 
often of much greater interest than the constituent monocyclic compounds. Recently, 
1,2,4-triazolo[1,5-a]pyrimidines have aroused increasing attention from the chemical 
and biological view points, due to their diverse pharmacological activities, such as 
antitumor potency [5,6], inhibition of KDR kinase [7], antifungal effect [8] and 
macrophage activation [9]. They have proved to be promising anticancer agents with 
dual mechanisms of tubulin polymerization promotion [5,6] as well as cyclin 
dependent kinases-2 inhibition [10]. Some examples of published derivatives of 1,2,4-
triazolo[1,5-a]pyrimidine with their biological activities are as following. 
 
N
N
N
N
NH2
O
(5) Activity: A2A adenosine receptor antagonists
R
N
N
N
N
CH3
H3C
NH S
O
O
CH3
(6) Activity: latent leishmanicidal activity
N
N
N
N
HN
Cl
CH3
F3C H
F
FOHN
CH3
(7) Activity: Anticancer acticity
(10) Activity: Acetohydroxyacid synthase 
                       inhibitor
N
N
N
N
SO2NH
F
F
O
H3C
N
N
N
N
NH
O
HN
Me2NO2S
H2N
(11) Activity: CDK-2 inhibitors
N
N
N
N
PhO2S
CH3
(12) Actvity: Antiinflammatory
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N
N
N
N
S
CH3
H3C
O
NN
SCH3CH2(CH3)CH
(8) Activity: antifungal
N
N
N
N
CH3
H3C
O
N
Et
Et
OHO
(9) Activity: Hepatitis C virus 
      polymerase inhibitor
N
N
N
N
HN
H3C
CF3
S
O
N
(13) Activity: Antiproliferative
N
N
N
N
NEt2
(14) Trapidil: Antiischemic and
        cardiatonic agent
 
 
4.2 Reported synthetic strategies 
 
4.2.1 Amino-1,2,4-triazole and 1,3-bifunctional synthons 
 
4.2.1.1 Principle and Conditions 
 
By far the most triazolo[1,5-a]pyrimidine synthesis are condensations of 
dinucleophilic 5-amino-1,2,4-triazoles with 1,3-bifunctional synthons as shown in the 
formation of triazolo[1,5-a]pyrimidine (15) (Scheme 4.1) [21-24]. New synthetic 
conditions recently described involve melting under microwave irradiation, a reaction 
that is environmental friendly and gives higher yields than conventional heating in 
solvent [25]. Furthermore, certain lithium 1,3-diketonates have proven to be better 
synthons than the corresponding diketones [26].  
 
COOEt
OH3C
+
NHN
NH2N NH
N
N
N
O
H3C
(15)
Scheme 4.1
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 Previous mechanistic conclusions have been confirmed by isolating stable 
intermediate 5-amino-1,2,4-triazole derivatives such as enamine (16) (Scheme 4.2) on 
reacting 5-amino-1,2,4-triazoles with 3-ketovinyl ethers [27], 3-ketoenamines [28], 3-
ketoaldehydes [29], enamine-2-carboxylic esters [30] or ethoxymethylene malonates 
[31].  
 
OEt
+
NHN
NH2N N
H
HN
CO
N
N
Ar
(16)
Scheme 4.2
Ar
O
EtOOC
EtOH
EtOOC
CH3CN /KF
N
N
N
N
Ar
EtOOC
 
 
That means, the overall reaction starts with the interaction of the 5-amino-
1,2,4-triazoles amino group and the enolic (or analogous) functionality of the three-
carbon synthon. In the two-step examples, just mentioned, the first step proceeds 
under milder conditions (sometimes just in ethanol at room temperature), but the final 
cyclization (or the one-step reaction, if the intermediate is not trapped) requires 
stronger means (e.g., PPA or boiling acetic acid). Under extreme conditions, 
triazolylamide (17) was subject to flash vacuum pyrolysis between 300 and 450 ºC to 
give about 50% triazolo[1,5-a]pyrimidine (18) (Scheme 4.3) [32]. Libraries of fused 
3-aminopyrimidin-4-ones (19) and other compounds were just recently prepared by 
the solid-phase and by the solution-phase parallel synthesis [33]. The latter method 
turned out to be advantageous with respect to yield and purity. 
 
COOEt
COOEt
+
NHN
NH2N N
H
HN
COOEt
N
N
O N
H
N
N
N
O
O
(17) (18)
COOEt
NMe2
AcHN NHN
NH2N
+
1. AcOH
2. HCl
N
N
N
H
N
O
H2N
HCl
(19)
Scheme 4.3
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4.2.1.2 Use of Modified 5-Amino-1,2,4-triazoles 
 
Scheme 4.4 shows two parallel paths of pyrimidine ring annulation: the 
conventional method, route A and a route B using a reactive 5-amino-1,2,4-triazole 
derivative [34]. Amidine (22), formed from 5-amino-1,2,4-triazole and DMF 
dimethylacetal, can be regarded as the result of incorporating one carbon of the three-
carbon synthon (20) into the amino-1,2,4-triazole molecule; condensation with a 
reactive two-carbon component leads to target triazolo[1,5-a]pyrimidine (21).  
 
NC
NMe2
O
Ph
+
NHN
NH2N
A
BNC
O
Ph
+ NHN
NN
NMe2 N
N
N
NNC
Ph
(20)
(21)
(22) Scheme 4.4
 
 
Path B also serves in confirming the structure of product (21). Similar 
syntheses of 7-aryl and 7-heterocyclyl triazolo[1,5-a]pyrimidines have been described 
[35-37], for example, that of an antipyrine derivative [38]. 
 
4.2.1.3 The diversity of 1,3-bifunctional synthons  
 
Examples of triazolo[1,5-a]pyrimidine synthesis published in the relevant 
period are listed in Table 1, arranged according to the bifunctional synthons used and 
to the substituents entering the positions 5 and 7. Triazolo[1,5-a]pyrimidines are 
included in reviews dealing with heterocyclic synthesis by the use of enamines [39], 
enamine-2-carboxylic esters [40] and ketene mercaptals [41]. 
 
N
N N
N
1
2
34
5
6
7
8
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Table 1. Syntheses of triazolo[1,5-a]pyrimidines from 1,3-bifunctional synthons and 5-amino-1,2,4-
triazoles 
Bifunctional  
Synthons 
R-5
b
 R-7
b
 Bifunctional  
Synthons 
R-5
b
 R-7
b
 
1,3-Dialdehyde [42] H H Enamine-2-carboxylate [59] H OH 
2-Formylacetal [43] H H Acetylenedicarboxylate [60] CO2Me OH 
1,3-Diacetal [44] H H 3-Ketocarboxylate [61] R OH 
2-Formylvinyl ether [45] H H 3-Alkoxyacrylate [62] OH R 
2-Formylvinylchloride [46] H R Alkoxyalkylene malonate [63] R OH 
3-Iminiovinylchloride [47] H R 2-Chloroacrylate [64]  OH R 
2-Formylenamine [48] H R Malonic ester [65] OH OH 
3-Iminioenamine [49] H R Malonyl chloride [66] OH OH 
3-Ketoaldehyde [50] R H 2-Acylketene mercaptal [67] SR R’ 
3-Ketoacetal [51] R H 2-Cyanoketene mercaptal [68] SR NH2 
3-Ketovinyl ether [52] H R Alkoxyalkylene cyanoacetate [69] R NH2 
3-Ketovinyl sulfone [53]
c
  R H Alkoxyalkylene malonitrile [70] R NH2 
3-Ketoenamine [54] H R 2-Formylnitrile [71] H NH2 
1,3-Diketone [55] R R’ 2-Cyanoenamine [72] H NH2 
3-Ketoalkyne [56] R
d
 H Malonitrile [73] NH2 NH2 
2-Formylcarboxylate [57] R OH 2-Thiocarbamylcarboxylate [74] NHR OH 
2-Alkoxycarbonylacetal [58] OH H    
a
or tautomeric form. 
b
Substituents on C-5 and C-7, respectively; R and R’ mean (possibly substituted) alkyl, aryl, 
heterocyclyl and H; OH means hydroxy or tautomeric oxo form. 
c
And regioisomeric 7-R compound. 
d
Deoxyaltrose derivative relating C-glycosides [75]. 
 
 In recent years, 3-ketoenamines have growing interest as building blocks for 
7-aryl triazolo[1,5-a]pyrimidines (Scheme 4.4, Path A) [76, 77]. They also serve to 
synthesize 7-heterocyclyl triazolo[1,5-a]pyrimidines [78, 79]. In addition to usual N, 
N-dimethyl compounds also analogues having a free amino group can be used as in 
the synthesis of 7-trifluoromethyl derivatives [80]. Enaminones can be formed in situ, 
for instance, from dimedone and DMF dimethylacetal [81]. 
 In the course of the cyclization of the stable tetrafluorobenzoyl derivative (23) 
(Scheme 4.5) fluorine at the o-position is involved in the reaction and is replaced to 
give trifluorobenzo triazolo[1,5-a]pyrimidine (24) [82]. Acetonyl is introduced as 
substituent into the 7-position by the use of triketone heptan-2,4,6-trione [83]. 
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F
F
F
F
COCl
+
NHN
NH2N
F
F
F
F
CO
NHN
NNH
DBU
F
F
F
N
H
N
N
N
O
(23) (24)
CNNC
NC CN
+
NHN
NH2N
N
N
N
N
CN
NC
H2N
(25)
COOEtAc
PhHN S
+
NHN
NH2N
N
H
N
N
N
O
(27)
PhHN
Scheme 4.5
(26)
 
 
The electron acceptor tetracyanoethylene on interaction with 5-amino-1,2,4-
triazole first forms a charge transfer complex that after loss of hydrocyanic acid is 
transformed into dicyano triazolo[1,5-a]pyrimidine (25) [84]. Fusion of 1,4-
naphthoquinone or indenone onto triazolo[1,5-a]pyrimidine can in a similar way be 
performed by the use of 2,3-dicyano-1,4-naphthoquinone or dicyanomethylene 
indane-1,3-dione, respectively. Another indeno-triazolo[1,5-a]pyrimidine is 
accessible from triketone 2-acetylindane-1,3-dione [85]. On the other hand, 
acetoacetic ester (26) with 5-amino-1,2,4-triazole suffers ester group cleavage to form 
anilino triazolo[1,5-a]pyrimidine (27) [86]. 
 
4.2.2 Other pyrimidine ring synthesis 
 
The annulation of pyrimidine onto the triazole ring can be accomplished by 
the use of heterocyclic precursors that can be regarded as masked 1,3-bifunctional 
reagents. This way, triacetic acid lactone (27) (Scheme 4.6) reacts as a masked 1,3-
diketone and transforms 5-amino-1,2,4-triazole to triazolo[1,5-a]pyrimidine (28) 
together with ring isomer (29) and decarboxylation product (30) [87]. Oxazolones 
play a similar [88-90]. Thus, enol ether (31) behaves as a masked 3-ethoxyacrylate 
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and yields, through intermediate (32), benzamido-4,5,6,7-tetrahydro-2-(methylthio)-7-
oxo-N-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-6-carbox- amide (TP) (33) that, under 
harsher conditions, directly forms from compound [30]. 
 
Scheme 4.6
O
OH
O
+
N
N
N
N
CH3
H3C
NHN
NN
O
HOOC
NHN
NH2N
N
N
N
N
H3C
COOEt
N
N
N
N
H3C
COOEt
+
(27)
(28) (29)
(30)
O
N O
Ph
+
NHN
NH2N SCH3
EtOH
N
N
H
N
N
H
SCH3
O
N O
Ph
(31) (32)
AcOH AcOH
N
H
N
N
N
O
PhHNOC
SCH3
(33)
 
4.2.3 2 Hydrazinopyrimidines and one-carbon synthons 
 
A second common triazolo[1,5-a]pyrimidine synthesis consists in the 
condensation of a C1-synthon with a 2-hydrazinopyrimidine derivative (e.g., 34, 
Scheme 4.7). A triazolo[4,3-a]-pyrimidine (35) initially forms that often can be 
isolated [91]. Harsher conditions allow it to isomerize to the target triazolo[1,5-
a]pyrimidine (36) by Dimroth rearrangement.  
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N
NH
NC
Ph
O
NH
NH2
HCOOH
N
H
N
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N
N
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N
H
N
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Ph
O
N
N
(34) (35) (36)
Scheme 4.7
 
 
4.2.4 Other triazole ring synthesis 
 
Most cyclization of 2,3-diaminopyrimidones (37) [92] or corresponding 
quinazolones proceed with the participation of carboxylic acids or their derivatives 
(esters, anhydrides, chlorides, or orthoesters) as shown in Scheme 4.8. Noncyclized or 
saturated intermediates (38, 39) can frequently be found during synthesis of 
triazolo[1,5-a]pyrimidines .  
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N
NH2
NH2
F3C
O
EtCOCl
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N
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F3C
O COEt
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N
N
H
H
N
O
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N
N
N
H
H
N
O
F3C
CH3
N
N
N
H
H
N
O
F3C
Et
(37)
(38)
(39)
Scheme 4.8
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4.3 Current work 
 
The biological importance of 1,2,4-triazolo[1,5-a]pyrimidines is well 
documented. Over the years, various substituted derivatives of these heterocycles 
have shown utility against a range of biological targets. For example, they have 
demonstrated activity against malaria and bronchospasm and shown activity as 
coronary vasodilators, antihypertensive agents, leishmanicides, antibiotics, adenosine 
A2a antagonists, immunosuppressants, antitumor agents, fungicides, xanthine oxidase 
inhibitors, and phosphodiesterase inhibitors.  
One of the synthetic pathways to 1,2,4-triazolo[1,5-a]pyrimidines is based on 
the Biginelli like cyclocondensation of aromatic aldehydes and acetoacetic acid 
derivatives with aminoazoles containing a guanidine fragment. There are literary data 
about the synthesis of triazolopyrimidines by treatment of 5-amino-1,2,4-triazole or 5-
aminotetrazole with aldehydes and ethyl acetoacetate or cyclic β-diketones [93]. The 
cyclocondensations were realized by heating of the starting materials in ethanol with 
catalytic amounts of hydrochloric acid under reflux conditions [93a-c] or using DMF 
as solvent [93d-e]. The use of acetoacetamides in these or similar reactions has not 
been described. 
Recognizing these facts, we have synthesised four new series of 1,2,4-
triazolo[1,5-a]pyrimidines (RHK-161 to 190) containing an acetoacetamide fragment. 
The structures of all the newly synthesized compounds were elucidated by FT-IR, 
mass spectra, 
1
H NMR and elemental analyses. The newly synthesized compounds 
were subjected to various biological activities viz., antimicrobial. 
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4.4 Reaction Scheme 
NH
O
O
+
R1
a
Reagents and conditions: (a) DMF, Reflux, 20 Minutes
HO
R2
HN
N
N
H2N
N
H
N
N
NN
H
O
R1
R2
RHK- 161 to 190
H3C
CH3
CH3
H3C
 
 
 
Code R1 R2 M.F. M.W. M.P. ºC Yield % Rf1 Rf2 
RHK-161 4-Cl 4-Cl C21H19Cl2N5O 428 202 66 0.52 0.70 
RHK-162 4-Cl 4-CH3 C22H22ClN5O 407 181 69 0.49 0.72 
RHK-163 4-Cl 4-OCH3 C22H22ClN5O2 423 257 78 0.45 0.66 
RHK-164 4-Cl 4-NO2 C21H19ClN6O3 438 222 70 0.48 0.59 
RHK-165 4-Cl 4-F C21H19ClFN5O 411 261 81 0.50 0.69 
RHK-166 4-Cl 3-NO2 C21H19ClN6O3 438 201 71 0.49 0.71 
RHK-167 4-Cl 3-Cl C21H19Cl2N5O 428 244 59 0.50 0.69 
RHK-168 4-Cl 2-NO2 C21H19ClN6O3 438 216 64 0.46 0.63 
RHK-169 4-Cl 4-OH C21H20ClN5O2 409 199 67 0.45 0.62 
RHK-170 4-Cl 3-Br C21H19BrClN5O 472 183 70 0.50 0.74 
RHK-171 3-Cl,4-F 4-Cl C21H18Cl2FN5O 445 256 68 0.48 0.70 
RHK-172 3-Cl,4-F 4-CH3 C22H21ClFN5O 425 227 66 0.46 0.66 
RHK-173 3-Cl,4-F 4-OCH3 C22H21ClFN5O2 441 257 62 0.45 0.65 
RHK-174 3-Cl,4-F 4-NO2 C21H18ClFN6O3 456 247 71 0.52 0.71 
RHK-175 3-Cl,4-F 4-F C21H18ClF2N5O 429 233 72 0.60 0.68 
RHK-176 3-Cl,4-F 3-NO2 C21H18ClFN6O3 456 246- 70 0.54 0.79 
RHK-177 3-Cl,4-F 3-Cl C21H18Cl2FN5O 445 235 63 0.53 0.71 
RHK-178 3-Cl,4-F 2-NO2 C21H18ClFN6O3 456 198 66 0.54 0.78 
RHK-179 3-Cl,4-F 4-OH C21H19ClFN5O2 427 209 80 0.42 0.61 
RHK-180 3-Cl,4-F 3-Br C21H18BrClFN5O 489 219 73 0.59 0.72 
RHK-181 4-F 4-Cl C21H19ClFN5O 411 208 70 0.44 0.56 
RHK-182 4-F 4-CH3 C22H22FN5O 391 233 68 0.49 0.66 
RHK-183 4-F 4-OCH3 C22H22FN5O2 407 217 62 0.55 0.68 
RHK-184 4-F 4-NO2 C21H19FN6O3 422 250 70 0.52 0.59 
RHK-185 4-F 4-F C21H19F2N5O 395 222 79 0.51 0.74 
RHK-186 4-F 3-NO2 C21H19FN6O3 422 218 68 0.44 0.66 
RHK-187 4-F 3-Cl C21H19ClFN5O 411 241 69 0.52 0.75 
RHK-188 4-F 2-NO2 C21H19FN6O3 422 228 67 0.53 0.74 
RHK-189 4-F 4-OH C21H20FN5O2 393 258 70 0.55 0.71 
RHK-190 4-F 3-Br C21H19BrFN5O 456 213 65 0.46 0.70 
 
 
TLC Solvent system Rf1: Hexane: Ethyl acetate – 6:4;  
                                   Rf2: Chloroform: Methanol - 9:1. 
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4.5 Plausible Reaction Mechanism 
N
H
N
N
NN
H
O
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NH2N
HO
R2
R2
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N
N
H2N
N
H
HN
N
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H
O
R1 NH
O
O
R1
HO
R2
-2 H2O-H2O
CH3
H3C
H3C
CH3
NH
O
O
R1
H3C
CH3
CH3
H3C
 
 
4.6 Experimental 
 
4.6.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. IR spectra were recorded 
Shimadzu FT-IR-8400 instrument using potassium bromide (KBr) pellet method. 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using direct 
injection probe technique. 
1
H NMR was determined in DMSO-d6 solution on a bruker 
Ac 400 MHz spectrometer. Elemental analysis of the all the synthesized compounds 
was carried out on elemental vario EL III carlo erba 1108 model and the results are in 
agreements with the structures assigned. 
 
4.6.2 Synthesis of N-(substituted phenyl)-4-methyl-3-oxopentanamide 
 
Synthesis of N-(substituted phenyl)-4-methyl-3-oxopentanamide was achieved using 
previously published methods [97]. 
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4.6.3 General procedure for the synthesis of N,7-bis(substitutedphenyl)-4,7-dihydro-
5-isopropyl-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamide (RHK - 161 to 190) 
 
A mixture of the 3-amino-1,2,4-triazole (0.01 M), N-(substituedphenyl)-4-
methyl-3-oxopentanamide (0.01 M) and an appropriate aromatic aldehydes (0.01 M) 
was refluxed in DMF (4 ml) for 20 min. After cooling, methanol (~10 ml) was added. 
The reaction mixture was allowed to stand overnight and then filtered to give the solid 
triazolopyrimidine products (RHK- 161 to 170), which were recrystallized from 
ethanol. 
 
4.6.3.1 N,7-bis(4-chlorophenyl)-4,7-dihydro-5-isopropyl-[1,2,4]triazolo-[1,5-a] 
pyrimidine-6-carboxamide (RHK-161) 
Yield: 66%; mp 202ºC; Anal. Calcd. for 
C21H19Cl2N5O: C, 58.89; H, 4.47; Cl, 16.55; N, 
16.35; O,3.74. Found: C, 58.79; H, 4.37; Cl, 16.33; 
N, 16.24; O,3.66%; IR (cm
-1
): 3344 (N-H stretching 
of secondary amine), 3070 (C-H stretching of 
aromatic ring), 2901 (C-H asymmetrical stretching 
of CH3 group), 2802 (C-H asymmetrical stretching of CH3 group), 1687 (C=O 
stretching of amide), 1599 (C=N stretching of triazole ring), 1531 (N-H deformation 
of pyrimidine ring), 1492 (C=C stretching of aromatic ring), 1381 (C-H asymmetrical 
deformation of CH3 group), 1309 (C-H symmetrical deformation of CH3 group), 
1247(C-N stretching), 1093 (C-H in plane deformation of aromatic ring), 833 (C-H 
out of plane bending of 1,4-disubstituion), 661 (C-Cl stretching); MS: m/z 428; 
1
H 
NMR (DMSO-d6) δ ppm: 1.15-117 (d, 3H, Ha, J = 10.00 Hz), 1.25-1.27 (d, 3H, Hb, J 
= 6.80 Hz), 3.20-3.27 (m, 1H, Hc), 6.50 (s, 1H, Hd), 7.12-7.16 (m, 2H, Hee’ ), 7.21-
7.25 (m, 2H, Hff’, J = 14.00 Hz), 7.29-7.32 (d, 2H, Hgg’, J = 8.80 Hz), 7.49-7.52 (d,  
2H, Hhh’, J = 8.80 Hz), 7.66 (s, 1H, Hi), 10.02 (s, 1H, Hj),10.09 (s, 1H, Hk). 
 
N
N
H
N
N
N
H
O
CH3
H3C
Cl
Cl
a b
h
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4.6.3.2 N-(4-chlorophenyl)-4,7-dihydro-5-isopropyl-7-p-tolyl-[1,2,4]triazolo- 
[1,5-a]pyrimidine-6-carboxamide (RHK-162) 
Yield: 69%; mp 181ºC; Anal. Calcd. for 
C21H19Cl2N5O: C, 58.89; H, 4.47; Cl, 16.55; N, 
16.35; O, 3.74; Found: C, 58.79; H, 4.37; Cl, 16.33; 
N, 16.24; O, 3.66%; IR (cm
-1
): 3383 (N-H stretching 
of secondary amine), 3030 (C-H stretching of 
aromatic ring), 2970 (C-H asymmetrical stretching 
of CH3 group), 2872 (C-H asymmetrical stretching of CH3 group), 1674 (C=O 
stretching of amide), 1550 (C=N stretching of triazole ring), 1519 (N-H deformation 
of pyrimidine ring), 1492 (C=C stretching of aromatic ring), 1402 (C-H asymmetrical 
deformation of CH3 group), 1342 (C-H symmetrical deformation of CH3 group), 1244 
(C-N stretching), 1138 (C-H in plane deformation of aromatic ring), 827(C-H out of 
plane bending of 1,4-disubstituion), 661 (C-Cl streching); MS: m/z 407; 
1
H NMR 
(DMSO-d6) δ ppm: 1.00-119 (d, 3H, Ha), 1.25-1.27 (d, 3H, Hb, J = 6.80 Hz),2.22 (s, 
3H, Hc) 3.24-3.30 (m, 1H, Hd), 6.47 (s, 1H, He), 7.05-7.10 (m, 4H, Hff’-gg’ ), 7.29-7.31 
(d, 2H, Hhh ’, J = 8.40 Hz), 7.53-7.55 (d, 2H, Hii’, J = 8.40 Hz), 7.64 (s, 1H, Hj), 9.96 
(s, 1H, Hk) 10.09 (s, 1H, Hl). 
 
4.6.3.3 N-(4-chlorophenyl)-4,7-dihydro-5-isopropyl-7-(4-methoxyphenyl)-[1,2,4]-tri- 
azolo[1,5-a]pyrimidine-6-carboxamide (RHK-163) 
 Yield: 78%; mp 257ºC; Anal. Calcd. for 
C22H22ClN5O2: C, 62.34; H, 5.23; Cl, 8.36; N, 16.52; 
O, 7.55; Found: C, 62.22; H, 5.00; Cl, 8.20; N, 16.40; 
O, 7.42%; IR (cm
-1
): 3292 (N-H stretching of 
secondary amine), 3070 (C-H stretching of aromatic 
ring), 2994 (C-H asymmetrical stretching of CH3 
group), 2868 (C-H asymmetrical stretching of CH3 group), 1631 (C=O stretching of 
amide), 1593 (C=N stretching of triazole ring), 1558 (N-H deformation of pyrimidine 
ring), 1491 (C=C stretching of aromatic ring), 1398 (C-H asymmetrical deformation 
of CH3 group), 1342 and 1303 (C-NO2 stretching), 1300 (C-H symmetrical 
deformation of CH3 group), 1244 (C-O-C asymmetrical stretching of OCH3), 1236 
(C-N stretching), 1206 (C-O-C asymmetrical stretching of OCH3), 1033 (C-H in plane 
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deformation of aromatic ring), 1012 (C-O-C symmetrical stretching of OCH3), 825 
(C-H out of plane bending of 1,4-disubstituion), 661 (C-Cl stretching); MS: m/z 
423;
1
H NMR (DMSO-d6) δ ppm: 1.12-1.17 (d, 3H, Ha), 1.28-1.29 (d, 3H, Hb, J = 6.80 
Hz), 3.29-3.31 (m, 1H, Hc, J = 7.20 Hz), 3.68 (s, 3H, Hd) 6.50 (s, 1H, He), 6.84-6.87 
(d, 2H, Hff’, J = 8.80 Hz), 7.13-7.15 (d, 2H, Hgg ’, J = 8.40 Hz), 7.54-7.58 (d, 1H, Hh, J 
= 8.40 Hz), 7.65 (s, 1H, Hi), 7.85-7.89 (m, 2H, Hjk) 8.54 (s, 1H, Hl) 10.03 (s, 1H, Hm) 
10.41 (s, 1H, Hn). 
 
4.6.3.4 N-(4-chlorophenyl)-4,7-dihydro-5-isopropyl-7-(4-nitrophenyl)-[1,2,4]- tria- 
zolo[1,5-a]pyrimidine-6-carboxamide (RHK-164) 
Yield: 70%; mp 222ºC; Anal. Calcd. for 
C21H19ClN6O3: C, 57.47; H, 4.36; Cl, 8.08; N, 19.15; 
O, 10.94; Found: C, 57.35; H, 4.25; Cl, 8.01; N, 
19.00; O, 10.86%; MS: m/z 438. 
 
 
 
4.6.3.5 N-(4-chlorophenyl)-7-(4-fluorophenyl)-4,7-dihydro-5-isopropyl- [1,2,4]- tria 
-zolo[1,5-a]pyrimidine-6-carboxamide (RHK-165) 
Yield: 81%; mp 261ºC; Anal. Calcd. for 
C21H19ClFN5O: C, 61.24; H, 4.65; Cl, 8.61; F, 4.61; 
N, 17.00; O, 3.88; Found: C, 61.14; H, 4.54; Cl, 8.45; 
F, 4.50; N, 16.89; O, 3.75; MS: m/z 411. 
 
 
 
4.6.3.6 N-(4-chlorophenyl)-4,7-dihydro-5-isopropyl-7-(3-nitrophenyl)-[1,2,4] triazo- 
lo[1,5-a]pyrimidine-6-carboxamide (RHK-166)  
Yield: 71%; mp 201ºC; Anal. Calcd. for 
C21H19ClN6O3: C, 57.47; H, 4.36; Cl, 8.08; N, 19.15; 
O, 10.94; Found: C, 57.35; H, 4.25; Cl, 8.01; N, 
19.00; O, 10.86%; MS: m/z 438. 
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4.6.3.7 7-(3-chlorophenyl)-N-(4-chlorophenyl)-4,7-dihydro-5-isopropyl-[1,2,4]- tria- 
zolo[1,5-a]pyrimidine-6-carboxamide (RHK-167) 
Yield: 59%; mp 244ºC; Anal. Calcd. for 
C21H19Cl2N5O: C, 58.89; H, 4.47; Cl, 16.55; N, 
16.35; O, 3.74; Found: C, 58.74; H, 4.34; Cl, 16.45; 
N, 16.24; O, 3.64%; MS: m/z 428. 
 
 
 
4.6.3.8 N-(4-chlorophenyl)-4,7-dihydro-5-isopropyl-7-(2-nitrophenyl)-[1,2,4]triazo 
-lo[1,5-a]pyrimidine-6-carboxamide (RHK-168) 
Yield: 64%; mp 216ºC; Anal. Calcd. for 
C21H19ClN6O3: C, 57.47; H, 4.36; Cl, 8.08; N, 19.15; 
O, 10.94; Found: C, 57.33; H, 4.23; Cl, 8.00; N, 
19.05; O, 10.88%; MS: m/z 438. 
 
 
 
4.6.3.9 N-(4-chlorophenyl)-4,7-dihydro-7-(4-hydroxyphenyl)-5-isopropyl-[1,2,4] 
triazolo[1,5-a]pyrimidine-6-carboxamide 
(RHK-169)  
Yield: 67%; mp 199 ºC; Anal. Calcd. for 
C21H20ClN5O2 : C, 61.54; H, 4.92; Cl, 8.65; N, 
17.09; O, 7.81; Found: C, 61.35; H, 4.85; Cl, 8.53; 
N, 17.00; O, 7.71%; MS: m/z 409. 
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4.6.3.10 7-(3-bromophenyl)-N-(4-chlorophenyl)-4,7-dihydro-5-isopropyl-[1,2,4] tria 
-zolo[1,5-a]pyrimidine-6-carboxamide (RHK-170) 
Yield: 70%; mp 183ºC; Anal. Calcd. for 
C21H19BrClN5O: C, 53.35; H, 4.05; Br, 16.90; Cl, 
7.50; N, 14.81; O, 3.38; Found: C, 53.13; H, 4.00; 
Br, 16.81; Cl, 7.41; N, 14.72; O, 3.23%; MS: m/z 
472. 
 
 
4.6.4 General procedure for the synthesis of N-(3-chloro-4-fluorophenyl)-7-(4-
chlorophenyl)-4,7-dihydro-5-isopropyl-[1,2,4]triazolo[1,5-a]pyrimidine-6-
carboxamide (RHK-171to180) 
 
A mixture of the 3-amino-1,2,4-triazole (0.01 mol), N-(3-chloro-4- 
fluorophenyl)-4-methyl-3-oxopentanamide (0.01 mol) and an appropriate aromatic 
aldehydes (0.01 mol) was refluxed in 0.4 ml of DMF for 12-15 min. After cooling, 
methanol (~10 ml) was added. The reaction mixture was allowed to stand overnight 
and then filtered to give the solid triazolopyrimidine products RHK- 171 to 180, 
which were crystallized from ethanol. 
 
4.6.4.1 N-(3-chloro-4-fluorophenyl)-7-(4-chlorophenyl)-4,7-dihydro-5-isopropyl-[1,2,4] tria- 
zolo[1,5-a]pyrimidine-6-carboxamide (RHK-171)  
Yield: 68%; mp 256ºC; Anal. Calcd. for 
C21H18Cl2FN5O: C, 56.51; H, 4.07; Cl, 15.89; F, 
4.26; N, 15.69; O, 3.58; Found: C, 56.40; H, 4.00; 
Cl, 15.75; F, 4.15; N, 15.56; O, 3.42%; MS: m/z 445. 
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4.6.4.2 N-(3-chloro-4-fluorophenyl)-4,7-dihydro-5-isopropyl-7-p-tolyl-[1,2,4]tria- 
zolo[1,5-a]pyrimidine-6-carboxamide (RHK-172) 
Yield: 66%; mp 227ºC; Anal. Calcd. for 
C22H21ClFN5O: C, 62.04; H, 4.97; Cl, 8.32; F, 4.46; 
N, 16.44; O, 3.76; Found: C, 61.89; H, 4.82; Cl, 8.20; 
F, 4.31; N, 16.36; O, 3.62; IR (cm
-1
): 3377 (N-H 
stretching of secondary amine), 3022 (C-H 
stretching of aromatic ring), 2970 (C-H 
asymmetrical stretching of CH3 group), 2870 (C-H asymmetrical stretching of CH3 
group), 1666 (C=O stretching of amide), 1577 (C=N stretching of triazole ring), 1550 
(N-H deformation of pyrimidine ring), 1529 and 1500 (C=C stretching of aromatic 
ring), 1408 (C-H asymmetrical deformation of CH3 group), 1307 (C-H symmetrical 
deformation of CH3 group), 1282 (C-N stretching), 1078 (C-H in plane deformation 
of aromatic ring), 1141 (C-F stretching) 815 (C-H out of plane bending of 1,4-
disubstituion), 667 (C-Cl stretching); MS: m/z 425; 
1
H NMR (DMSO-d6) δ ppm: 
1.15-1.17 (d, 3H, Ha, J = 7.20 Hz), 1.27-1.29 (d, 3H, Hb, J = 7.20 Hz), 2.20 (s, 3H, 
Hc) 3.28-3.33 (m, 1H, Hd),) 6.42 (s, 1H, Hd), 6.93-6.97 (m, 1H, Hf), 7.01-7.03 (d, 2H, 
Hgg ’, J = 8.00 Hz), 7.09-7.11 (d, 1H, Hhh’, J = 8.00 Hz), 7.25-7.29 (m, 1H, Hi), 7.49 
(m, 1H, Hj), 7.62 (s, 1H, Hk), 9.65 (s, 1H, Hl), 9.74 (s, 1H, Hm). 
 
4.6.4.3 N-(3-chloro-4-fluorophenyl)-4,7-dihydro-5-isopropyl-7-(4-methoxyphenyl) 
-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamide 
(RHK-173) 
Yield: 62%; mp 257ºC; Anal. Calcd. for 
C22H21ClFN5O2: C, 59.80; H, 4.79; Cl, 8.02; F, 4.30; 
N, 15.85; O, 7.24; Found: C, 59.70; H, 4.66; Cl, 7.89; 
F, 4.21; N, 15.74; O, 7.11; IR (cm
-1
): 3369 (N-H 
stretching of secondary amine), 3084 (C-H 
stretching of aromatic ring), 2970 (C-H asymmetrical stretching of CH3 group), 2868 
(C-H asymmetrical stretching of CH3 group), 1664 (C=O stretching of amide), 1664 
(C=N stretching of triazole ring), 1573 (N-H deformation of pyrimidine ring), 1550 
(C=C stretching of aromatic ring), 1468 (C-H asymmetrical deformation of CH3 
group), 1307 (C-H symmetrical deformation of CH3 group), 1280 (C-N stretching), 
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1247 (C-O-C stretching),1035 (C-F stretching), 1076 (C-H in plane deformation of 
aromatic ring), 779 (C-H out of plane bending of 1,4-disubstituion), 663 (C-Cl 
stretching); MS: m/z 441; 
1
H NMR (DMSO-d6) δ ppm: 1.23-1.25 (d, 3H, Ha, J = 7.20 
Hz), 1.36-1.38 (d, 3H, Hb, J = 7.20 Hz), 3.38-3.45 (m, 1H, Hc), 3.73-3.75 (s, 3H, Hd)  
6.49 (s, 1H, He), 6.81-6.84 (d, 2H, Hff’, J = 13.60 Hz), 7.00-7.04 (m, 1H, Hg), 7.24-
7.27 (d, 2H, Hhh’, J = 11.60 Hz), 7.31-7.35 (m, 1H, Hi), 7.58 (s, 1H, Hj), 7.64 (s, 1H, 
Hk), 9.66 (s, 1H, Hl), 9.84 (s, 1H, Hm). 
 
4.6.4.4 N-(3-chloro-4-fluorophenyl)-4,7-dihydro-5-isopropyl-7-(4-nitrophenyl)-
[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamide 
(RHK-174) 
Yield: 71%; mp 247ºC; Anal. Calcd. for 
C21H18ClFN6O3: C, 55.21; H, 3.97; Cl, 7.76; F, 4.16; 
N, 18.40; O, 10.51; Found: C, 55.12; H, 3.84; Cl, 
7.61; F, 4.03; N, 18.34; O, 10.41; MS: m/z 456. 
 
 
4.6.4.5 N-(3-chloro-4-fluorophenyl)-4,7-dihydro-5-isopropyl-7-(4-fluorophenyl) -
[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamide 
(RHK-175) 
 Yield: 72%; mp 233ºC; Anal. Calcd. for 
C21H18ClF2N5O: C, 58.68; H, 4.22; Cl, 8.25; F, 8.84; 
N, 16.29; O, 3.72; Found: C, 58.68; H, 4.11; Cl, 8.10; 
F, 8.68; N, 16.12; O, 3.62; IR (cm
-1
): 3421 (N-H 
stretching of secondary amine), 3024 (C-H 
stretching of aromatic ring), 2924 (C-H asymmetrical stretching of CH3 group), 2875 
(C-H asymmetrical stretching of CH3 group), 1668 (C=O stretching of amide), 1575 
(C=N stretching of triazole ring), 1552 (N-H deformation of pyrimidine ring), 1498 
(C=C stretching of aromatic ring), 1410 (C-H asymmetrical deformation of CH3 
group), 1305 (C-H symmetrical deformation of CH3 group), 1242 (C-N stretching),  
1087 (C-H in plane deformation of aromatic ring), 1012 (C-F stretching), 819 (C-H 
out of plane bending of 1,4-disubstituion), 686 (C-Cl stretching); MS: m/z 429;  
1
H 
NMR (DMSO-d6) δ ppm: 1.15-1.17 (d, 3H, Ha, J = 7.20 Hz), 1.27-1.29 (d, 3H, Hb, J 
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= 7.20 Hz), 3.30-3.37 (m, 1H, Hc), 6.41 (s, 1H, Hd), 6.73-6.75 (d, 2H, Hee’, J = 8.80 
Hz), 6.82-6.87 (m, 2H, Hfg), 7.16-7.18 (d, 1H, Hh, J = 8.40 Hz), 7.36-7.40 (m, 1H, 
Hi), 7.48 (s, 1H, Hj), 7.67 (s, 1H, Hk) ,9.50 (s, 1H, Hl), 9.71 (s, 1H, Hm). 
 
4.6.4.6 N-(3-chloro-4-fluorophenyl)-4,7-dihydro-5-isopropyl-7-(3-nitrophenyl)- 
[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamide 
(RHK-176) 
Yield: 70%; mp 247ºC; Anal. Calcd. for 
C21H18ClFN6O3: C, 55.21; H, 3.97; Cl, 7.76; F, 4.16; 
N, 18.40; O, 10.51; Found: C, 55.21; H, 3.97; Cl, 
7.76; F, 4.16; N, 18.40; O, 10.51%; MS: m/z 456. 
 
 
4.6.4.7 N-(3-chloro-4-fluorophenyl)-4,7-dihydro-5-isopropyl-7-(3-chlorophenyl) 
-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamide 
(RHK-177) 
Yield: 63%; mp 235ºC; Anal. Calcd. for 
C21H18Cl2FN5O: C, 56.51; H, 4.07; Cl, 15.89; F, 
4.26; N, 15.69; O, 3.58; Found: C, 56.43; H, 4.00; 
Cl, 15.72; F, 4.10; N, 15.54; O, 3.42%; MS: m/z 445. 
 
 
4.6.4.8 N-(3-chloro-4-fluorophenyl)-4,7-dihydro-5-isopropyl-7-(2-nitrophenyl)-
[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamide 
(RHK-178) 
Yield: 66%; mp 198ºC; Anal. Calcd. for 
C21H18ClFN6O3: C, 55.21; H, 3.97; Cl, 7.76; F, 4.16; 
N, 18.40; O, 10.51;Found: C, 55.10; H, 3.88; Cl, 
7.64; F, 4.05; N, 18.31; O, 10.42%; MS: m/z 456. 
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4.6.4.9 N-(3-chloro-4-fluorophenyl)-4,7-dihydro-5-isopropyl-7-(4-nitrophenyl)-
[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamide 
(RHK-179) 
Yield: 80%; mp 209 ºC; Anal. Calcd. for 
C21H19ClFN5O2: C, 58.95; H, 4.48; Cl, 8.29; F, 4.44; 
N, 16.37; O, 7.48; Found: C, 58.87; H, 4.34; Cl, 8.10; 
F, 4.34; N, 16.23; O, 7.34%; MS: m/z 427. 
 
 
4.6.4.10 N-(3-chloro-4-fluorophenyl)-4,7-dihydro-5-isopropyl-7-(3-bromophenyl) 
-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamide 
(RHK-180)  
Yield: 73%; mp 219 ºC; Anal. Calcd. for 
C21H18BrClFN5O: C, 51.40; H, 3.70; Br, 16.28; Cl, 
7.22; F, 3.87; N, 14.27; O, 3.26; Found: C, 51.31; H, 
3.61; Br, 16.15; Cl, 7.10; F, 3.76; N, 14.14; O, 
3.12%; MS: m/z 489. 
 
4.6.5 General procedure for the synthesis of N-7-(4-chlorophenyl)-N-(4-
fluorophenyl)-4,7-dihydro-5-isopropyl-[1,2,4]triazolo[1,5-a]pyrimidine-6-
carboxamide (RHK 181 to190) 
 
A mixture of the 5-amino-1,2,4-triazole (0.01 mol), N-(4-fluorophenyl)-3-
oxobutanamide (0.01 mol) and an appropriate aromatic aldehydes (0.01 mol) was 
refluxed in 0.4 ml of DMF for 20 min. After cooling, methanol (~10 ml) was added. 
The reaction mixture was allowed to stand overnight and then filtered to give the solid 
triazolopyrimidine products RHK- 181 to 190, which were crystallized from ethanol 
and subsequently dried in air. 
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4.6.5.1 7-(4-chlorophenyl)-N-(4-fluorophenyl)-4,7-dihydro-5-isopropyl-[1,2,4]tria- 
zolo[1,5-a]pyrimidine-6-carboxamid (RHK-181) 
Yield: 70%; mp 208ºC; Anal. Calcd. for 
C21H19ClFN5O: C, 61.24; H, 4.65; Cl, 8.61; F, 4.61; 
N, 17.00; O, 3.88; Found: C, 61.13; H, 4.56; Cl, 8.52; 
F, 4.54; N, 16.86; O, 3.76%;   
 
 
 
4.6.5.2  N-(4-fluorophenyl)-4,7-dihydro-5-isopropyl-7-p-tolyl-[1,2,4]triazolo[1,5-a] 
pyrimidine-6-carboxamide (RHK-182) 
Yield: 68%; mp 233ºC; Anal. Calcd. for 
C22H22FN5O: C, 67.50; H, 5.66; F, 4.85; N, 17.89; O, 
4.09; Found: C, 67.44; H, 5.54; F, 4.72; N, 17.70; O, 
4.00;  IR (cm
-1
): 3389 (N-H stretching of secondary 
amine), 3020 (C-H stretching of aromatic ring), 
2928 (C-H asymmetrical stretching of CH3 group), 
2864 (C-H asymmetrical stretching of CH3 group), 1668 (C=O stretching of amide), 
1581 (C=N stretching of triazole ring),1566 (N-H deformation of pyrimidine ring), 
1510 and 1475 (C=C stretching of aromatic ring), 1404 (C-H asymmetrical 
deformation of CH3 group), 1305 (C-H symmetrical deformation of CH3 group), 1220 
(C-N stretching), 1139 (C-F stretching), 1072 (C-H in plane deformation of aromatic 
ring), 827 (C-H out of plane bending of 1,4-disubstituion); MS: m/z 391;
1
H NMR 
(DMSO-d6) δ ppm: 1.15-1.16 (d, 3H, Ha, J = 7.20 Hz), 1.26-1.28 (d, 3H, Hb, J = 7.20 
Hz), 2.21 (s, 3H, Hc) 3.27-3.34 (m, 1H, Hd),) 6.43 (s, 1H, Hd), 6.85-6.90 (m, 2H, Hfg), 
7.01-7.03 (d, 2H, Hhh’, J = 8.00 Hz), 7.08-7.10 (d, 1H, Hii’, J = 8.00 Hz), 7.40-7.47 
(m, 2H, Hjk), 7.86 (m, 1H, Hl), 9.69 (s, 1H, Hm), 9.65 (s, 1H, Hl), 9.72 (s, 1H, Hn). 
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4.6.5.3 7-(4-chlorophenyl)-N-(4-methoxyphenyl)-4,7-dihydro-5-isopropyl-[1,2,4] 
triazolo[1,5-a]pyrimidine-6-carboxamide      
(RHK-183)  
Yield: 62%; mp 217 ºC; Anal. Calcd. for 
C22H22FN5O2: C, 64.85; H, 5.44; F, 4.66; N, 17.19; 
O, 7.85; Found: C, 64.72; H, 5.33; F, 4.54; N, 17.10; 
O, 7.72%; IR (cm
-1
): 3375 (N-H stretching of 
secondary amine), 3020 (C-H stretching of aromatic 
ring), 2929 (C-H asymmetrical stretching of CH3 group), 2877 (C-H asymmetrical 
stretching of CH3 group), 1664 (C=O stretching of amide), 1606 (C=N stretching of 
triazole ring), 1577 (N-H deformation of pyrimidine ring), 1533 and 1508 (C=C 
stretching of aromatic ring), 1475 (C-H asymmetrical deformation of CH3 group), 
1311 (C-H symmetrical deformation of CH3 group), 1244 (C-O-C asymatrical 
stretching of OCH3), 1217 (C-N stretching), 1074 (C-H in plane deformation of 
aromatic ring), 1031 (C-F stretching), 831 (C-H out of plane bending of 1,4-
disubstituion); MS: m/z 407;
 1
H NMR (DMSO-d6) δ ppm: 1.15-1.17 (d, 3H, Ha, J = 
7.20 Hz), 1.27-1.29 (d, 3H, Hb, J = 7.20 Hz), 3.28-3.33 (m, 1H, Hc), 3.76 (s, 3H, Hd)  
6.42 (s, 1H, He), 6.93-6.97 (m, 1H, Hf), 7.01-7.03 (d, 2H, Hgg’, J = 8.00 Hz), 7.09-7.11 
(d, 2H, Hhh’, J = 8.00 Hz), 7.25-7.29 (m, 2H, Hij), 7.49 (s, 1H, Hk), 7.62 (s, 1H, Hl), 
9.65 (s, 1H, Hm), 9.74 (s, 1H, Hn). 
. 
4.6.5.4 7-(4-chlorophenyl)-N-(4-nitrophenyl)-4,7-dihydro-5-isopropyl-[1,2,4]tria- 
zolo[1,5-a]pyrimidine-6-carboxamide (RHK-184) 
Yield: 70%; mp 250ºC; Anal. Calcd. for 
C21H19FN6O3: C, 59.71; H, 4.53; F, 4.50; N, 19.90; 
O, 11.36; Found: C, 59.64; H, 4.46; F, 4.43; N, 
19.87; O, 11.23%; MS: m/z 422. 
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4.6.5.5  N,7-bis(4-fluorophenyl)-4,7-dihydro-5-isopropyl-[1,2,4]triazolo[1,5-a]pyri- 
midine-6-carboxamide (RHK-185) 
Yield: 79%; mp 222ºC; Anal. Calcd. for 
C21H19F2N5O: C, 63.79; H, 4.84; F, 9.61; N, 17.71; 
O, 4.05 Found: C, 63.64; H, 4.76; F, 9.51; N, 17.60; 
O, 4.00%; IR (cm
-1
): 3281 (N-H stretching of 
secondary amine), 3030 (C-H stretching of aromatic 
ring), 2931 (C-H asymmetrical stretching of CH3 
group), 2875 (C-H asymmetrical stretching of CH3 group), 1658 (C=O stretching of 
amide), 1635 (C=N stretching of triazole ring), 1587 (N-H deformation of pyrimidine 
ring), 1512 (C=C stretching of aromatic ring), 1408 (C-H asymmetrical deformation 
of CH3 group), 1319 (C-H symmetrical deformation of CH3 group), 1226 (C-N 
stretching), 1085 (C-H in plane deformation of aromatic ring), 1014 (C-F stretching), 
831 (C-H out of plane bending of 1,4-disubstituion); MS: m/z 411; 
1
H NMR (DMSO-
d6) δ ppm: 1.15-1.17 (d, 3H, Ha, J = 7.20 Hz), 1.27-1.29 (d, 3H, Hb, J = 7.20 Hz), 
3.26-3.34 (m, 1H, Hc), 6.48 (s, 1H, Hd), 6.84-6.95 (m, 2H, Hef), 7.22-7.26 (m, 2H, 
Hgh), 7.37-7.40 (m, 2H, Hij, J = 11.20 Hz), 7.50-7.54 (m, 2H, Hkl), 7.73 (s, 1H, Hm), 
9.66 (s, 1H, Hn), 9.79 (s, 1H, Ho). 
 
4.6.5.6 7-(4-chlorophenyl)-N-(3-nitrophenyl)-4,7-dihydro-5-isopropyl-[1,2,4]triazolo 
[1,5-a]pyrimidine-6- carboxamide (RHK-186)   
Yield: 68%; mp 218ºC; Anal. Calcd. for 
C21H19FN6O3: C, 59.71; H, 4.53; F, 4.50; N, 19.90; 
O, 11.36; Found: C, 59.62; H, 4.41; F, 4.40; N, 
19.79; O, 11.12%; MS: m/z 422. 
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4.6.5.7 7-(4-chlorophenyl)-N-(3-chlorophenyl)-4,7-dihydro-5-isopropyl-[1,2,4 tria- 
zolo[1,5-a]pyrimidine-6-carboxamide (RHK-187)   
Yield: 69%; mp 241ºC; Anal. Calcd. for 
C21H19ClFN5O: C, 61.24; H, 4.65; Cl, 8.61; F, 4.61; 
N, 17.00; O, 3.88; Found: C, 61.12; H, 4.52; Cl, 8.54; 
F, 4.51; N, 16.88; O, 3.74%; MS: m/z 411. 
 
 
 
4.6.5.8 7-(4-chlorophenyl)-N-(2-nitrophenyl)-4,7-dihydro-5-isopropyl-[1,2,4]tria- 
zolo[1,5-a]pyrimidine-6-carboxamide (RHK-188)   
Yield: 67%; mp 228ºC; Anal. Calcd. for 
C21H19FN6O3: C, 59.71; H, 4.53; F, 4.50; N, 19.90; 
O, 11.36; Found: C, 59.64; H, 4.43; F, 4.42; N, 
19.80; O, 11.21%; MS: m/z 422. 
 
 
 
4.6.5.9 7-(4-chlorophenyl)-N-(4-hydroxyphenyl)-4,7-dihydro-5-isopropyl-[1,2,4]tria- 
zolo[1,5-a]pyrimidine-6-carboxamide (RHK-189)  
Yield: 70%; mp 258ºC; Anal. Calcd. for 
C21H20FN5O2: C, 64.11; H, 5.12; F, 4.83; N, 17.80; 
O, 8.13; Found. C, 64.11; H, 5.12; F, 4.83; N, 17.80; 
O, 8.13%; MS: m/z 393. 
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4.6.5.10 7-(4-chlorophenyl)-N-(3-bromophenyl)-4,7-dihydro-5-isopropyl-[1,2,4]tria-  
zolo[1,5-a]pyrimidine-6-carboxamide (RHK-190) 
Yield: 65%; mp 213ºC; Anal. Calcd. for 
C21H19BrFN5O: C, 55.27; H, 4.20; Br, 17.51; F, 
4.16; N, 15.35; O, 3.51; Found: C, 55.27; H, 4.20; 
Br, 17.51; F, 4.16; N, 15.35; O, 3.51%; MS: m/z 
456 
 
 
4.7 Spectral discussion 
 
4.7.1 Mass spectral study 
 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using 
Direct Injection Probe technique. Systematic fragmentation pattern was observed in 
mass spectral analyses. Molecular ion peak was observed in agreement with 
molecular weight of respective compound. Mass fragmentation pattern for a 
representative compound of each series is depicted below. 
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4.7.1.1 Mass fragmentation pattern for RHK-162 
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4.7.1.2 Mass fragmentation pattern for RHK-173 
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4.7.1.2 Mass fragmentation pattern for RHK-181 
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4.7.2 IR spectral study 
 
IR spectra were recorded on Shimadzu FT-IR-8400 model using potassium 
bromide (KBr) pellet method. Various functional groups present in molecule were 
identified by characteristic frequency obtained for them. For triazolopyrimidines 
RHK-161to190, confirmatory bands for secondary amine and amidic carbonyl groups 
were observed at 3414-3282 cm
-1 
and 1690-1600 cm
-1 
respectively. Another 
characteristic C=N stretching band of triazole ring was observed at 1626-1500 cm
-1
, 
which suggested formation of desired products RHK- 161 to 190.
 
  
 
4.7.3 
1
H NMR spectral study 
 
1
H NMR spectra were recorded in DMSO-d6 solution on a bruker Ac 400 
MHz spectrometer using TMS as an internal standard. Number of protons and their 
chemical shifts were found to support the structure of the synthesized compounds. 
1
H NMR spectra confirmed the structures of triazolopyrimidines (RHK- 161 
to 190) on the basis of following signals: a singlet for the methine proton of 
pyrimidine ring at 6.40-6.82 δ ppm, a singlet for the methine proton of triazole ring at 
7.20-8.30 δ ppm and singlets for amino and amide group protons at 7.50-9.90 and 
9.45-10.50 δ ppm, respectively. The aromatic ring protons and J value were found to 
be in accordance with substitution pattern on phenyl ring.  
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IR spectrum of RHK - 161 
 
Mass spectrum of RHK - 161 
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1
H NMR spectrum of RHK - 161 
 
Expanded 
1
H NMR spectrum of RHK - 161 
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IR spectrum of RHK - 162 
 
Mass spectrum of RHK - 162 
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1
H NMR spectrum of RHK - 162 
 
Expanded 
1
H NMR spectrum of RHK - 162 
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IR spectrum of RHK - 163 
 
Mass spectrum of RHK - 163 
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1
H NMR spectrum of RHK - 163 
 
Expanded 
1
H NMR spectrum of RHK - 163 
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IR spectrum of RHK - 172 
 
 Mass spectrum of RHK - 172 
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1
H NMR spectrum of RHK - 172 
 
Expanded 
1
H NMR spectrum of RHK - 172 
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IR spectrum of RHK - 173 
 
Mass spectrum of RHK - 173 
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1
H NMR spectrum of RHK – 173 
 
Expanded 
1
H NMR spectrum of RHK - 173 
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IR spectrum of RHK - 175 
 
Mass spectrum of RHK - 175 
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1
H NMR spectrum of RHK - 175 
 
Expanded 
1
H NMR spectrum of RHK - 175 
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IR spectrum of RHK - 182 
 
Mass spectrum of RHK - 182 
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1
H NMR spectrum of RHK - 182 
 
Expanded 
1
H NMR spectrum of RHK - 182 
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IR spectrum of RHK - 183 
 
Mass spectrum of RHK - 183 
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1
H NMR spectrum of RHK - 183 
 
Expanded 
1
H NMR spectrum of RHK - 183 
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IR spectrum of RHK - 185 
 
Mass spectrum of RHK - 185 
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1
H NMR spectrum of RHK - 185 
 
Expanded 
1
H NMR spectrum of RHK - 185 
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4.8 Biological evaluation 
 
4.8.1 Antimicrobial evaluation 
 
All of the synthesized compounds (RHK - 161 TO 190) were tested for their 
antibacterial and antifungal activity (MIC) in vitro by broth dilution method [98-100] 
with two Gram-positive bacteria Staphylococcus aureus MTCC-96, Streptococcus 
pyogenes MTCC 443, two Gram-negative bacteria Escherichia coli MTCC 442, 
Pseudomonas aeruginosa MTCC 441 and three fungal strains Candida albicans 
MTCC 227, Aspergillus Niger MTCC 282, Aspergillus clavatus MTCC 1323 taking 
gentamycin, ampicillin, chloramphenicol, ciprofloxacin, norfloxacin, nystatin and 
greseofulvin as standard drugs. The standard strains were procured from the Microbial 
Type Culture Collection (MTCC), Institute of Microbial Technology, Chandigarh, 
India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the compound 
preventing the visible growth, were determined by using micro dilution broth method 
according to NCCLS standards [98].  
 
Minimal Inhibition Concentration [MIC]:- 
 
The main advantage of the ‘Broth Dilution Method’ for MIC determination 
lies in the fact that it can readily be converted to determine the MIC as well. 
 
1. Serial dilutions were prepared in primary and secondary screening. 
2. The control tube containing no antibiotic is immediately subcultured (before 
inoculation) by spreading a loopful evenly over a quarter of plate of medium 
suitable for the growth of the test organism and put for incubation at 37
 0
C 
overnight.  
3. The MIC of the control organism is read to check the accuracy of the drug 
concentrations.  
4. The lowest concentration inhibiting growth of the organism is recorded as the 
MIC.  
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5. The amount of growth from the control tube before incubation (which 
represents the original inoculums) is compared.  
 
Methods used for primary and secondary screening: - 
 
Each synthesized drug was diluted obtaining 2000 µg mL
-1 
concentration, as a 
stock solution. Inoculum size for test strain was adjusted to 10
8
 cfu (colony forming 
unit) per milliliter by comparing the turbidity. 
Primary screen: - In primary screening 1000 µg mL
-1
, 500 µg mL
-1 
and 250 µg mL
-1 
concentrations of the synthesized drugs were taken. The active synthesized drugs 
found in this primary screening were further tested in a second set of dilution against 
all microorganisms.  
Secondary screen: - The drugs found active in primary screening were similarly 
diluted to obtain 200 µg mL
-1
, 100 µg mL
-1
, 50 µg mL
-1
, 25 µg mL
-1
, 12.5 µg mL
-1
, 
and 6.250 µg mL
-1
 concentrations.  
 
Reading Result: - The highest dilution showing at least 99 % inhibition zone is taken 
as MIC. The result of this is much affected by the size of the inoculums. The test 
mixture should contain 10
8 
organism/mL.           
                 
The results obtained from antimicrobial susceptibility testing are depicted in Table 1. 
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Table 1. Antibacterial and antifungal activity of synthesized compounds RHK- 
161 to 190 
 
 
 
 
 
 
 
 
Code Minimal inhibition concentration (µg mL
-1 
) 
Gram-positive Gram-negative Fungal species 
S.a. S. p. E.c. P.a. C. a. A. n. A.c. 
RHK-161 1000 1000 500 500 250 1000 1000 
RHK-162 100 200 100 100 500 500 500 
RHK-163 250 250 200 250 >1000 250 250 
RHK-164 1000 500 500 100 250 >1000 >1000 
RHK-165 250 250 250 250 >1000 1000 1000 
RHK-166 150 200 200 100 1000 500 500 
RHK-167 1000 500 250 500 1000 500 1000 
RHK-168 150 250 250 250 250 1000 1000 
RHK-169 150 200 250 100 500 500 1000 
RHK-170 62.5 500 250 1000 500 250 250 
RHK-171 250 250 250 250 500 500 500 
RHK-172 200 200 50 100 250 1000 1000 
RHK-173 250 250 500 500 500 250 250 
RHK-174 250 500 100 200 500 200 200 
RHK-175 100 200 100 250 1000 >1000 >1000 
RHK-176 250 100 250 500 1000 >1000 >1000 
RHK-177 200 50 50 100 500 500 1000 
RHK-178 250 500 150 200 500 1000 >1000 
RHK-179 500 1000 500 500 500 1000 1000 
RHK-180 100 100 500 250 200 1000 1000 
RHK-181 150 200 250 250 >1000 500 250 
RHK-182 100 200 200 250 500 500 500 
RHK-183 200 250 250 250 >1000 >1000 >1000 
RHK-184 250 250 500 500 >1000 >1000 >1000 
RHK-185 1000 1000 500 250 1000 250 250 
RHK-186 250 500 150 500 1000 250 500 
RHK-187 1000 1000 1000 500 1000 500 500 
RHK-188 200 250 200 100 250 >1000 >1000 
RHK-189 500 250 500 250 >1000 1000 1000 
RHK-190 200 250 62.5 100 1000 500 500 
Gentamycin 0.25 0.5 0.05 1 - - - 
Ampicillin 250 100 100 100 - - - 
Chloramphenicol 50 50 50 50 - - - 
Iprofloxacin 50 50 25 25 - - - 
Norfloxacin 10 10 10 10 - - - 
Nystatin - - - - 100 100 100 
Griseofulvin - - - - 500 100 100 
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4.8.2 Antimycobacterial, anticancer and antiviral evaluation 
 
Antimycobacterial, anticancer and antiviral screening of all the newly 
synthesized compounds (RHK- 161 to 190) is currently under investigation and 
results are awaited.  
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CHAPTER 5  
Synthesis and biological evaluation of 
1,4-dihydropyrimido[1,2- a]benz- 
imidazole 
 
 
5.1 Introduction 
 
Polysubstituted pyrimido[1,2-a]benzimidazoles possess a wide spectrum of 
biological activities and they are structurally related to natural purine bases. 
                                              
N
N
N
Pyrimido[1,2-a]benzimidazole(1)
 
 
From the standpoint of biological activity, fused heteroaromatic systems are 
often of much greater interest than the constituent monocyclic compounds. 
Antimicrobial [1-4], antimalarial [5], antiproliferative [6], protein kinase inhibitor, [7], 
T cell activation, [8], angioprotein receptors and/or vascular endothelial growth factor 
receptor-2 (VEGFR-2) inhibitory activities. [9], hypotensive, spasmolytic, and 
antiaggregant activities [10], anesthetic  activity [11] and diuretic [12], 
antiInflammatory (2) [13, 14], antiamoebic [15], substance P receptor binding activity 
[16], antiarrhythmic [17], central nervous system-depressing [18], antidiabetics [19], 
virucidal [20], neurotropic [21], benzodiazepine receptor binding activity (4) [22], 
antiparasitic (6) [23], herbicidal [24], DNA-topoisomerase I inhibitory activity (7) 
[25], immunotropic activity (12) [26], antineoplastic activity (8) [27] etc. activities 
have been reported for certain pyrimido[1,2-a]benzimidazole derivatives. Some 
examples of published derivatives of certain pyrimido[1,2-a]benzimidazole with their 
biological activities are as following. 
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5.2 Reported synthetic strategies 
 
5.2.1 From 2-aminobenzimidazole 
 
5.2.1.1 Use of α, β- unsaturated compounds 
 
Literature survey revealed number of reports involving reaction of 2-
aminobenzimidazole with α, β-unsaturated nitriles, especially arylidene malononitriles 
and arylidene cyanoacetates. Komykhov A. et al. have reported chemo and 
regioselective reaction of 2-aminobenzimidazole with arylidene malononitriles [28]. 
The structures of products were determined by modern nuclear magnetic resonance 
(NMR) techniques [including Correlation spectroscopy (COSY), Nuclear overhauser 
effect spectroscopy (NOESY), Heteronuclear multiple quantum coherence (HMQC) 
and Heteronuclear multiple bond coherence (HMBC) techniques].   
 
Ph
HC C
H
CN
N
H
N
NH2 15 min.
reflux
N
N N
H
N
N
H
N
N
N
NH2
Ph
H
N
NH N
H
N
(10) (11)
DMF
 
 
Nofal Z. M. et al. have taken the synthesis pyrimido[1,2-a]benzimidazole 
derivatives by reaction of 2-aminobenzimidazole with arylidene malononitriles and 
arylidene cyanoacetates and tested them for antimicrobial and molluscicidal activities 
[29]. 
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H
N
N
NH2
Me
CH C
CN
CN
EtOHPiperidine/
N
N
N NH2
CN
Me
(12)
 
 
H
N
N
NH2
F
CH C
CN
COOEt
EtOHPiperidine/
H
N
N
N O
CN
F
(13)
 
 
Several new pyrimidol[1,2-a]benzimidazole derivatives have synthesized by 
reaction of  2-aminobenzimidazole with benzoylacetonitrile derivatives [30]. 
 
H
N
N
NH2
Cl
CH C
CN
C
EtOHPiperidine/
N
N
N NH2
C
Cl
O
Ph
O
Ph
(14)
 
 
The reaction of 2-aminobenzimidazole with esters of substituted cinnamic 
acids and arylidene derivatives of 2,2-dimethyl-1,3-dioxane-4,6-dione (meldrum's 
acid) have been studied by Lipson V. et al. [31]. Similar reaction via one-pot two-
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component thermal of cyclization of 2-aminobenzimidazole and aryl-substituted 
methyl cinnamates by Abdel H. et al. [27]. 
 
H
N
N
NH2
H
N
N
N O
C
O
OMe C
H
C
H
Ph
DMF
(15)
 
 
H
N
N
NH2
H
N
N
N O
PhNO2
O
O
Me
Me
O
C
H
O
Ph
(16)
 
 
Synthesis and immunotropic activity of pyrimido[1,2-a]benzimidazole  have 
been reported by Nawrocka W. et al. The have achieved by reaction of 2-
aminobenzimidazole with different α,β-unsaturated acids and α,β-unsaturated ketones 
[26]. Recent literature survey also revealed number of synthesis for pyrimido [1,2-
a]benzimidazoles other reports involving reaction of 2-aminobenzimidazoles with 
chalcones [32, 33] and other α,β-unsaturated ketones [34, 36]. 
 
H
N
N
NH2
H
N
N
N
Me
O
Ph
E 1. DMF
2. HCl
3. EtOH
R
OH
MeS
(17)
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H
N
N
NH2
H
N
N
N
EtO
O
Ph
E
O
(MeOCH2CH2)2O
(18)
 
 
Similar reaction with trifluromethyl-substituted α,β-unsaturated ketone have 
been reported by Desenko S. M. et al. [37]. 
 
H
N
N
NH2
H
N
N
N CF3
1. MeOH, 2 d, 25 0C
CF3C
O
C
H
C
H
Ph
2. p-MeC6H4SO3H,
Ph
MeOH, 2 h, reflux
(19)
 
 
Zhuang Q. et al. have reported a microwave assisted rapid and efficient 
method for synthesis pyrimido[1,2-a]benzimidazole derivatives by the reaction of 2-
aminobenzimidazole with 4-arylidene-2-phenyloxazol-5(4H)-one in glycol [38].  
Similar reaction of, 2-aminobenzimidazole with 2-aryl-4-arylidene-4H-oxazol-5-ones 
(azlactones) was studied under classical heating by Chebanov  V. A. et al. [39]. 
 
H
N
N
NH2
H
N
N
N O
(CH2OH)2,N
O
Ph
O
C
H S
S
R
S
N
H
O
Ph
7 min, 110 0C
(20)
 
 
Lipson V. V. et al. have reported reaction of 2-aminobenzimidazole with 
diethyl benzylidenemalonate furnishing pyrimido[1,2-a]benzimidazole [40]. Similar 
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reaction of 2-aminobenzimidazole with diethyl benzylidenemalonate, diethyl 
ethoxymethylene malonate and ethyl 2-cyano-3-ethoxyacrylate have been reported by 
Kovigin Y. A. et al. [41]. 
 
H
N
N
NH2
H
N
N
N O
MeOH, reflux
EtO C
O
C
CH
C
O
OEt
Ph
C
O
OEt
(21)
 
 
Shaabani. M. et al. have reported reaction of 2-aminobenzimidazole with 3-
(dimethylamino)-2-(phenylsulfonyl) acrylonitrile furnishing pyrimido [1,2-a] 
benzimidazole (26 )  [42]. 
 
H
N
N
CH2
N
N
NH2C5H5N, 4-8 h, reflux
S
O
Ph
CN
S
O
O Ph
CNC C
H
NMe2
O
CN
(22)
 
 
5.2.1.3 Use of 1,3-dicarbonyl compounds  
 
There are Several reports in literature involving reaction of 2-
aminobenzimidazole with 1,3-dicarbonyl compounds among 1,3-dicarbonyl 
compounds, 1,3-diketones [43-49], 3-oxo esters and their derivatives [43] are 
generally employed.  
A microwave-assisted, one-pot, multi-component reaction of aromatic 
aldehydes with 2-aminobenzimidazole and 1,2-diphenylethanone in polyethylene 
glycol in the presence of potassium carbonate ( K2CO3 ) was reported recently [50]. 
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H
N
N
NH2
H
N
N
N Ph
K2CO3
Ph C
O H2
C Ph
MeO
OMe
MeO CHO 18 min, 120 0C
Ph
OMeMeO
OMe
HOCH2CH2OH polymer
(23)
 
 
Shikhaliev K. S. et al. have reported the three-component condensation 
reaction of an aromatic aldehydes, ethylacetoacete and 2-aminobenzimidazole 
affording the pyrimido[1,2-a]benzimidazoles using ethanol as solvent [51]. Shaabani 
A. et al. performed the three-component reaction of 2-aminobenzimidazole with 
different β-ketoesters in N,N,N',N'-tetramethylguanidinium trifluoroacetate (TMGT) 
as ionic liquid and obtained the pyrimido[1,2-a]benzimidazoles, with the limitation 
that the benzaldehydes must be substituted in the para-position [52]. 
 
TMGT
 100 0C, 5h
R1CHO
R2
O O
R3
X
N
NH2
R1
H COR2
R3
R1= Ph
       4-MeO-C6H4
       4-Br-C6H4
       4-NO2-C6H4
R2= OEt, OMe
R3= Me, Ph
X= NH,S
(24)
 
 
A simple convenient procedure for the synthesis of benzo[4,5]imidazo[1,2-
a]pyrimidine derivatives was developed through a three-component reaction of 
aromatic aldehyde, different β-dicarbonyl compounds  and 2-aminobenzimidazole 
catalyzed by sulfamic acid in a solvent-free condition [53]. 
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N
H
N
NH2 R
1CHO R2
O O
R3
SA
N
N
N
H
R3
COR2
R1
(25)
R1= Ph
       4-MeO-C6H4
       4-Br-C6H4
       4-NO2-C6H4
R2= OEt, OMe
R3= Me, Ph
X= NH, S
 
 
An environment-friendly three-component condensation of 3-amino-1,2,4-
triazole or 2-aminobenzimidazole, an aromatic aldehydes such as β-dicarbonyl 
compounds and malononitrile, affording benz[4,5]imidazo[1,2-a]pyrimidne have been 
reported by Shaabani K. S. et al. [54]. 
 
H
N
N
NH2
H
N
N
N Me
H2O, 12 h, 90 
0C
Me
C
O
H2
C
C
C
O
OMe
O
OMe
Br CHO
Br
(26)
 
 
H
N
N
NH2
H
N
N
N Me
H2O, 9 h, 90 
0C
Me
C
O
H2
C
C
CO
OEt
O
OEt
CHO
NO2
NO2
(27)
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H
N
N
NH2
H
N
N
N NH2
H2O, 9 h, 90 
0C
CN
Cl
C
H2
C
C
N N
CHO
Cl Cl Cl
(28)
 
 
Tu W. et al. have reported microwave-assisted efficient synthesis of 
benz[4,5]imidazo[1,2-a]pyrimidine derivatives in water under catalyst-free conditions 
using 1,3-diketones and β-ketoesters [55]. 
 
H
N
N
NH2
H
N
N
N Me
H2O, 4 min
Me
C
O
H2
C
C
O
Me
Cl
Cl
Cl
CHO
Ac
Cl
(29)
 
 
H
N
N
NH2
H
N
N
N Me
H2O, 4 min
Me
C
O
H2
C
C
O
OEt
NO2
COOEt
CHO
O2N
(30)
 
 
The multicomponent reaction of (methylsulfonyl) acetone [or α-
(methylsulfonyl) acetophenone] with aromatic aldehydes and aminoazoles (or urea) 
under microwave irradiation to yield 5,8-dihydroimidazolo[1,2-a]pyrimidines [56]. 
 
 
Chapter-5                                                                              1,4-dihydro pyrimido[1,2-a]benzimidazoles 
     
Studies on Some Organic Compounds of Therapeutic Interest 
   197
H
N
N
NH2
H
N
N
N Me
1. DMF, 30 min, 1350C
CHO
Me C
O H2
C S
O
O
Me
OCH3
2. Me2CO, 2-3 min, reflux
rt; overnight, -50C
MeO
S
O
O
Me
(31)
 
 
Synthesis of 2,3-Diarylpyrimido[1,2-a]benzimidazole by the cyclo-
condensations of 2-aminobenzimidazole with isoflavone have been recently reported 
[57]. 
OR1
R2
R3 O
R6
R5
R4
N
H
N
NH2
MeOH/MeONa
R1
R2
R3
OH
N
N
N
R6
R5
R4
(32)
 
 
5.2.2 Miscellaneous 
 
Reaction of 2-aminobenzimidazole and 2-amino-5,6-dimethylbenzimidazol 
with various epoxy bromides is reported to afford 3-hydroxy-1,2,3,4-
tetrahydropyrimido [1,2-a]benzimidazoles [58]. 
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Halene W. et al. have synthesized pyrimido[1,2-a]benzimidazoles from 
substituted acetylenic nitriles and 2-aminobenzimidazoles [59]. 
 
N
H
N
NH2
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R2
N
H
NR1
R2
Ph CN
Ph
CN
H
NH
N
NR1
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NH
NH
a: R1 = R2 = H; b: R1 = R2 = CH3
N
NR1
R2
Ph
N
NH2
(34)
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5.3 Current work 
 
The biological importance of 1,4-dihydropyrimido[1,2-a]benzimidazoles is 
well documented. Over the years, various substituted derivatives of these heterocycles 
have shown utility against a range of biological targets.  
One of the synthetic pathways to 1,4-dihydropyrimido[1,2-a]benzimidazoles 
is based on the Biginelli like cyclocondensation of aromatic aldehydes and acetoacetic 
acid derivatives with 2-amino benzimidazole containing a guanidine fragment. There 
are literary data about the synthesis of 1,4-dihydropyrimido[1,2-a]benzimidazoles by 
treatment of 2-amino benzimidazole with aldehydes and ethyl acetoacetate or cyclic 
β-diketones. The cyclocondensations were achieved by heating of the starting 
materials in ethanol with catalytic amounts of hydrochloric acid under reflux 
conditions or using dimethylformamide (DMF) as solvent. The use of 
acetoacetamides in these or similar reactions has not been described. 
Recognizing these facts, we have synthesised four new series of 1,4-
dihydropyrimido[1,2-a]benzimidazoles (RHK-191 to 220) containing an 
acetoacetamide fragment. The structures of all the newly synthesized compounds 
were elucidated by FT-IR, mass spectra, 
1
H NMR and elemental analyses. The newly 
synthesized compounds were subjected to antimicrobial activity. 
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5.4 Reaction Scheme 
NH
O
O
+
R1
a
Reagents and conditions: (a) DMF, Reflux, 30 Minutes
HO
R2
HN
N
H2N
N
H
N
N
N
H
O
R1
R2
RHK-191 to 220
H3C
CH3
CH3
H3C
 
 
Code R1 R2 M.F. M.W. M.P. 
ºC 
Yield % Rf1 Rf2 
RHK-191 4-Cl 4-OCH3 C27H25ClN4O2 472 198 68 0.49 0.68 
RHK-192 4-Cl 4-CH3 C27H25ClN4O 456 185 66 0.45 0.62 
RHK-193 4-Cl 4-Cl C26H22Cl2N4O 476 250 76 0.43 0.68 
RHK-194 4-Cl 4-F C26H22ClFN4O 460 211 71 0.47 0.69 
RHK-195 4-Cl 3-Br C26H22BrClN4O 520 240 80 0.49 0.68 
RHK-196 4-Cl 3-Cl C26H22Cl2N4O 476 200 77 0.59 0.61 
RHK-197 4-Cl 4-NO2 C26H22ClN5O3 487 203 58 0.40 0.68 
RHK-198 4-Cl 3-NO2 C26H22ClN5O3 487 201 60 0.48 0.66 
RHK-199 4-Cl 2-NO2 C26H22ClN5O3 487 189 72 0.45 0.66 
RHK-200 4-Cl 4-OH C26H23ClN4O2 458 186 70 0.50 0.78 
RHK-201 4-F 4-OCH3 C27H25FN4O2 456 221 74 0.58 0.60 
RHK-202 4-F 4-CH3 C27H25FN4O 440 204 69 0.42 0.68 
RHK-203 4-F 4-Cl C26H22ClFN4O 460 224 66 0.45 0.65 
RHK-204 4-F 4-F C26H22F2N4O 444 212 68 0.53 0.76 
RHK-205 4-F 3-Br C26H22BrFN4O 504 211 64 0.54 0.68 
RHK-206 4-F 3-Cl C26H22ClFN4O 460 221 59 0.51 0.79 
RHK-207 4-F 4-NO2 C26H22FN5O3 471 201 64 0.50 0.71 
RHK-208 4-F 3-NO2 C26H22FN5O3 471 199 66 0.46 0.78 
RHK-209 4-F 2-NO2 C26H22FN5O3 471 200 80 0.42 0.66 
RHK-210 4-F 4-OH C26H23FN4O2 442 209 73 0.59 0.62 
RHK-211 3-Cl,4-F 4-OCH3 C27H24ClFN4O2 490 202 70 0.44 0.56 
RHK-212 3-Cl,4-F 4-CH3 C27H24ClFN4O 474 221 68 0.49 0.68 
RHK-213 3-Cl,4-F 4-Cl C26H21Cl2FN4O 494 212 61 0.55 0.68 
RHK-214 3-Cl,4-F 4-F C26H21ClF2N4O 478 251 72 0.52 0.56 
RHK-215 3-Cl,4-F 3-Br C26H21BrClFN4O 538 218 64 0.54 0.76 
RHK-216 3-Cl,4-F 3-Cl C26H21Cl2FN4O 494 211 72 0.54 0.68 
RHK-217 3-Cl,4-F 4-NO2 C26H21ClFN5O3 505 242 71 0.45 0.76 
RHK-218 3-Cl,4-F 3-NO2 C26H21ClFN5O3 505 213 57 0.50 0.74 
RHK-219 3-Cl,4-F 2-NO2 C26H21ClFN5O3 505 246 65 0.44 0.78 
RHK-220 3-Cl,4-F 4-OH C26H22ClFN4O2 476 210 66 0.56 0.78 
 
 
TLC Solvent system Rf1: Hexane: Ethyl acetate – 6:4;  
                                   Rf2: Chloroform: Methanol - 9:1. 
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5.5 Plausible Reaction Mechanism 
N
H
N
N
N
H
O
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H
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R1 NH
O
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-2 H2O
-H2OCH3
H3C
H3C
CH3
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O
O
R1
H3C
CH3
CH3
H3C
-H2O
 
5.6 Experimental 
 
5.6.1 Materials and Methods 
 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine. IR spectra were recorded 
Shimadzu FT-IR-8400 instrument using potassium bromide (KBr) pellet method. 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using direct 
injection probe technique. 
1
H NMR was determined in DMSO-d6 solution on a bruker 
Ac 400 MHz spectrometer. Elemental analysis of the all the synthesized compounds 
was carried out on elemental vario EL III carlo erba 1108 model and the results are in 
agreements with the structures assigned. 
 
5.6.2 Synthesis of N-(substituted phenyl)-4-methyl-3-oxopentanamides 
 
Synthesis of N-(substituted phenyl)-4-methyl-3-oxopentanamide was achieved 
using previously published method [60]. 
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5.6.3 General procedure for the synthesis of N-(chlorophenyl)-2-isopropyl-4-(4-
sustitutedphenyl)-1,4-dihydropyrimido[1,2-a]benzimidazole-3-carboxamide      
(RHK- 191 to 200) 
 
A mixture of the 2-amino benzimidazole (0.01 M), N-(substituted phenyl)-4-
methyl-3-oxopentanamide (0.01 M) and appropriate aromatic aldehydes (0.01 M) was 
refluxed in DMF (4 ml) for 30 min. After cooling, methanol (~12 ml) was added. The 
reaction mixture was allowed to stand overnight and then filtered to give the solid 1,4-
dihydro pyrimido[1,2-a]benzimidazoles products (RHK- 191 to 220), which were 
recrystallized from ethanol. 
 
5.6.3.1 N-(4-chlorophenyl)-2-isopropyl-4-(4-methoxyphenyl)-1,4-dihydropyrimido- 
[1,2-a]benzimidazole-3-carboxamide (RHK-191) 
Yield: 68%; mp 198ºC; Anal. Calcd. for 
C27H25ClN4O2: C, 68.56; H, 5.33; Cl, 7.50; N, 
11.85; O, 6.77; Found: C, 68.42; H, 5.13; Cl, 7.46; 
N, 11.76; O, 6.64%; MS: m/z 472;  
 
 
 
5.6.3.2 N-(4-chlorophenyl)-2-isopropyl-4-(4-methlyphenyl)-1,4-dihydropyri- 
mido[1,2-a]benzimidazole-3-carboxamide 
(RHK-192) 
Yield: 66%; mp 185ºC; Anal. Calcd. for 
C27H25ClN4O: C, 70.97; H, 5.51; Cl, 7.76; N, 
12.26; O, 3.50. Found: C, 70.84; H, 5.41; Cl, 7.64; 
N, 12.12; O, 3.41%; IR (cm
-1
): 3227 (N-H 
stretching of secondary amine), 3049 (C-H 
stretching of aromatic ring), 2975 (C-H asymmetrical stretching of CH3 group), 2883 
(C-H asymmetrical stretching of CH3 group), 1651 (C=O stretching of amide), 1631 
(N-H deformation of pyrimidine ring), 1622, 1564 and 1519 (C=C stretching of 
aromatic ring), 1456 (C-H asymmetrical deformation of CH3 group), 1392 (C-H 
symmetrical deformation of CH3 group), 1298 and 1247 (C-N stretching), 1078 (C-H 
N
N
N
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N
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CH3
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in plane deformation of aromatic ring), 825 (C-H out of plane bending of 1,4-
disubstituion) 738 and 680 (C-Cl stretching); MS: m/z 456; 
1
H NMR (DMSO-d6) δ 
ppm: 1.24-1.26 (d, 3H, Ha, J = 7.20 Hz), 1.34-1.36 (d, 3H, Hb, J = 7.20 Hz), 2.24 (s, 
3H, Hc), 3.39-3.46 (m, 1H, Hd), 6.52 (s, 1H, He), 6.89-6.98 (m, 2H, Hfg), 7.03-7.08 
(m, 3H, Hhij’, J = 16.40 Hz), 7.10-7.22 (m, 4H, Hkk’-ll’), 7.39-7.41 (d, 1H, Hm, J = 7.60 
Hz), 7.50-7.52 (d, 2H, Hnn’, J = 8.80 Hz), 9.35 (s, 1H, Ho), 9.56 (s, 1H, Hp). 
 
5.6.3.3 N-(4-chlorophenyl)-2-isopropyl-4-(4-chlorophenyl)-1,4-dihydropyrimido 
[1,2-a]benzimidazole-3-carboxamide (RHK-193) 
Yield: 76%; mp 250ºC; Anal. Calcd. for 
C26H22Cl2N4O: C, 65.41; H, 4.65; Cl, 14.85; N, 
11.74; O, 3.35; Found: C, 65.34; H, 4.60; Cl, 
14.75; N, 11.64; O, 3.24%; MS: m/z 476. 
 
 
 
5.6.3.4 N-(4-chlorophenyl)-2-isopropyl-4-(4-fulorophenyl)-1,4-dihydro pyrimido -
[1,2-a]benzimidazole-3-carboxamide (RHK-194) 
Yield: 71%; mp 211ºC; Anal. Calcd. for 
C26H22ClFN4O: C, 67.75; H, 4.81; Cl, 7.69; F, 
4.12; N, 12.16; O, 3.47; Found: C, 67.61; H, 4.71; 
Cl, 7.51; F, 4.04; N, 12.10; O, 3.40%; IR (cm
-1
): 
3238 (N-H stretching of secondary amine), 3053 
(C-H stretching of aromatic ring), 2974 (C-H 
asymmetrical stretching of CH3 group), 2887 (C-H asymmetrical stretching of CH3 
group), 1637 (C=O stretching of amide), 1606 (N-H deformation of pyrimidine ring), 
1573,1556 and 1508 (C=C stretching of aromatic ring), 1454 (C-H asymmetrical 
deformation of CH3 group), 1394 (C-H symmetrical deformation of CH3 group), 1294 
and 1246 (C-N stretching), 1084 (C-H in plane deformation of aromatic ring), 1012 
(C-F stretching), 827 (C-H out of plane bending of 1,4-disubstituion), 734 (C-Cl 
stretching); MS: m/z 460;
 1
H NMR (DMSO-d6) δ ppm: 1.19-1.19 (d, 3H, Ha, J = 2.00 
Hz), 1.24-1.26 (d, 3H, Hb, J = 6.40 Hz), 3.35-3.40 (m, 1H, Hc), 6.59 (s, 1H, Hd) 6.90-
6.98 (m, 4H, Hee’-ff’), 7.03-7.07 (m, 1H, Hg), 7.20-7.22 (d, 2H, Hhh’, J = 8.80 Hz), 
N
H
N
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7.27-7.30 (m, 2H, Hij, J = 14.00 Hz), 7.37-7.39 (d, 1H, Hk, J = 8.00 Hz), 7.52-7.54 (d, 
2H, Hll’, J = 8.80 Hz), 9.68 (s, 1H, Hm), 9.84 (s, 1H, Hn). 
 
5.6.3.5 N-(4-chlorophenyl)-2-isopropyl-4-(3-bromophenyl)-1,4-dihydropyrimido 
[1,2-a]benzimidazole-3-carboxamide (RHK-195) 
Yield: 80%; mp 240ºC; Anal. Calcd. for 
C26H22BrClN4O: C, 59.84; H, 4.25; Br, 15.31; Cl, 
6.79; N, 10.74; O, 3.07; Found: C, 59.75; H, 4.13; 
Br, 15.24; Cl, 6.62; N, 10.64; O, 3.00%; IR (cm
-1
): 
3294 (N-H stretching of secondary amine), 3053 
(C-H stretching of aromatic ring), 2958 (C-H 
asymmetrical stretching of CH3 group), 2854 (C-H asymmetrical stretching of CH3 
group), 1649 (C=O stretching of amide), 1641 (N-H deformation of pyrimidine ring), 
1560, 1521 and 1506 (C=C stretching of aromatic ring), 1456 (C-H asymmetrical 
deformation of CH3 group), 1388 (C-H symmetrical deformation of CH3 group), 1294 
and 1236 (C-N stretching), 1078 (C-H in plane deformation of aromatic ring), 833 (C-
H out of plane bending of 1,4-disubstituion), 729 (C-Cl stretching), 678 (C-Br 
stretching); MS: m/z 520;
 1
H NMR (DMSO-d6) δ ppm: 1.24-1.26 (d, 3H, Ha, J = 7.20 
Hz), 1.34-1.36 (d, 3H, Hb, J = 6.80 Hz), 3.37-3.40 (m, 1H, Hc), 6.58 (s, 1H, Hd) 6.92-
6.93 (m, 2H, Hee’, J = 4.00 Hz), 7.05-7.08 (m, 1H, Hf, J = 12.40 Hz) 7.18-7.24 (m, 
6H, Hgg’-hh’-ii’, J = 8.80 Hz), 7.39-7.41 (d, 1H, Hj, J = 8.00 Hz), 7.52-7.54 (d, 2H, Hkk’, 
J = 8.80 Hz), 9.69 (s, 1H, Hl), 9.84 (s, 1H, Hm). 
 
5.6.3.6 N-(4-chlorophenyl)-2-isopropyl-4-(4-cholorophenyl)-1,4-dihydropyrimido 
[1,2-a]benzimidazole-3-carboxamide (RHK-196)  
Yield: 77%; mp 200ºC; Anal. Calcd. for 
C26H22Cl2N4O: C, 65.41; H, 4.65; Cl, 14.85; N, 
11.74; O, 3.35; Found: C, 65.30; H, 4.56; Cl, 
14.42; N, 11.65; O, 3.23%; MS: m/z 476. 
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5.6.3.7 N-(4-chlorophenyl)-2-isopropyl-4-(4-nitrophenyl)-1,4-dihydropyrimido[1,2-a] 
benzimidazole-3-carboxamide (RHK-197) 
Yield: 58%; mp 203ºC; Anal. Calcd. for 
C26H22ClN5O3: C, 64.00; H, 4.54; Cl, 7.27; N, 
14.35; O, 9.84; Found: C, 63.84; H, 4.54; Cl, 7.10; 
N, 14.21; O, 9.72%; MS: m/z 487. 
 
 
 
5.6.3.8 N-(4-chlorophenyl)-2-isopropyl-4-(4-nitrophenyl)-1,4-dihydropyrimido 
[1,2-a]benzimidazole-3-carboxamide (RHK-198) 
Yield: 60%; mp 201ºC; Anal. Calcd. for 
C26H22ClN5O3: C, 64.00; H, 4.54; Cl, 7.27; N, 
14.35; O, 9.84; Found: C, 63.79; H, 4.42; Cl, 7.13; 
N, 14.24; O, 9.74%; MS: m/z 487. 
 
 
 
5.6.3.9 N-(4-chlorophenyl)-2-isopropyl-4-(4-nitrophenyl)-1,4-dihydropyrimido[1,2-a] 
benzimidazole-3-carboxamide (RHK-199)  
Yield: 72%; mp 189ºC; Anal. Calcd. for 
C26H22ClN5O3 C, 64.00; H, 4.54; Cl, 7.27; N, 
14.35; O, 9.84; Found: C, 63.95; H, 4.45; Cl, 7.13; 
N, 14.24; O, 9.75%; MS: m/z 487. 
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5.6.3.10 N-(4-chlorophenyl)-2-isopropyl-4-(4-hydrooxyphenyl)-1,4-dihydropyri-
mido[1,2-a]benzimidazole-3-carboxamide  
(RHK-200) 
Yield: 70%; mp 186ºC; Anal. Calcd. for 
C26H23ClN4O2: C, 68.04; H, 5.05; Cl, 7.72; N, 
12.21; O, 6.97; Found: C, 68.00; H, 5.00; Cl, 7.64; 
N, 12.08; O, 6.85%; MS: m/z 458. 
 
 
5.6.4 General procedure for the synthesis of N-(fluorophenyl)-2-isopropyl-4-(4-
sustitutedphenyl)-1,4-dihydropyrimido[1,2-a]benzimidazole-3-carboxamide      
(RHK - 201 to 210) 
 
A mixture of the 2-amino benzimidazole (0.01mol), N-(4-chlorophenyl)-4-
methyl-3-oxopentanamide (0.01mol) and an appropriate aromatic aldehydes (0.01mol) 
was refluxed in 4 ml of DMF for 30 min. After cooling, methanol (~12 ml) was added. 
The reaction mixture was allowed to stand overnight and then filtered to give the solid 
1,4-dihydropyrimido[1,2-a]benzimidazoles products RHK- 201 to 210, which were 
crystallized from ethanol. 
 
5.6.4.1 N-(4-fluorophenyl)-2-isopropyl-4-(4-methoxyphenyl)-1,4-dihydropyrimido 
[1,2-a]benzimidazole-3-carboxamide (RHK-201) 
Yield: 79%; mp 221ºC; Anal. Calcd. for 
C27H25FN4O2: C, 71.04; H, 5.52; F, 4.16; N, 12.27; 
O, 7.01; Found: C, 71.00; H, 5.34; F, 4.05; N, 
12.10; O, 6.79%; IR (cm
-1
): 3157 (N-H stretching 
of secondary amine), 3051 (C-H stretching of 
aromatic ring), 2958 (C-H asymmetrical 
stretching of CH3 group), 2899 (C-H asymmetrical stretching of CH3 group), 1683 
(C=O stretching of amide), 1627 (N-H deformation of pyrimidine ring), 1575 and 
1510 (C=C stretching of aromatic ring), 1454 (C-H asymmetrical deformation of CH3 
group), 1365 (C-H symmetrical deformation of CH3 group), 1261 (C-O-C 
asymmetrical stretching of OCH3), 1174 (C-N stretching), 1095 (C-H in plane 
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deformation of aromatic ring), 1030 (C-F stretching), 825 (C-H out of plane bending 
of 1,4-disubstituion); MS: m/z 456; 
1
H NMR (DMSO-d6) δ ppm: 1.24-1.26 (d, 3H, Ha, 
J = 6.80 Hz), 1.34-1.36 (d, 3H, Hb, J = 6.80 Hz), 3.38-3.43 (m, 1H, Hc), 3.73 (s, 1H, 
Hd), 5.96-5.97 (s, 1H, He), 6.78-6.80 (m, 3H, Hfgh, J = 8.40 Hz), 6.82-6.86 (m, 3H, 
Hijk, J = 15.20 Hz), 6.95-6.99 (m, 2H, Hlm, J = 16.40 Hz), 7.21-7.23 (m, 3H, Hnop), 
7.27-7.29 (s, 1H, Hq), 9.27 (s, 2H, Hs). 
 
5.6.4.2 N-(4-fluorophenyl)-2-isopropyl-4-(4-methlyphenyl)-1,4-dihydropyrimi- 
do[1,2-a]benzimidazole-3-carboxamide 
(RHK-202) 
Yield: 69%; mp 204ºC; Anal. Calcd. for 
C27H25FN4O: C, 73.62; H, 5.72; F, 4.31; N, 12.72; 
O, 3.63; Found: C, 73.50; H, 5.61; F, 4.21; N, 
12.61; O, 3.54%; MS: m/z 440.   
 
 
5.6.4.3 N-(4-fluorophenyl)-2-isopropyl-4-(4-chlorophenyl)-1,4-dihydropyrimido 
[1,2-a]benzimidazole-3-carboxamide (RHK-203) 
Yield: 66%; mp 224ºC; Anal. Calcd. for 
C26H22ClFN4O: C, 67.75; H, 4.81; Cl, 7.69; F, 
4.12; N, 12.16; O, 3.47; Found: C, 67.64; H, 4.76; 
Cl, 7.64; F, 4.04; N, 12.00; O, 3.30%; MS: m/z 
460.   
 
 
5.6.4.4 N-(4-fluorophenyl)-2-isopropyl-4-(4-fulorophenyl)-1,4-dihydropyrimido- 
[1,2-a]benzimidazole-3-carboxamide (RHK-204) 
Yield: 68%; mp 212ºC; Anal. Calcd. for 
C26H22F2N4O: C, 70.26; H, 4.99; F, 8.55; N, 12.61; 
O, 3.60; Found: C, 70.11; H, 4.87; F, 8.44; N, 
12.52; O, 3.46%; IR (cm
-1
): 3273 (N-H stretching 
of secondary amine), 3057 (C-H stretching of 
aromatic ring), 2970 (C-H asymmetrical stretching 
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of CH3 group), 2895 (C-H asymmetrical stretching of CH3 group), 1637 (C=O 
stretching of amide), 1688 (N-H deformation of pyrimidine ring), 1508 and 1467 
(C=C stretching of aromatic ring), 1410 (C-H asymmetrical deformation of CH3 
group), 1357 (C-H symmetrical deformation of CH3 group), 1294 and 1228 (C-N 
stretching), 1087 (C-H in plane deformation of aromatic ring), 1012 (C-F stretching), 
819 (C-H out of plane bending of 1,4-disubstituion); MS: m/z 444;
 1
H NMR (DMSO-
d6) δ ppm: 1.24-1.26 (d, 3H, Ha, J = 6.80 Hz), 1.34-1.36 (d, 3H, Hb, J = 6.80 Hz), 
3.38-3.42 (m, 1H, Hc, J = 14.00 Hz), 6.59 (s, 1H, Hd) 6.90-6.98 (m, 6H, Hee’-ff’-gg’), 
7.05-7.07 (m, 1H, Hh, J = 16.40 Hz), 7.28-7.31 (m, 2H, Hij, J =12.00 Hz), 7.37-7.39 
(d, 1H, Hk, J = 7.60 Hz), 7.48-7.52 (m, 2H, Hlm, J = 14.00 Hz), 9.53(s, 1H, Hl), 9.72 
(s, 1H, Hm). 
 
5.6.4.5 N-(4-fluorophenyl)-2-isopropyl-4-(3-bromophenyl)-1,4-dihydropyrimido 
[1,2-a]benzimidazole-3-carboxamide (RHK-205) 
Yield: 64%; mp 211ºC; Anal. Calcd. for 
C26H22BrFN4O: C, 61.79; H, 4.39; Br, 15.81; F, 
3.76; N, 11.09; O, 3.17; Found: C, 61.66; H, 4.24; 
Br, 15.71; F, 3.70; N, 11.00; O, 3.07; IR (cm
-1
): 
3288 (N-H stretching of secondary amine), 3055 
(C-H stretching of aromatic ring), 2978 (C-H 
asymmetrical stretching of CH3 group), 2824 (C-H asymmetrical stretching of CH3 
group), 1651 (C=O stretching of amide), 1624 (N-H deformation of pyrimidine ring), 
1562 and 1510 (C=C stretching of aromatic ring), 1458 (C-H asymmetrical 
deformation of CH3 group), 1280 (C-H symmetrical deformation of CH3 group), 1228 
(C-N stretching), 1076 (C-H in plane deformation of aromatic ring), 833 (C-H out of 
plane bending of 1,4-disubstituion), 738 (C-Cl stretching), 682 (C-Br stretching); MS: 
m/z 504;
 1
H NMR (DMSO-d6) δ ppm: 1.25-1.26 (d, 3H, Ha, J = 7.20 Hz), 1.35-1.36 
(d, 3H, Hb, J = 6.80 Hz), 3.37-3.42 (m, 1H, Hc), 6.57 (s, 1H, Hd), 6.90-6.99 (m, 4H, 
Hee’-ff’), 7.06-7.10 (m, 1H, Hg), 7.17-7.23 (m, 4H, Hhh’-ii’), 7.41-7.43 (d, 1H, Hj, J = 
8.00 Hz), 7.48-7.51 (m, 2H, Hkl), 9.53 (s, 1H, Hm), 9.69 (s, 1H, Hn). 
 
a b
c
d
e
f
gh k
m
n
ij
l
f'
e'
h'
i'N
H
N
N
H
N
O
H3C
CH3
Cl
Br
 
 
Chapter-5                                                                              1,4-dihydro pyrimido[1,2-a]benzimidazoles 
     
Studies on Some Organic Compounds of Therapeutic Interest 
   209
5.6.4.6 N-(4-fluorophenyl)-2-isopropyl-4-(4-cholorophenyl)-1,4-dihydropyrimido 
[1,2-a]benzimidazole-3-carboxamide (RHK-206)  
Yield: 59%; mp 221ºC; Anal. Calcd. for 
C26H22ClFN4O: C, 67.75; H, 4.81; Cl, 7.69; F, 
4.12; N, 12.16; O, 3.47; Found: C, 67.62; H, 4.77; 
Cl, 7.53; F, 4.01; N, 12.12; O, 3.21%; MS: m/z 
460. 
 
 
5.6.4.7 N-(4-fluorophenyl)-2-isopropyl-4-(4-nitrophenyl)-1,4-dihydropyrimido[1,2-a] 
benzimidazole-3-carboxamide (RHK-207) 
Yield: 64%; mp 201ºC; Anal. Calcd. for 
C26H22FN5O3: C, 66.23; H, 4.70; F, 4.03; N, 14.85; 
O, 10.18; Found: C, 66.00; H, 4.45; F, 4.00; N, 
14.75; O, 10.00%; MS: m/z 471. 
 
 
 
5.6.4.8 N-(4-fluorophenyl)-2-isopropyl-4-(4-nitrophenyl)-1,4-dihydropyrimido 
[1,2-a]benzimidazole-3-carboxamide (RHK-208) 
Yield: 66%; mp 199ºC; Anal. Calcd. for 
C26H22FN5O3: C, 66.23; H, 4.70; F, 4.03; N, 14.85; 
O, 10.18; Found: C, 66.15; H, 4.66; F, 3.79; N, 
14.80; O, 10.00%; MS: m/z 471. 
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5.6.4.9 N-(4-fluorophenyl)-2-isopropyl-4-(4-nitrophenyl)-1,4-dihydropyrimido[1,2-a] 
benzimidazole-3-carboxamide (RHK-209)  
Yield: 80%; mp 200ºC; Anal. Calcd. for 
C26H22FN5O3 : C, 66.23; H, 4.70; F, 4.03; N, 14.85; 
O, 10.18; Found: C, 66.15; H, 4.66; F, 3.89; N, 
14.80; O, 10.10%; MS: m/z 471. 
 
 
 
5.6.4.10 N-(4-fluorophenyl)-2-isopropyl-4-(4-hydrooxyphenyl)-1,4-dihydropyrimido 
[1,2-a]benzimidazole-3-carboxamide  (RHK-210) 
Yield: 73%; mp 209ºC; Anal. Calcd. for 
C26H23FN4O2: C, 70.57; H, 5.24; F, 4.29; N, 12.66; 
O, 7.23; Found: C, 70.45; H, 5.11; F, 4.13; N, 
10.66; O, 7.12%; MS: m/z 442. 
 
 
 
5.6.5 General procedure for the synthesis of N-(fluorophenyl)-2-isopropyl-4-(4-
sustitutedphenyl)-1,4-dihydropyrimido[1,2-a]benzimidazole-3-carboxamide      
(RHK - 211 to 220) 
 
A mixture of the 2-amino benzimidazole (0.01mol), N-(4-chlorophenyl)-4-
methyl-3-oxopentanamide (0.01mol) and an appropriate aromatic aldehydes (0.01mol) 
was refluxed in 4 ml of DMF for 30 min. After cooling, methanol (~12 ml) was added. 
The reaction mixture was allowed to stand overnight and then filtered to give the solid 
1,4-dihydropyrimido[1,2-a]benzimidazoles products RHK- 211 to 220, which were 
crystallized from ethanol.  
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5.6.5.1 N-(4-fluoro,3-chlorophenyl)-2-isopropyl-4-(4-methoxyphenyl)-1,4-dihydro- 
pyrimido [1,2-a]benzimidazole-3-carboxamide 
(RHK-211) 
Yield: 70%; mp 202ºC; Anal. Calcd. for 
C27H24ClFN4O2: C, 66.05; H, 4.93; Cl, 7.22; F, 
3.87; N, 11.41; O, 6.52; Found: C, 66.00; H, 4.88; 
Cl, 7.11; F, 3.76; N, 11.31; O, 6.42%; IR (cm
-1
): 
3308 (N-H stretching of secondary amine), 3051 
(C-H stretching of aromatic ring), 2976 (C-H asymmetrical stretching of CH3 group), 
2827 (C-H asymmetrical stretching of CH3 group), 1670 (C=O stretching of amide), 
1618 (N-H deformation of pyrimidine ring), 1583 and 1508 (C=C stretching of 
aromatic ring), 1454 (C-H asymmetrical deformation of CH3 group), 1386 (C-H 
symmetrical deformation of CH3 group), 1296 (C-N stretching), 1249 (C-O-C 
asymmetrical stretching of OCH3), 1045 (C-F stretching), 1045 (C-H in plane 
deformation of aromatic ring), 798 (C-H out of plane bending of 1,4-disubstituion), 
736 (C-Cl stretching); MS: m/z 490; 
1
H NMR (DMSO-d6) δ ppm: 1.25-1.26 (d, 3H, 
Ha, J = 7.20 Hz), 1.35-1.36 (d, 3H, Hb, J = 6.80 Hz), 3.37-3.41 (m, 1H, Hc), 3.71 (s, 
1H, Hd), 6.59 (s, 1H, He), 6.75-6.77 (m, 2H, Hff’, J = 8.80), 6.92-6.97 (m, 2H, Hgh), 
7.103-7.08 (m, 2H, Hij), 7.22-7.24 (d, 2H, Hkk’, J = 8.80 Hz), 7.39-7.45 (m, 2H, 
Hlm),7.81-7.83 (m, 1H, Hn, J = 9.60), 9.59 (s, 1H, Ho), 10.21 (s, 1H, Hp). 
 
5.6.5.2 N-(4-fluoro,3-chlorophenyl)-2-isopropyl-4-(4-methlyphenyl)-1,4-dihy- 
dropyri mido[1,2-a]benzimidazole-3-carbo- 
xamide (RHK-212) 
Yield: 68%; mp 221ºC; Anal. Calcd. for 
C27H24ClFN4O: C, 68.28; H, 5.09; Cl, 7.46; F, 
4.00; N, 11.80; O, 3.37. Found: C, 68.12; H, 5.00; 
Cl, 7.34; F, 3.88; N, 11.71; O, 3.30%; MS: m/z 
474. 
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5.6.5.3 N-(4-fluoro,3-chlorophenyl) -2-isopropyl-4-(4-chlorophenyl)-1,4-dihydro- 
pyrimido[1,2-a]benzimidazole-3-carboxamide 
(RHK-213) 
Yield: 61%; mp 212ºC; Anal. Calcd. for 
C26H21Cl2FN4O: C, 63.04; H, 4.27; Cl, 14.31; F, 
3.84; N, 11.31; O, 3.23; Found: C, 62.89; H, 4.13; 
Cl, 14.21; F, 3.75; N, 11.21; O, 3.11%; MS: m/z 
494. 
 
5.6.5.4 N-(4-fluoro,3-chlorophenyl)-2-isopropyl-4-(4-fulorophenyl)-1,4-dihydropyr- 
imido[1,2-a]benzimidazole-3-carboxamide 
(RHK-214) 
Yield: 72%; mp 251ºC; Anal. Calcd. for 
C26H21ClF2N4O: C, 57.85; H, 3.92; Br, 14.80; Cl, 
6.57; F, 3.52; N, 10.38; O, 2.96 Found: C, 57.76; 
H, 3.84; Br, 14.70; Cl, 6.45; F, 3.42; N, 10.24; O, 
2.87%; IR (cm
-1
): 3274 (N-H stretching of 
secondary amine), 3053 (C-H stretching of aromatic ring), 2976 (C-H asymmetrical 
stretching of CH3 group), 2845 (C-H asymmetrical stretching of CH3 group), 1651 
(C=O stretching of amide), 1608 (N-H deformation of pyrimidine ring), 1560,1529 
and 1504 (C=C stretching of aromatic ring), 1458 (C-H asymmetrical deformation of 
CH3 group), 1392 (C-H symmetrical deformation of CH3 group), 1280 and 1253 (C-N 
stretching), 1074 (C-H in plane deformation of aromatic ring), 1074 (C-F stretching), 
812 (C-H out of plane bending of 1,4-disubstituion), 731 (C-Cl stretching); MS: m/z 
478;
 1
H NMR (DMSO-d6) δ ppm: 1.24-1.26 (d, 3H, Ha, J = 7.20 Hz), 1.34-1.36 (d, 
3H, Hb, J = 6.80 Hz), 3.35-3.41 (m, 1H, Hc), 6.60 (s, 1H, Hd), 6.88-7.00 (m, 4H, Hee’-
ff’), 7.03-7.08 (m, 1H, Hg), 7.10-7.12 (m, 1H, Hh, J = 9.20 Hz), 7.27-7.32 (d, 1H, Hk, J 
= 8.00 Hz), 7.40-7.44 (m, 1H, Hl), 7.79-7.82 (m, 1H, Hm, J = 9.60), 9.77 (s, 1H, Hn), 
9.97 (s, 1H, Ho). 
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5.6.5.5 N-(4-fluoro,3-chlorophenyl) -2-isopropyl-4-(3-bromophenyl)-1,4-dihydropy -
-rimido[1,2-a]benzimidazole-3-carboxamide 
(RHK-215) 
Yield: 64%; mp 218ºC; Anal. Calcd. for 
C26H21BrClFN4O: C, 57.85; H, 3.92; Br, 14.80; 
Cl, 6.57; F, 3.52; N, 10.38; O, 2.96; Found: C, 
57.76; H, 3.84; Br, 14.76; Cl, 6.46; F, 3.42; N, 
10.23; O, 2.87%; IR (cm
-1
): 3288 (N-H stretching 
of secondary amine), 3057 (C-H stretching of aromatic ring), 2976 (C-H 
asymmetrical stretching of CH3 group), 2888 (C-H asymmetrical stretching of CH3 
group), 1651 (C=O stretching of amide), 1624 (N-H deformation of pyrimidine ring), 
1562,1529 and 1502 (C=C stretching of aromatic ring), 1458 (C-H asymmetrical 
deformation of CH3 group), 1394 (C-H symmetrical deformation of CH3 group), 1257 
and 1220 (C-N stretching), 1078 (C-H in plane deformation of aromatic ring), 1012 
(C-F stretching), 817 (C-H out of plane bending of 1,4-disubstituion), 740 (C-Cl 
stretching), 590 (C-Br stretching);  MS: m/z 538;
 1
H NMR (DMSO-d6) δ ppm:1.25-
1.26 (d, 3H, Ha, J = 6.80 Hz), 1.34-1.36 (d, 3H, Hb, J = 6.80 Hz), 3.34-3.43 (m, 1H, 
Hc), 6.60 (s, 1H, Hd), 6.93-6.95 (m, 2H, Hef, J = 9.20 Hz), 7.04-7.12 (m, 2H, Hgh) 
7.19-7.27 (m,4H, Hii’-jj’), 7.39-7.44 (m, 2H, Hkl),7.79-7.81 (m,1H,Hm, J = 9.20), 9.87 
(s, 1H, Hn), 9.98 (s, 1H, Ho). 
 
 
5.6.5.6 N-(4-fluoro,3-chlorophenyl) -2-isopropyl-4-(4-cholorophenyl)-1,4-dihydro- 
pyrimido[1,2-a]benzimidazole-3-carboxamide 
(RHK-216)  
Yield: 72%; mp 211ºC; Anal. Calcd. for 
C26H21Cl2FN4O: C, 63.04; H, 4.27; Cl, 14.31; F, 
3.84; N, 11.31; O, 3.23; Found: C, 63.00; H, 4.13; 
Cl, 14.22; F, 3.74; N, 11.24; O, 3.12%; MS: m/z 
494. 
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5.6.5.7 N-(4-fluoro,3-chlorophenyl) -2-isopropyl-4-(4-nitrophenyl)-1,4-dihydropyri-
mido[1,2-a] benzimidazole-3-carboxamide 
(RHK-217) 
Yield: 71%; mp 242ºC; Anal. Calcd. for 
C26H21ClFN5O3: C, 61.72; H, 4.18; Cl, 7.01; F, 
3.76; N, 13.84; O, 9.49; Found: C, 61.61; H, 4.11; 
Cl, 6.87; F, 3.62; N, 13.72; O, 9.34%; MS: m/z 
505. 
 
5.6.5.8 N-(4-fluoro,3-chlorophenyl)-2-isopropyl-4-(4-nitrophenyl)-1,4-dihydropyri- 
mido[1,2-a]benzimidazole-3-carboxamide 
(RHK-218) 
Yield: 57%; mp 213ºC; Anal. Calcd. for 
C26H21ClFN5O3: C, 61.72; H, 4.18; Cl, 7.01; F, 
3.76; N, 13.84; O, 9.49; Found: C, 61.64; H, 4.02; 
Cl, 6.89; F, 3.64; N, 13.77; O, 9.33%; MS: m/z 
505. 
 
5.6.5.9 N-(4-fluoro,3-chlorophenyl)-2-isopropyl-4-(4-nitrophenyl)-1,4-dihydro-pyri- 
mido[1,2-a] benzimidazole-3-carboxamide  
(RHK-219)  
Yield: 65%; mp 246ºC; Anal. Calcd. for 
C26H21ClFN5O3: C, 61.72; H, 4.18; Cl, 7.01; F, 
3.76; N, 13.84; O, 9.49; FoundC, 61.61; H, 4.03; 
Cl, 7.00; F, 3.66; N, 13.75; O, 9.34%; MS: m/z 
505. 
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5.6.5.10 N-(4-fluoro,3-chlorophenyl)-2-isopropyl-4-(4-hydrooxyphenyl)-1,4-dihydro 
-pyrimido[1,2-a]benzimidazole-3-carboxamide  
(RHK-220) 
Yield: 66%; mp 210ºC; Anal. Calcd. for 
C26H22ClFN4O2: C, 65.48; H, 4.65; Cl, 7.43; F, 
3.98; N, 11.75; O, 6.71. Found: C, 65.34; H, 4.54; 
Cl, 7.31; F, 3.87; N, 11.61; O, 6.64%; MS: m/z 
476. 
 
5.7 Spectral discussion 
 
5.7.1 Mass spectral study 
 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using 
Direct Injection Probe technique. Systematic fragmentation pattern was observed in 
mass spectral analyses. Molecular ion peak was observed in agreement with 
molecular weight of respective compound. Mass fragmentation pattern for a 
representative compound of each series is depicted below. 
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5.7.1.1 Mass fragmentation pattern for RHK-192 
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5.7.1.2 Mass fragmentation pattern for RHK-204 
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5.7.1.3 Mass fragmentation pattern for RHK-214 
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5.7.2 IR spectral study 
 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr pellet 
method. Various functional groups present in molecule were identified by 
characteristic frequency obtained for them. For 1,4-dihydropyrimido[1,2-a] 
benzimidazoles RHK- 191 to 220, confirmatory bands for secondary amine and 
amidic carbonyl groups were observed at 3414-3282 cm
-1 
and 1690-1600 cm
-1 
respectively. Another characteristic C=N stretching band of triazole ring was 
observed at 1626-1500 cm
-1
, which suggested formation of desired products RHK-
191 to 220.
 
  
 
5.7.3 
1
H NMR spectral study 
 
1
H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 400 
MHz spectrometer using TMS as an internal standard. Number of protons and their 
chemical shifts were found to support the structure of the synthesized compounds.
1
H 
NMR spectra confirmed the structures of 1,4-dihydro-pyrimido[1,2-a] benzimidazoles 
RHK- 191 to 220 on the basis of following signals: a singlet for the methine proton of 
pyrimidine ring at 6.00-6.90 δ ppm, and singlets for amino and amide group protons 
at 7.50-9.90 and 9.45-10.50 δ ppm, respectively. The aromatic ring protons and J 
value were found to be in accordance with substitution pattern on phenyl ring. 
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IR spectrum of RHK-192 
 
Mass spectrum of RHK-192 
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1
H NMR spectrum of RHK-192 
 
Expanded 
1
H NMR spectrum of RHK-192 
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IR spectrum of RHK-194 
 
Mass spectrum of RHK-194 
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1
H NMR spectrum of RHK-194 
 
Expanded 
1
H NMR spectrum of RHK-194 
 
 
 
Chapter-5                                                                              1,4-dihydro pyrimido[1,2-a]benzimidazoles 
     
Studies on Some Organic Compounds of Therapeutic Interest 
   224
IR spectrum of RHK-195 
 
Mass spectrum of RHK-195 
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1
H NMR spectrum of RHK-195 
 
Expanded 
1
H NMR spectrum of RHK-195 
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IR spectrum of RHK-201 
 
Mass spectrum of RHK-201 
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1
H NMR spectrum of RHK-201 
 
Expanded 
1
H NMR spectrum of RHK-201 
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IR spectrum of RHK-204 
  
Mass spectrum of RHK-204 
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1
H NMR spectrum of RHK-204 
 
Expanded 
1
H NMR spectrum of RHK-204 
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IR spectrum of RHK-205 
 
Mass spectrum of RHK-205 
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1
H NMR spectrum of RHK-205 
 
Expanded 
1
H NMR spectrum of RHK-205 
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IR spectrum of RHK-211 
  
Mass spectrum of RHK-211 
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1
H NMR spectrum of RHK-211 
 
Expanded 
1
H NMR spectrum of RHK-211 
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IR spectrum of RHK-214 
 
Mass spectrum of RHK-214 
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1
H NMR spectrum of RHK-214 
 
Expanded 
1
H NMR spectrum of RHK-214 
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IR spectrum of RHK-215 
  
Mass spectrum of RHK-215 
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1
H NMR spectrum of RHK-215 
 
Expanded 
1
H NMR spectrum of RHK-215 
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5.8 Biological evaluation 
 
5.8.1 Antimicrobial evaluation 
 
All of the synthesized compounds (RHK- 191 to 220) were tested for their 
antibacterial and antifungal activity (MIC) in vitro by broth dilution method [126-128] 
with two Gram-positive bacteria Staphylococcus aureus MTCC-96, Streptococcus 
pyogenes MTCC 443, two Gram-negative bacteria Escherichia coli MTCC 442, 
Pseudomonas aeruginosa MTCC 441 and three fungal strains Candida albicans 
MTCC 227, Aspergillus Niger MTCC 282, Aspergillus clavatus MTCC 1323 taking 
gentamycin, ampicillin, chloramphenicol, ciprofloxacin, norfloxacin, nystatin and 
greseofulvin as standard drugs. The standard strains were procured from the Microbial 
Type Culture Collection (MTCC), Institute of Microbial Technology, Chandigarh, 
India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the compound 
preventing the visible growth, were determined by using micro dilution broth method 
according to NCCLS standards [126].  
 
Minimal Inhibition Concentration [MIC]:-  
 
The main advantage of the ‘Broth Dilution Method’ for MIC determination 
lies in the fact that it can readily be converted to determine the MIC as well. 
 
1. Serial dilutions were prepared in primary and secondary screening. 
2. The control tube containing no antibiotic is immediately subcultured (before 
inoculation) by spreading a loopful evenly over a quarter of plate of medium 
suitable for the growth of the test organism and put for incubation at 37
 0
C 
overnight.  
3. The MIC of the control organism is read to check the accuracy of the drug 
concentrations.  
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4. The lowest concentration inhibiting growth of the organism is recorded as the 
MIC.  
5. The amount of growth from the control tube before incubation (which 
represents the original inoculums) is compared.  
 
Methods used for primary and secondary screening: - 
 
Each synthesized drug was diluted obtaining 2000 µg mL
-1 
concentration, as a 
stock solution. Inoculum size for test strain was adjusted to 10
8
 cfu (colony forming 
unit) per milliliter by comparing the turbidity. 
Primary screen: - In primary screening 1000 µg mL
-1
, 500 µg mL
-1 
and 250 µg mL
-1 
concentrations of the synthesized drugs were taken. The active synthesized drugs 
found in this primary screening were further tested in a second set of dilution against 
all microorganisms.  
Secondary screen: - The drugs found active in primary screening were similarly 
diluted to obtain 200 µg mL
-1
, 100 µg mL
-1
, 50 µg mL
-1
, 25 µg mL
-1
, 12.5 µg mL
-1
, 
and 6.250 µg mL
-1
 concentrations.  
 
Reading Result: - The highest dilution showing at least 99 % inhibition zone is taken 
as MIC. The result of this is much affected by the size of the inoculums. The test 
mixture should contain 10
8 
organism/mL.           
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Table-1:-   in vitro Antimicrobial Screening Results for RHK-191 to 220 
 
Code Minimal inhibition concentration (µg mL
-1 
) 
Gram-positive Gram-negative Fungal species 
S.a. S. p. E.c. P.a. C. a. A. n. A.c. 
RHK-191 200 200 62.5 200 >1000 >1000 >1000 
RHK-192 250 250 50 200 >1000 >1000 >1000 
RHK-193 500 500 250 250 >1000 >1000 >1000 
RHK-194 100 100 250 250 >1000 500 500 
RHK-195 200 250 100 100 >1000 >1000 >1000 
RHK-196 500 500 100 200 250 1000 1000 
RHK-197 1000 250 1000 500 250 1000 1000 
RHK-198 150 250 500 250 500 >1000 1000 
RHK-199 100 200 100 250 500 500 1000 
RHK-200 150 500 250 250 500 >1000 >1000 
RHK-201 500 500 250 250 500 500 500 
RHK-202 500 500 250 250 500 500 500 
RHK-203 1000 1000 500 500 500 500 500 
RHK-204 250 500 250 500 500 500 500 
RHK-205 500 500 500 500 1000 250 250 
RHK-206 150 500 1000 1000 250 1000 1000 
RHK-207 1000 250 250 500 250 1000 1000 
RHK-208 1000 150 1000 500 250 1000 1000 
RHK-209 250 250 150 150 1000 500 1000 
RHK-210 1000 500 500 250 500 >1000 1000 
RHK-211 200 500 150 200 1000 250 500 
RHK-212 250 500 100 200 1000 500 500 
RHK-213 500 1000 250 500 1000 1000 >1000 
RHK-214 500 500 250 200 1000 >1000 >1000 
RHK-215 200 250 200 200 1000 >1000 >1000 
RHK-216 1000 250 500 150 1000 500 500 
RHK-217 150 500 100 150 500 >1000 >1000 
RHK-218 1000 250 100 500 >1000 >1000 >1000 
RHK-219 200 62.5 62.5 500 >1000 >1000 >1000 
RHK-220 500 500 1000 1000 500 500 1000 
Gentamycin 0.25 0.5 0.05 1 - - - 
Ampicillin 250 100 100 100 - - - 
Chloramphenicol 50 50 50 50 - - - 
Iprofloxacin 50 50 25 25 - - - 
Norfloxacin 10 10 10 10 - - - 
Nystatin - - - - 100 100 100 
Greseofulvin - - - - 500 100 100 
 
 
5.8.2 Antimycobacterial, anticancer and antiviral evaluation 
 
Antimycobacterial, anticancer and antiviral screening of all the newly 
synthesized compounds (RHK- 191 to RHK- 220) is currently under investigation 
and results are awaited.  
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Summary 
 
The work presented in the Thesis entitled “Studies on Some Heterocycles of 
Medicinal Interest” can be summarized as below. 
Chapter 1 briefly introduces importance of bicyclic and tricyclic aromatic 
heterocycles in drug discovery as well as concept of “privileged structures”. Chapter 1 
further describes aims and objectives of the proposed research work. 
Chapter 2 outlines the biological significance and medical significance of 
pyrimidines. Also, an attempt has been made to include most of the physiologically as 
well as medicinally important compounds containing pyrimidine and its derivatives to 
further elaborate the importance of these class of compounds. 
In Chapter 3, synthesis of six novel 1,2,3,4-tetrahydropyrimidines is reported, 
which occupy a special position among fused pyrimidines due to a very wide 
spectrum of their biological activities. 
In section-I keeping in mind various biomedical applications and with a view 
to further assess the pharmacological profile of these class of compounds, three novel 
series of 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(substituted phenyl)-1,2,3,4-tetrahydro-
6-methyl-2-oxopyrimidine-5-carboxamide are synthesized. The synthesis of was 
achieved by acid catalysed cyclocondensation of N-(substituted)-3-oxobutanamide, 
substituted urea and 4-(2,4-dinitrophenoxy)benzaldehydes.  
In section-II keeping in mind various biomedical applications and with a view 
to further assess the pharmacological profile of these class of compounds, three novel 
series of 4-(4-(2,4-dinitrophenoxy)phenyl)-N-(4-substitutedphenyl)-1,2,3,4-tetrahydro 
-6-isopropyl-2-oxopyrimidine-5-carboxamide are synthesized. The synthesis of was 
achieved by acid catalysed cyclocondensation of N-(substituted phenyl)-4-methyl-3-
oxopentanamide, substituted urea and 4-(2,4-dinitrophenoxy)benzaldehydes 
In chapter- 4 mixture of the 3-amino-1,2,4-triazole, N-(substituted phenyl)-4-
methyl-3-oxopentanamide and an appropriate aromatic aldehydes was refluxed in 
DMF (4 ml) for 20 min. After cooling, methanol was added. The reaction mixture was 
allowed to stand overnight and then filtered to give the solid triazolopyrimidine 
products. 
In chapter- 5 recognizing these facts, we have synthesised four new series of 
1,4-dihydropyrimido[1,2-a]benzimidazoles containing an acetoacetamide fragment. 
The structures of all the newly synthesized compounds were elucidated by FT-IR, 
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mass spectra, 
1
H NMR and elemental analyses. The newly synthesized compounds 
were subjected to antimicrobial activity. 
A mixture of the 2-amino benzimidazole N-(substituted phenyl)-4-methyl-3-
oxopentanamide and appropriate aromatic aldehydes was refluxed in DMF (4 ml) for 
30 min. After cooling, methanol was added. The reaction mixture was allowed to 
stand overnight and then filtered to give the solid 1,4-dihydro pyrimido[1,2-
a]benzimidazoles products which were recrystallized from ethanol. 
 
All the synthesized compounds were characterized by various analytical 
techniques like IR spectroscopy, Mass spectromentry, 
1
H NMR spectroscopy and 
elemental analyses. 
Thus, 110 compounds are synthesized and characterized in entire thesis work. 
The synthesized compounds are screened for antimicrobial activity, results of which 
are incorporated in the thesis. Looking at the antimicrobial activity results (i.e. 
antibacterial and antifungal), remarkable number of compounds have demonstrated 
excellent antimicrobial activity as compared to the standard drugs.  
All the newly synthesized compounds are also under antimycobacterial, 
anticancer and antiviral evaluation and their results are awaited.  
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